piperaquine profile

Piperaquine is a synthetic antimalarial drug that is used in combination therapy to treat uncomplicated malaria. Its mechanism of action involves inhibiting the formation of hemozoin, a detoxification product of heme, which is crucial for the survival of the malaria parasite Plasmodium falciparum. Piperaquine is effective against both chloroquine-sensitive and chloroquine-resistant strains of P. falciparum. It has a long half-life, allowing for once-weekly or even once-monthly dosing regimens, which enhances treatment adherence and reduces the risk of drug resistance development. Piperaquine is typically used in combination with artemisinin derivatives, such as artemether or artesunate, forming artemisinin-based combination therapies (ACTs) that are considered the gold standard for malaria treatment. Piperaquine is particularly important for the treatment of malaria in areas where resistance to other antimalarial drugs is prevalent. Ongoing research focuses on investigating the optimal dosage regimens, understanding the mechanisms of drug resistance, and exploring potential new drug combinations involving piperaquine for improved malaria control. '

piperaquine : An aminoquinoline that is 1,3-di(piperazin-1-yl)propane in which the nitrogen at position 4 of each of the piperazine moieties is replaced by a 7-chloroquinolin-4-yl group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	122262
CHEMBL ID	303933
CHEBI ID	91231
SCHEMBL ID	131649
MeSH ID	M0106912

Synonym
brn 0905079
quinoline, 4,4'-(trimethylenedi-4,1-piperazinediyl)bis(7-chloro-
piperaquine
piperaquinoline
quinoline, 4,4'-(1,3-propanediyldi-4,1-piperazinediyl)bis(7-chloro-
4,4'-(propane-1,3-diyldipiperazine-4,1-diyl)bis(7-chloroquinoline)
piperaquine phosphate
CHEMBL303933
FT-0650576
7-chloro-4-[4-[3-[4-(7-chloroquinolin-4-yl)piperazin-1-yl]propyl]piperazin-1-yl]quinoline
4085-31-8
7-chloro-4-[4-[3-[4-(7-chloro-4-quinolyl)piperazin-1-yl]propyl]piperazin-1-yl]quinoline;1,3-bis[4-(7-chloro-4-quinolinyl)-1-piperazinyl]propane tetraphosphate tetrahydrate
A825322
7-chloro-4-[4-[3-[4-(7-chloro-4-quinolyl)piperazin-1-yl]propyl]piperazin-1-yl]quinoline
5-23-03-00072 (beilstein handbook reference)
unii-a0hv2q956y
a0hv2q956y ,
NCGC00344515-02
AKOS015896173
SCHEMBL131649
piperaquine [who-dd]
7-chloro-4-(4-{3-[4-(7-chloroquinolin-4-yl)piperazin-1-yl]propyl}piperazin-1-yl)quinoline
1,3-bis[4-(7-chloroquinolin-4-yl)piperazin-1-yl]propane
CHEBI:91231
1,3-bis(4-(7-chloroquinolin-4-yl)piperazin-1-yl)propane
quinoline, 4,4'-(1,3-propanediyldi-4,1-piperazinediyl)bis[7-chloro-
DTXSID00193825
gtpl10025
4,4-(1,3-propanediyldi-4,1-piperazinediyl)bis(7-chloroquinoline)phosphate
DB13941
4,4'-(1,3-propanediydi-4,1-piper-azinediyl)bis[7-chloroquinoline]
BCP09615
Q7197338
SB19150
piperaquine-phosphate
1,3-bis[4-(7-chloroquinoline-4-yl)piperazin-1-yl]propane
bdbm50519563
HY-B1896
CS-0013957
piperaquine-d6

Excerpt	Reference	Relevance
"Piperaquine (PQ) is an important partner in antimalarial treatment strategies. "	( Pharmacokinetics and pharmacodynamics of piperaquine in a murine malaria model. Andrzejewski, C; Batty, KT; Ilett, KF; Jago, JD; Moore, BR; Page-Sharp, M, 2008)	2.05
"Piperaquine was found to be a reversible, potent inhibitor of CYP3A with the following parameter estimates (%CV): IC"	( Inhibition of CYP3A by Antimalarial Piperaquine and Its Metabolites in Human Liver Microsomes With IVIV Extrapolation. Ashton, M; Aziz, MY; Hoffmann, KJ, 2018)	1.48
"Piperaquine is an important partner drug used in artemisinin-based combination therapies (ACTs). "	( Photo-Induced Electron Transfer Real-Time PCR for Detection of Plasmodium falciparum plasmepsin 2 Gene Copy Number. L'Episcopia, M; Lucchi, NW; Severini, C; Souza, SS; Udhayakumar, V, 2018)	1.92
"Piperaquine (PQ) is an important partner drug in antimalarial combination treatments, but the long half-life of PQ raises concerns about drug resistance. "	( Piperaquine pharmacodynamics and parasite viability in a murine malaria model. Batty, KT; Ilett, KF; Jago, JD; Moore, BR; Page-Sharp, M, 2009)	3.24
"Piperaquine is a bisquinoline antimalarial drug extensively used as monotherapy in China in the 1980s and subsequently included as one of the components of the artemisinin-based combination therapies (ACTs) in the 1990s. "	( Antimalarial efficacy of piperaquine-based antimalarial combination therapies: facts and uncertainties. Bassat, Q; Cenci, F; Gargano, N, 2011)	2.12
"Piperaquine is a promising anti-malarial partner drug used in a fixed-dose combination with dihydroartemisinin."	( A population pharmacokinetic model of piperaquine in pregnant and non-pregnant women with uncomplicated Plasmodium falciparum malaria in Sudan. Adam, I; Ashton, M; Day, NP; Hanpithakpong, W; Hoglund, RM; Lindegardh, N; Nosten, F; Tarning, J; White, NJ, 2012)	1.37
"Piperaquine (PQ) is an antimalarial drug enjoying a resurgence of use in combination with an artemisinin derivative because of parasite resistance to standard treatments. "	( Measurement of piperaquine in plasma by liquid chromatography with ultraviolet absorbance detection. Davis, TM; Hung, TY; Ilett, KF, 2003)	2.11
"Piperaquine is a highly lipid-soluble drug with a large Vss/F, long t1/2,z and a clearance that is markedly higher in children than in adults."	( Population pharmacokinetics of piperaquine in adults and children with uncomplicated falciparum or vivax malaria. Davis, TM; Denis, MB; Hewitt, S; Hung, TY; Ilett, KF; Karunajeewa, H; Lim, C; Socheat, D, 2004)	2.05
"Piperaquine is a bisquinoline antimalarial drug that was first synthesised in the 1960s, and used extensively in China and Indochina as prophylaxis and treatment during the next 20 years. "	( Piperaquine: a resurgent antimalarial drug. Davis, TM; Hung, TY; Ilett, KF; Karunajeewa, HA; Sim, IK, 2005)	3.21
"Piperaquine (PQ) is an antimalarial drug whose high lipid solubility suggests that its absorption can be increased by a high-fat meal. "	( Effects of a high-fat meal on the relative oral bioavailability of piperaquine. Davis, TM; Ilett, KF; Sim, IK, 2005)	2.01
"Piperaquine phosphate is an orally active bisquinolone antimalarial drug that has been used for the past 3 decades. "	( Safety, tolerability, and single- and multiple-dose pharmacokinetics of piperaquine phosphate in healthy subjects. Ahmed, T; Batra, V; Ganguly, S; Gautam, A; Kothari, M; Moehrle, JJ; Paliwal, J; Saha, N; Sharma, P; Varshney, B, 2008)	2.02
"Piperaquine is an antimalarial drug that was extensively used in China during the 1980s and has recently received renewed interest as a partner drug in artemisinin-based combination therapy."	( Quantification of the antimalarial piperaquine in plasma. Lindegardh, N; Tarning, J, 2008)	1.34

Excerpt	Reference	Relevance
"Artekin is safe and effective combination therapy for uncomplicated malaria in children and adults."	( Safety evaluation of fixed combination piperaquine plus dihydroartemisinin (Artekin) in Cambodian children and adults with malaria. Davis, TM; Denis, MB; Hung, TY; Ilett, KF; Karunajeewa, H; Lim, C; Socheat, D, 2004)	0.59
" Adverse events and clinical and parasitological outcomes were recorded."	( Safety and efficacy of dihydroartemisinin/piperaquine (Artekin) for the treatment of uncomplicated Plasmodium falciparum malaria in Rwandan children. D'Alessandro, U; Fanello, CI; Karema, C; Ngamije, D; van Doren, W; van Geertruyden, JP; van Overmeir, C, 2006)	0.6
"Dihydroartemisinin-piperaquine, a fixed-dose combination antimalarial, is an inexpensive, safe and highly effective treatment for uncomplicated falciparum or vivax malaria."	( Efficacy and safety of dihydroartemisinin-piperaquine. Ashley, EA; Day, NP; Myint, HY; Nosten, F; White, NJ, 2007)	0.93
" There were no significant dose-related adverse effects, but leucocytes were mildly elevated (F(1) and F(2) mice) and serum albumin was reduced (F(1) only) in the 300 mg/kg/day group."	( Investigation of reproductive toxicity of piperaquine in mice. Batty, KT; Davis, TM; Ilett, KF; Karunajeewa, HA; Moore, BR; Mueller, I; Page-Sharp, M; Rogerson, SJ; Shilkin, KB; Stirling, V, 2010)	0.62
" Participants were actively monitored for adverse events for 28 days and then passively for up to 63 days after treatment."	( Safety and tolerability of artemether-lumefantrine versus dihydroartemisinin-piperaquine for malaria in young HIV-infected and uninfected children. Arinaitwe, E; Bigira, V; Dorsey, G; Gasasira, A; Homsy, J; Kakuru, A; Kamya, MR; Katrak, S; Sandison, TG; Tappero, JW; Wanzira, H, 2009)	0.58
" Most adverse events were rare, with only cough, diarrhoea, vomiting, and anaemia occurring in more than 1% of treatments."	( Safety and tolerability of artemether-lumefantrine versus dihydroartemisinin-piperaquine for malaria in young HIV-infected and uninfected children. Arinaitwe, E; Bigira, V; Dorsey, G; Gasasira, A; Homsy, J; Kakuru, A; Kamya, MR; Katrak, S; Sandison, TG; Tappero, JW; Wanzira, H, 2009)	0.58
"Both AL and DP were safe and well tolerated for the treatment of uncomplicated malaria in young HIV-infected and uninfected children."	( Safety and tolerability of artemether-lumefantrine versus dihydroartemisinin-piperaquine for malaria in young HIV-infected and uninfected children. Arinaitwe, E; Bigira, V; Dorsey, G; Gasasira, A; Homsy, J; Kakuru, A; Kamya, MR; Katrak, S; Sandison, TG; Tappero, JW; Wanzira, H, 2009)	0.58
"04), there were no differences between treatment arms in the occurrence of adverse events."	( Safety and efficacy of dihydroartemisinin-piperaquine versus artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Zambian children. Chaponda, M; D'Alessandro, U; Hachizovu, S; Mukwamataba, D; Mulenga, M; Nambozi, M; Ubben, D; Van Geertruyden, JP, 2011)	0.63
"DHA/PQP was as efficacious, safe and well tolerated in treatment of uncomplicated malaria as AL, though in the latter group more new infections during the follow up were observed."	( Safety and efficacy of dihydroartemisinin-piperaquine versus artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Zambian children. Chaponda, M; D'Alessandro, U; Hachizovu, S; Mukwamataba, D; Mulenga, M; Nambozi, M; Ubben, D; Van Geertruyden, JP, 2011)	0.63
" Few and mild adverse events were reported."	( Efficacy and safety of artemisinin-naphthoquine versus dihydroartemisinin-piperaquine in adult patients with uncomplicated malaria: a multi-centre study in Indonesia. Amansyah, F; Dedang, TA; Driyah, S; Ekowatiningsih, R; Hasugian, AR; Januar, L; Labora, J; Prasetyorini, B; Purnama, A; Purnamasari, T; Salwati, E; Siswantoro, H; Tjitra, E; Wijayanto, B; Yusnita, EA; Yuwarni, E, 2012)	0.61
"AN and DHP are confirmed very effective, safe and tolerate for treatment of any malaria."	( Efficacy and safety of artemisinin-naphthoquine versus dihydroartemisinin-piperaquine in adult patients with uncomplicated malaria: a multi-centre study in Indonesia. Amansyah, F; Dedang, TA; Driyah, S; Ekowatiningsih, R; Hasugian, AR; Januar, L; Labora, J; Prasetyorini, B; Purnama, A; Purnamasari, T; Salwati, E; Siswantoro, H; Tjitra, E; Wijayanto, B; Yusnita, EA; Yuwarni, E, 2012)	0.61
" Both DP and A + M were well tolerated, with the majority of adverse events of mild or moderate severity."	( Therapeutic efficacy and safety of dihydroartemisinin-piperaquine versus artesunate-mefloquine in uncomplicated Plasmodium falciparum malaria in India. Bacchieri, A; Bhattacharyya, PC; Corsi, M; Dev, V; Dubashi, N; Gargano, N; Ghosh, SK; Kumar, A; Rao, BH; Srivastava, B; Tommasini, S; Ubben, D; Valecha, N, 2012)	0.63
" No serious adverse event was noted during the study period."	( Monitoring the efficacy and safety of three artemisinin based-combinations therapies in Senegal: results from two years surveillance. Abiola, A; Faye, B; Folly, K; Gaye, O; Lo, AC; Ndiaye, JL; Ndiaye, LA; Ndiaye, M; Sow, D; Sylla, K; Tine, RC, 2013)	0.39
"In the context of scaling up of ACTs in Senegal, ASAQ, AL and DHAPQ are highly effective and safe antimalarial drugs."	( Monitoring the efficacy and safety of three artemisinin based-combinations therapies in Senegal: results from two years surveillance. Abiola, A; Faye, B; Folly, K; Gaye, O; Lo, AC; Ndiaye, JL; Ndiaye, LA; Ndiaye, M; Sow, D; Sylla, K; Tine, RC, 2013)	0.39
" Incidence of adverse events was related to underlying disease; malaria being reported in both treatment arms."	( Efficacy and safety of artemether-lumefantrine and dihydroartemisinin-piperaquine in the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children aged less than five years: results of an open-label, randomized, single-centre study. Akhwale, W; Eyase, F; Johnson, JD; Juma, E; Koskei, N; Obonyo, C; Ogutu, BR; Omollo, R; Omondi, EK; Ongecha, JM; Onyango, KO; Otieno, GA; Otieno, L; Perkins, DJ, 2014)	0.64
" Both ACT regimens were safe and well tolerated."	( Artemisinin-based combination therapies are efficacious and safe for treatment of uncomplicated malaria in HIV-infected Ugandan children. Achan, J; Arinaitwe, E; Charlebois, E; Clark, TD; Dorsey, G; Havlir, D; Ikilezi, G; Kakuru, A; Kamya, MR; Muhindo, MK; Mwangwa, F; Rosenthal, PJ; Ruel, T; Tappero, JW, 2014)	0.4
"Treatment of uncomplicated malaria with AL or DP was efficacious and safe in HIV-infected children taking ART."	( Artemisinin-based combination therapies are efficacious and safe for treatment of uncomplicated malaria in HIV-infected Ugandan children. Achan, J; Arinaitwe, E; Charlebois, E; Clark, TD; Dorsey, G; Havlir, D; Ikilezi, G; Kakuru, A; Kamya, MR; Muhindo, MK; Mwangwa, F; Rosenthal, PJ; Ruel, T; Tappero, JW, 2014)	0.4
"9% of side reaction with 7 cases suffering from mild adverse responses among 71 of full-course medication."	( [Therapeutic efficacy and safety of compound dihydroartemisinin/piperaquine for uncomplicated Plasmodium falciparum infection in Laiza City of Myanmar bordering on China]. Deng, Y; Lasi, JH; Sun, XD; Sun, XY; Wang, H; Wang, J; Yang, YC; Zhang, ZX, 2011)	0.61
"DHAPIP is efficacious and safe for the treatment of uncomplicated falciparum malaria in Laiza city of Myanmar in the border area."	( [Therapeutic efficacy and safety of compound dihydroartemisinin/piperaquine for uncomplicated Plasmodium falciparum infection in Laiza City of Myanmar bordering on China]. Deng, Y; Lasi, JH; Sun, XD; Sun, XY; Wang, H; Wang, J; Yang, YC; Zhang, ZX, 2011)	0.61
" There were no differences between the study arms in the incidence of serious adverse events during the intervention and the incidence of malaria during the 1-y period after the intervention was stopped."	( Protective efficacy and safety of three antimalarial regimens for the prevention of malaria in young Ugandan children: a randomized controlled trial. Achan, J; Aweeka, FT; Bigira, V; Clark, TD; Dorsey, G; Havlir, DV; Huang, L; Kamya, MR; Kapisi, J; Kinara, S; Muhindo, MK; Mwangwa, F; Osterbauer, B; Rosenthal, PJ, 2014)	0.4
" No statistical significant differences were observed in the occurrence of adverse events among treatment groups."	( Randomized non-inferiority and safety trial of dihydroartemisin-piperaquine and artesunate-amodiaquine versus artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Cameroonian children. Ali, IM; Chedjou, JP; Ekollo, AM; Evehe, MS; Froeschl, G; Heumann, C; Mansmann, U; Mbacham, WF; Moyeh, MN; Ndikum, VN; Ngongang, EO; Nji, AM; Ogundahunsi, O, 2015)	0.66
" Patients were contacted on day 5 ± 2 to assess adherence and adverse events (AEs)."	( Prospective observational study to evaluate the clinical safety of the fixed-dose artemisinin-based combination Eurartesim® (dihydroartemisinin/piperaquine), in public health facilities in Burkina Faso, Mozambique, Ghana, and Tanzania. Abdulla, S; Adjei, A; Adjuik, M; Akparibo, R; Baiden, R; Binka, F; Compaoré, G; Gyapong, M; Halidou, T; Macete, E; Mulokozi, A; Oduro, A; Ogutu, B; Osei, I; Owusu-Agyei, S; Sevene, E; Sie, A; Smith, P; Upunda, GL; Valea, I; Yawson, A, 2015)	0.62
" Most patients,95% (10,359/10,925), did not report any adverse event following at least one dose of Eurartesim®."	( Prospective observational study to evaluate the clinical safety of the fixed-dose artemisinin-based combination Eurartesim® (dihydroartemisinin/piperaquine), in public health facilities in Burkina Faso, Mozambique, Ghana, and Tanzania. Abdulla, S; Adjei, A; Adjuik, M; Akparibo, R; Baiden, R; Binka, F; Compaoré, G; Gyapong, M; Halidou, T; Macete, E; Mulokozi, A; Oduro, A; Ogutu, B; Osei, I; Owusu-Agyei, S; Sevene, E; Sie, A; Smith, P; Upunda, GL; Valea, I; Yawson, A, 2015)	0.62
" Safety was analysed based on adverse events (AE), laboratory abnormalities and abnormalities on electrocardiograph."	( Efficacy and safety of fixed dose combination of arterolane maleate and piperaquine phosphate dispersible tablets in paediatric patients with acute uncomplicated Plasmodium falciparum malaria: a phase II, multicentric, open-label study. Anvikar, AR; Arora, S; Iyer, SS; Jalali, RK; Mishra, P; Rao, BS; Roy, A; Rulisa, S; Saha, N; Sharma, P; Toure, OA; Valecha, N, 2015)	0.65
" The primary endpoint was the PCR-corrected adequate clinical and parasitological response (ACPR) at day 28 (D28); the secondary endpoints included ACPR at D42, clearance times for parasites, fever, and gametocytes, and the incidence of adverse events."	( [Evaluation of the efficacy and safety of three 2-drug combinations for the treatment of uncomplicated Plasmodium falciparum malaria in Senegal: artesunate-amodiaquine, dihydroartemisinin-piperaquine, and artemether-lumefantrine]. Abiola, A; Ba, MS; Dieng, Y; Faye, B; Gaye, O; Lo, AC; Ndiaye, JL; Ndiaye, M; Pene, M; Seck, A; Sow, D; Sylla, K; Tine, RC, )	0.32
" The combinations were well tolerated, with no serious adverse events reported during the follow-up period."	( [Evaluation of the efficacy and safety of three 2-drug combinations for the treatment of uncomplicated Plasmodium falciparum malaria in Senegal: artesunate-amodiaquine, dihydroartemisinin-piperaquine, and artemether-lumefantrine]. Abiola, A; Ba, MS; Dieng, Y; Faye, B; Gaye, O; Lo, AC; Ndiaye, JL; Ndiaye, M; Pene, M; Seck, A; Sow, D; Sylla, K; Tine, RC, )	0.32
" Safety endpoints were analysis of adverse events, vital signs, laboratory data, and abnormalities on electrocardiograph."	( Comparison of the safety and efficacy of fixed-dose combination of arterolane maleate and piperaquine phosphate with chloroquine in acute, uncomplicated Plasmodium vivax malaria: a phase III, multicentric, open-label study. Anvikar, AR; Arora, S; Gogtay, N; Iyer, SS; Jalali, RK; Kochar, SK; Kumar, NB; Lakhani, JD; Rajadhyaksha, GC; Rao, BH; Roy, A; Saha, N; Savargaonkar, D; Sharma, P; Solanki, BB; Srivastava, B; Tripathi, SK; Valecha, N, 2016)	0.66
" Incidence of adverse events was 82."	( Comparison of the safety and efficacy of fixed-dose combination of arterolane maleate and piperaquine phosphate with chloroquine in acute, uncomplicated Plasmodium vivax malaria: a phase III, multicentric, open-label study. Anvikar, AR; Arora, S; Gogtay, N; Iyer, SS; Jalali, RK; Kochar, SK; Kumar, NB; Lakhani, JD; Rajadhyaksha, GC; Rao, BH; Roy, A; Saha, N; Savargaonkar, D; Sharma, P; Solanki, BB; Srivastava, B; Tripathi, SK; Valecha, N, 2016)	0.66
"AZI-PQ appears to be well tolerated and safe in pregnancy."	( Safety, tolerability and pharmacokinetic properties of coadministered azithromycin and piperaquine in pregnant Papua New Guinean women. Auyeung, SO; Batty, KT; Benjamin, JM; Davis, TM; Griffin, S; Moore, BR; Mueller, I; Page-Sharp, M; Rogerson, SJ; Salman, S; Siba, PM; Yadi, G, 2016)	0.66
" Monthly IPT-DP was associated with fewer serious adverse events than placebo, daily co-trimoxazole, or monthly SP."	( Safety, tolerability, and efficacy of repeated doses of dihydroartemisinin-piperaquine for prevention and treatment of malaria: a systematic review and meta-analysis. Dorsey, G; Gutman, J; Kovacs, S; Stergachis, A; Ter Kuile, FO, 2017)	0.69
"In endemic areas, malaria and its adverse effects in schoolchildren may be prevented by intermittent preventive treatment (IPTsc)."	( Efficacy and safety of intermittent preventive treatment in schoolchildren with sulfadoxine/pyrimethamine (SP) and SP plus piperaquine in Democratic Republic of the Congo: a randomised controlled trial. da Luz, RI; Doua, JY; Lutumba, P; Matangila, JR; Mitashi, P; Van Geertruyden, JP, 2017)	0.66
"Uncommon and rare adverse events (AEs), with delayed onset may not be detected before new drugs are licensed and deployed."	( Post-licensure safety evaluation of dihydroartemisinin piperaquine in the three major ecological zones across Ghana. Adjei, A; Adjuik, M; Baiden, R; Binka, F; Gyapong, M; Oduro, AR; Osei, I; Owusu-Agyei, S; Sobe, E; Yawson, A, 2017)	0.7
" There were nine adverse events of special interest (AESI); itching/pruritus (7), dizziness (1), and skin lesions (1)."	( Post-licensure safety evaluation of dihydroartemisinin piperaquine in the three major ecological zones across Ghana. Adjei, A; Adjuik, M; Baiden, R; Binka, F; Gyapong, M; Oduro, AR; Osei, I; Owusu-Agyei, S; Sobe, E; Yawson, A, 2017)	0.7
" Dizziness, nausea, vomiting, headache and asthenia as adverse events (AEs) were more common in MQAS than in AL or DHAPQ (p < 0."	( Artemisinin-based combination therapy in pregnant women in Zambia: efficacy, safety and risk of recurrent malaria. Buyze, J; D'Alessandro, U; Hachizovu, S; Kabuya, JB; Kasongo, W; Mulenga, J; Mulenga, M; Mwakazanga, D; Nambozi, M; Van Geertruyden, JP, 2017)	0.46
" For quinine, clindamycin, and mefloquine and the combinations of sulfadoxine+pyrimethamine and artemether+lumefantrine, there are reports (including studies without internal comparison groups) that combined describe 304 to >1100 exposures of women in the first trimester for each drug with no conclusive evidence of adverse effects on pregnancy at therapeutic doses."	( Animal Embryotoxicity Studies of Key Non-Artemisinin Antimalarials and Use in Women in the First Trimester. Clark, RL, 2017)	0.46
" Both the treatments were found to be safe and well tolerated."	( Assessment of Efficacy and Safety of Arterolane Maleate-Piperaquine Phosphate Dispersible Tablets in Comparison With Artemether-Lumefantrine Dispersible Tablets in Pediatric Patients With Acute Uncomplicated Plasmodium falciparum Malaria: A Phase 3, Rando Anvikar, AR; Behra, N; Das, RR; Gaye, O; Jalali, RK; Maheshwar, AV; Mishra, P; Mwapasa, V; Nasa, A; Roy, A; Sagara, I; Sharma, P; Sharma, SK; Thompson, R; Toure, OA; Tshefu, AK; Valecha, N, 2017)	0.7
" Its adverse effects are generally tolerable and temporary."	( Choreoathetosis - an unusual adverse effect of dihydroartemisinin-piperaquine: a case report. Kadia, BM; Morfaw, C; Simo, ACG, 2017)	0.69
"Although dihydroartemisinin-piperaquine is increasingly popular as a well-tolerated/efficacious antimalarial drug, clinicians must note the rare possibility of choreoathetosis as an adverse effect of this medication and educate patients accordingly."	( Choreoathetosis - an unusual adverse effect of dihydroartemisinin-piperaquine: a case report. Kadia, BM; Morfaw, C; Simo, ACG, 2017)	0.99
" The majority of adverse events affected the gastrointestinal and respiratory tracts and were transient and mild to moderate in severity."	( Efficacy and Safety of Fosmidomycin-Piperaquine as Nonartemisinin-Based Combination Therapy for Uncomplicated Falciparum Malaria: A Single-Arm, Age De-escalation Proof-of-Concept Study in Gabon. Adegnika, AA; Cattaneo, C; Duparc, S; Endamne, L; Flohr, L; Groger, M; Hutchinson, D; Kabwende, L; Kim, J; Kremsner, PG; Lell, B; Lötsch, F; Mischlinger, J; Moehrle, J; Mombo-Ngoma, G; Mordmüller, B; Nguyen, TT; Ramharter, M; Remppis, J; Sievers, M; Velavan, TP; Veletzky, L; Zoleko Manego, R, 2018)	0.76
" The combination appeared to have high efficacy and be safe and well tolerated despite observed transient changes in electrocardiogram with prolongation of the QT interval."	( Efficacy and Safety of Fosmidomycin-Piperaquine as Nonartemisinin-Based Combination Therapy for Uncomplicated Falciparum Malaria: A Single-Arm, Age De-escalation Proof-of-Concept Study in Gabon. Adegnika, AA; Cattaneo, C; Duparc, S; Endamne, L; Flohr, L; Groger, M; Hutchinson, D; Kabwende, L; Kim, J; Kremsner, PG; Lell, B; Lötsch, F; Mischlinger, J; Moehrle, J; Mombo-Ngoma, G; Mordmüller, B; Nguyen, TT; Ramharter, M; Remppis, J; Sievers, M; Velavan, TP; Veletzky, L; Zoleko Manego, R, 2018)	0.76
" After exclusion of blue urine, adverse events were similar across all groups (59 [74%] of 80 participants had 162 adverse events overall, 145 [90%] of which were mild)."	( Efficacy and safety of primaquine and methylene blue for prevention of Plasmodium falciparum transmission in Mali: a phase 2, single-blind, randomised controlled trial. Bousema, T; Bradley, J; Brown, JM; Chen, I; Diarra, K; Diawara, H; Dicko, A; Drakeley, C; Gosling, R; Hwang, J; Issiaka, D; Keita, S; Kone, DT; Lanke, K; Mahamar, A; McCulloch, C; Müller, O; Roh, ME; Sanogo, K; Soumare, HM; Srinivasan, V; Stone, WJR; Traore, SF, 2018)	0.48
" Additional outcomes included intervention coverage, treatment adherence, occurrence of adverse events, and cumulative incidences 3, 12, and 16 months post-MDA."	( A cluster randomised controlled trial of two rounds of mass drug administration in Zanzibar, a malaria pre-elimination setting-high coverage and safety, but no significant impact on transmission. Ali, AS; Ali, SM; Aydin-Schmidt, B; Bennett, A; Björkman, A; Hodzic, L; Islam, A; Jovel, I; Khamis, M; Magnusson, E; Mårtensson, A; Mkali, H; Morris, U; Msellem, MI; Poirot, E; Sachs, MC; Shija, SJ; Tarning, J, 2018)	0.48
" Adverse events were reported in 11."	( A cluster randomised controlled trial of two rounds of mass drug administration in Zanzibar, a malaria pre-elimination setting-high coverage and safety, but no significant impact on transmission. Ali, AS; Ali, SM; Aydin-Schmidt, B; Bennett, A; Björkman, A; Hodzic, L; Islam, A; Jovel, I; Khamis, M; Magnusson, E; Mårtensson, A; Mkali, H; Morris, U; Msellem, MI; Poirot, E; Sachs, MC; Shija, SJ; Tarning, J, 2018)	0.48
"Plasmodium falciparum and Plasmodium vivax infections are important causes of adverse pregnancy outcomes in the Asia-Pacific region."	( Efficacy and safety of intermittent preventive treatment and intermittent screening and treatment versus single screening and treatment with dihydroartemisinin-piperaquine for the control of malaria in pregnancy in Indonesia: a cluster-randomised, open-la Adams, ER; Ahmed, R; Asih, PBS; Chen, T; Faragher, B; Khairallah, C; Lukito, T; Maratina, SS; Pace, C; Poespoprodjo, JR; Price, RN; Santana-Morales, MA; Smedley, J; Syafruddin, D; Ter Kuile, FO; Unwin, VT; Wang, D; Williams, CT, 2019)	0.71
" Conditions related to the pregnancy, the puerperium, and the perinatal period were the most common serious adverse events for the mothers, and infections and infestations for the infants."	( Efficacy and safety of intermittent preventive treatment and intermittent screening and treatment versus single screening and treatment with dihydroartemisinin-piperaquine for the control of malaria in pregnancy in Indonesia: a cluster-randomised, open-la Adams, ER; Ahmed, R; Asih, PBS; Chen, T; Faragher, B; Khairallah, C; Lukito, T; Maratina, SS; Pace, C; Poespoprodjo, JR; Price, RN; Santana-Morales, MA; Smedley, J; Syafruddin, D; Ter Kuile, FO; Unwin, VT; Wang, D; Williams, CT, 2019)	0.71
" They received a directly-observed 3-day standard treatment of DPQ and were followed up until day 63 for malaria infection and adverse events."	( Efficacy and safety of dihydroartemisinin-piperaquine for treatment of Plasmodium falciparum uncomplicated malaria in adult patients on antiretroviral therapy in Malawi and Mozambique: an open label non-randomized interventional trial. Banda, CG; Kalilani-Phiri, L; Khoo, SH; Lalloo, DG; Macuacua, S; Maculuve, S; Mallewa, J; Mukaka, M; Mwapasa, V; Piqueras, M; Sevene, E; Terlouw, DJ; Vala, A, 2019)	0.78
"DPQ was highly efficacious and safe for the treatment of malaria in HIV-infected patients concurrently taking efavirenz- or nevirapine-based ART, despite known pharmacokinetic interactions between dihydroartemisinin-piperaquine and efavirenz- or nevirapine-based ART regimens."	( Efficacy and safety of dihydroartemisinin-piperaquine for treatment of Plasmodium falciparum uncomplicated malaria in adult patients on antiretroviral therapy in Malawi and Mozambique: an open label non-randomized interventional trial. Banda, CG; Kalilani-Phiri, L; Khoo, SH; Lalloo, DG; Macuacua, S; Maculuve, S; Mallewa, J; Mukaka, M; Mwapasa, V; Piqueras, M; Sevene, E; Terlouw, DJ; Vala, A, 2019)	0.96
" Although piperaquine administration resulted in QTc prolongation, no cardiovascular adverse events were found in these patients."	( Pooled Multicenter Analysis of Cardiovascular Safety and Population Pharmacokinetic Properties of Piperaquine in African Patients with Uncomplicated Falciparum Malaria. Abdulla, S; Adjei, A; Adjuik, M; Asante, KP; Baiden, R; Binka, F; Compaore, G; Day, NPJ; Gyapong, M; Kabanywanyi, AM; Macete, E; Oduro, A; Ogutu, B; Osei, I; Owusu-Agyei, S; Sevene, E; Sie, A; Tarning, J; Tinto, H; Valea, I; Wattanakul, T; White, NJ; Winterberg, M, 2020)	1.18
" Adverse events were assessed within four hours of drugs intake."	( Efficacy and safety of praziquantel and dihydroartemisinin piperaquine combination for treatment and control of intestinal schistosomiasis: A randomized, non-inferiority clinical trial. Aklillu, E; Kamuhabwa, A; Kinung'hi, S; Minzi, O; Mnkugwe, RH, 2020)	0.8
"4%) of the study participants experienced mild and transient treatment-associated adverse events, post-treatment abdominal pain (27."	( Efficacy and safety of praziquantel and dihydroartemisinin piperaquine combination for treatment and control of intestinal schistosomiasis: A randomized, non-inferiority clinical trial. Aklillu, E; Kamuhabwa, A; Kinung'hi, S; Minzi, O; Mnkugwe, RH, 2020)	0.8
" The computed tomography (CT) imaging changes within 10 days, corrected QT interval changes, adverse events, and abnormal laboratory parameters were the secondary outcomes."	( Safety and efficacy of artemisinin-piperaquine for treatment of COVID-19: an open-label, non-randomised and controlled trial. Deng, C; Guan, X; Guo, J; Jin, C; Li, G; Li, H; Song, J; Tang, Y; Wang, Q; Xie, F; Xu, Q; Yu, W; Yuan, M; Yuan, Y; Zhang, H; Zou, Y, 2021)	0.9
" Both groups had mild adverse events."	( Safety and efficacy of artemisinin-piperaquine for treatment of COVID-19: an open-label, non-randomised and controlled trial. Deng, C; Guan, X; Guo, J; Jin, C; Li, G; Li, H; Song, J; Tang, Y; Wang, Q; Xie, F; Xu, Q; Yu, W; Yuan, M; Yuan, Y; Zhang, H; Zou, Y, 2021)	0.9
" Both treatments were safe and well-tolerated."	( Efficacy and safety of dihydroartemisinin-piperaquine versus artemether-lumefantrine for treatment of uncomplicated Plasmodium falciparum malaria in Ugandan children: a systematic review and meta-analysis of randomized control trials. Assefa, DG; Bekele, D; Getachew, E; Joseph, M; Manyazewal, T; Tesfahunei, HA; Zeleke, ED, 2021)	0.89
" Adverse events (AE) were collected, with a special focus on cardiovascular safety by including electrocardiogram QT intervals evaluated after correction with either Bazett's (QTcB) or Fridericia's (QTcF) methods, at baseline and after treatment."	( Longitudinal study based on a safety registry for malaria patients treated with artenimol-piperaquine in six European countries. Angheben, A; Bacchieri, A; Bardají, A; Behrens, RH; Bisoffi, Z; Bottieau, E; Bouchaud, O; Bourhis, Y; Calleri, G; Duparc, S; Hatz, C; Iannucelli, M; Jelinek, T; Martin, C; Mattera, GG; Mechain, M; Merlo Pich, E; Nothdurft, HD; Ramos, JM; Rapp, C; Rojo-Marcos, G; Salas-Coronas, J; Tommasini, S; Velasco, M; Vignier, N; Visser, LG, 2021)	0.84
" Reactive focal mass drug administration (rfMDA) may be safe and more effective."	( Effectiveness and safety of reactive focal mass drug administration (rfMDA) using dihydroartemisinin-piperaquine to reduce malaria transmission in the very low-endemic setting of Eswatini: a pragmatic cluster randomised controlled trial. Baltzell, K; Benjamin-Chung, J; Bhangu, K; Dlamini, B; Dlamini, N; Dufour, MK; Gosling, R; Greenhouse, B; Helb, D; Hsiang, MS; Kalungero, M; Kunene, S; Malambe, C; Maphalala, G; Mngadi, N; Nhlabathi, N; Ntshalintshali, N; Pindolia, D; Prach, LM; Tesfa, G; Vilakati, S; Whittemore, B, 2021)	0.84
" No serious adverse events occurred."	( Effectiveness and safety of reactive focal mass drug administration (rfMDA) using dihydroartemisinin-piperaquine to reduce malaria transmission in the very low-endemic setting of Eswatini: a pragmatic cluster randomised controlled trial. Baltzell, K; Benjamin-Chung, J; Bhangu, K; Dlamini, B; Dlamini, N; Dufour, MK; Gosling, R; Greenhouse, B; Helb, D; Hsiang, MS; Kalungero, M; Kunene, S; Malambe, C; Maphalala, G; Mngadi, N; Nhlabathi, N; Ntshalintshali, N; Pindolia, D; Prach, LM; Tesfa, G; Vilakati, S; Whittemore, B, 2021)	0.84
" Imatinib + SOC-treated participants exhibited no increase in number or severity of adverse events, a significantly accelerated decline in parasite density and pyrexia, and no DPC."	( Imatinib augments standard malaria combination therapy without added toxicity. Chien, HD; Kesely, KR; Low, PS; Noomuna, P; Pantaleo, A; Putt, KS; Tuan, TA; Turrini, FM, 2021)	0.62
" The commonly reported clinical adverse event was vomiting."	( Efficacy and safety of fixed dose combination of arterolane maleate and piperaquine phosphate in comparison with chloroquine phosphate in children with acute uncomplicated Anvikar, AR; Bahl, RK; Baliga, BS; Bhardwaj, AC; Choudhury, R; Das, RR; Ghosh, SK; Goyal, VK; Jalali, RK; Jauhri, N; Khurana, O; Mishra, DN; Nasa, A; Pandey, M; Punj, A; Roy, A; Sharma, SK; Soans, ST; Srivastava, B; Valecha, N, )	0.36
"Intermittent preventive treatment in pregnancy (IPTp) with sulfadoxine-pyrimethamine (SP) is recommended by the World Health Organization for the prevention of malaria in pregnancy (MIP)-associated adverse outcomes in high burden areas."	( Safety and efficacy of intermittent presumptive treatment with sulfadoxine-pyrimethamine using rapid diagnostic test screening and treatment with dihydroartemisinin-piperaquine at the first antenatal care visit (IPTp-SP+): study protocol for a randomized Champo, D; Chongwe, G; Ippolito, MM; Kabuya, JB; Manyando, C; Mulenga, M; Mwakazanga, D; Sikalima, J; Tende, C; Young, AMP, 2021)	0.82
" Secondary endpoints include incident MIP at other time points, placental malaria, congenital malaria, hemoglobin trends, birth outcomes, and incidence of adverse events in infants up to the first birthday."	( Safety and efficacy of intermittent presumptive treatment with sulfadoxine-pyrimethamine using rapid diagnostic test screening and treatment with dihydroartemisinin-piperaquine at the first antenatal care visit (IPTp-SP+): study protocol for a randomized Champo, D; Chongwe, G; Ippolito, MM; Kabuya, JB; Manyando, C; Mulenga, M; Mwakazanga, D; Sikalima, J; Tende, C; Young, AMP, 2021)	0.82
" Intermittent preventive treatment in pregnancy (IPTp) with sulphadoxine-pyrimethamine is recommended for malaria prevention in HIV-uninfected women, but it is contraindicated in those HIV-infected on cotrimoxazole prophylaxis (CTXp) due to potential adverse effects."	( Evaluation of the safety and efficacy of dihydroartemisinin-piperaquine for intermittent preventive treatment of malaria in HIV-infected pregnant women: protocol of a multicentre, two-arm, randomised, placebo-controlled, superiority clinical trial (MAMAH Dimessa, LB; El Gaaloul, M; Esen, M; Garcia-Otero, L; González, R; Lagler, H; Lell, B; Menendez, C; Mischlinger, J; Mombo-Ngoma, G; Nhampossa, T; Piqueras, M; Pons-Duran, C; Ramharter, M; Sanz, S; Saute, F; Sevene, E; Tchouatieu, AM; Zoleko Manego, R, 2021)	0.86
" Secondary outcomes include prevalence of malaria-related maternal and infant outcomes and proportion of adverse perinatal outcomes."	( Evaluation of the safety and efficacy of dihydroartemisinin-piperaquine for intermittent preventive treatment of malaria in HIV-infected pregnant women: protocol of a multicentre, two-arm, randomised, placebo-controlled, superiority clinical trial (MAMAH Dimessa, LB; El Gaaloul, M; Esen, M; Garcia-Otero, L; González, R; Lagler, H; Lell, B; Menendez, C; Mischlinger, J; Mombo-Ngoma, G; Nhampossa, T; Piqueras, M; Pons-Duran, C; Ramharter, M; Sanz, S; Saute, F; Sevene, E; Tchouatieu, AM; Zoleko Manego, R, 2021)	0.86
" There were no reported serious adverse events associated with any of the regimens."	( Efficacy and safety of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria and prevalence of molecular markers associated with artemisinin and partner drug resistance in Uganda. Asua, V; Belay, K; Bosco, A; Bwanika, JB; Ebong, C; Gonahasa, S; Gudoi, S; Halsey, ES; Kamya, MR; Kapisi, J; Kigozi, R; Kyabayinze, D; Lucchi, NW; Moriarty, LF; Mpimbaza, A; Namuganga, JF; Niang, M; Nsobya, SL; Opigo, J; Rubahika, D; Rutazana, D; Sebikaari, G; Souza, SSS; Sserwanga, A; Tibenderana, J; Yeka, A, 2021)	0.86
"DP remains highly effective and safe for the treatment of uncomplicated malaria in Uganda."	( Efficacy and safety of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria and prevalence of molecular markers associated with artemisinin and partner drug resistance in Uganda. Asua, V; Belay, K; Bosco, A; Bwanika, JB; Ebong, C; Gonahasa, S; Gudoi, S; Halsey, ES; Kamya, MR; Kapisi, J; Kigozi, R; Kyabayinze, D; Lucchi, NW; Moriarty, LF; Mpimbaza, A; Namuganga, JF; Niang, M; Nsobya, SL; Opigo, J; Rubahika, D; Rutazana, D; Sebikaari, G; Souza, SSS; Sserwanga, A; Tibenderana, J; Yeka, A, 2021)	0.86
" No delay in parasite clearance nor severe adverse reaction was observed."	( Efficacy and safety of dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum and Plasmodium vivax malaria in Papua and Sumatra, Indonesia. Anggraeni, ND; Asih, PBS; Basri, HH; Bustos, MDG; Dewayanti, FK; Hutahaean, J; Kusumaningsih, M; Mulyani, PS; Robaha, M; Rozi, IE; Sariwati, E; Syafruddin, D; Wangsamuda, S; Zulfah, S, 2022)	0.99
" Adverse events over the first 28 days were reported in 27 (54%) of 50 patients treated with dihydroartemisinin-piperaquine alone, 29 (58%) of 50 patients treated with tafenoquine plus dihydroartemisinin-piperaquine, and 22 (44%) of 50 patients treated with primaquine plus dihydroartemisinin-piperaquine."	( Tafenoquine co-administered with dihydroartemisinin-piperaquine for the radical cure of Plasmodium vivax malaria (INSPECTOR): a randomised, placebo-controlled, efficacy and safety study. Baird, JK; Berni, A; Budiman, W; Cedar, E; Chand, K; Crenna-Darusallam, C; Duparc, S; Ekawati, LL; Elyazar, I; Fernando, D; Fletcher, K; Goyal, N; Green, JA; Instiaty, I; Jones, S; Kleim, JP; Lardo, S; Martin, A; Noviyanti, R; Prasetya, CB; Rolfe, K; Santy, YW; Satyagraha, AW; Sharma, H; Soebandrio, A; Subekti, D; Sutanto, I; Tan, LK; Taylor, M, 2023)	1.37
" Dihydroartemisinin-piperaquine and artesunate-amodiaquine were associated with a small number of mild adverse events, and there were no treatment-related serious adverse events or deaths."	( Effectiveness and safety of intermittent preventive treatment with dihydroartemisinin-piperaquine or artesunate-amodiaquine for reducing malaria and related morbidities in schoolchildren in Tanzania: a randomised controlled trial. Baraka, V; Francis, F; Geertruyden, JV; Gesase, S; Kyaruzi, E; Lusingu, JPA; Madebe, R; Makenga, G; Minja, DTR; Mtove, G; Nakato, S, 2023)	1.46
"IPTsc with dihydroartemisinin-piperaquine or artesunate-amodiaquine is a safe and effective approach to reducing malaria parasitaemia, clinical malaria, and related morbidities, and is feasible to implement through programmes delivered by schoolteachers."	( Effectiveness and safety of intermittent preventive treatment with dihydroartemisinin-piperaquine or artesunate-amodiaquine for reducing malaria and related morbidities in schoolchildren in Tanzania: a randomised controlled trial. Baraka, V; Francis, F; Geertruyden, JV; Gesase, S; Kyaruzi, E; Lusingu, JPA; Madebe, R; Makenga, G; Minja, DTR; Mtove, G; Nakato, S, 2023)	1.42
" RCTs comparing IPTp DP versus recommended standard treatment for IPTp with these outcome measures were analyzed; change in QTc interval, serious adverse events (SAE), grade 3 or 4 adverse events possibly related to study drug and vomiting within 30 min after study drug administration."	( Safety and tolerability of repeated doses of dihydroartemisinin-piperaquine for intermittent preventive treatment of malaria in pregnancy: a systematic review and an aggregated data meta-analysis of randomized controlled trials. Abebe, A; Ahmedin, M; Atim, MG; Embaye, SM; Kahabuka, M; Kazembe, D; Manyazewal, T; Mesfin, T; Muthoka, EN; Namuganza, S; Usmael, K, 2023)	1.15

Excerpt	Reference	Relevance
"To investigate the pharmacokinetic properties of piperaquine after repeated oral administration of the antimalarial combination CV8 in healthy subjects."	( Pharmacokinetics of piperaquine after repeated oral administration of the antimalarial combination CV8 in 12 healthy male subjects. Ashton, M; Friberg Hietala, S; Hai, TN; Röshammar, D; Van Huong, N, 2006)	0.91
" Population pharmacokinetic parameter estimates were obtained by nonlinear mixed effects modeling of the observed data using NONMEM."	( Pharmacokinetics of piperaquine after repeated oral administration of the antimalarial combination CV8 in 12 healthy male subjects. Ashton, M; Friberg Hietala, S; Hai, TN; Röshammar, D; Van Huong, N, 2006)	0.66
" Piperaquine pharmacokinetics were characterized by a large volume of distribution and a terminal half-life of several days."	( Pharmacokinetics of piperaquine after repeated oral administration of the antimalarial combination CV8 in 12 healthy male subjects. Ashton, M; Friberg Hietala, S; Hai, TN; Röshammar, D; Van Huong, N, 2006)	1.57
"This study aimed to evaluate the pharmacokinetic properties of piperaquine in the rat after intravenous and oral administration, and to identify and characterize the main piperaquine metabolites in rat plasma, urine, faeces and bile after intravenous administration."	( Pharmacokinetics and metabolism of the antimalarial piperaquine after intravenous and oral single doses to the rat. Ashton, M; Day, NJ; Lindegardh, N; Sandberg, S; Tarning, J; White, NJ, 2008)	0.84
" However, there is a paucity of detailed preclinical and pharmacokinetic data to link PQ serum concentrations and toxicity or efficacy."	( Pharmacokinetics and pharmacodynamics of piperaquine in a murine malaria model. Andrzejewski, C; Batty, KT; Ilett, KF; Jago, JD; Moore, BR; Page-Sharp, M, 2008)	0.61
" Pharmacokinetic analysis for both the rising single- and multiple-dose studies was done using the noncompartmental approach."	( Safety, tolerability, and single- and multiple-dose pharmacokinetics of piperaquine phosphate in healthy subjects. Ahmed, T; Batra, V; Ganguly, S; Gautam, A; Kothari, M; Moehrle, JJ; Paliwal, J; Saha, N; Sharma, P; Varshney, B, 2008)	0.58
" (iii) Pharmacokinetic parameters determined from mice given 100mg/(kg day) PQP for 5 days."	( Toxicology and pharmacokinetics of piperaquine in mice. Batty, KT; Davis, TM; Ilett, KF; Karunajeewa, HA; Moore, BR; Mueller, I; Page-Sharp, M; Shilkin, KB; Stirling, V, 2008)	0.62
" The aim of this study was to determine the influence of a standard Vietnamese meal on the single-dose pharmacokinetics of piperaquine when administered in combination with dihydroartemisinin, and to gain extended data on the terminal half-life of piperaquine in healthy Vietnamese volunteers."	( The influence of food on the pharmacokinetics of piperaquine in healthy Vietnamese volunteers. Ashton, M; Hai, TN; Hietala, SF; Van Huong, N, 2008)	0.81
"0057), and the terminal elimination half-life was significantly shorter (17."	( Pharmacokinetics of dihydroartemisinin and piperaquine in pregnant and nonpregnant women with uncomplicated falciparum malaria. Laochan, N; Lindegardh, N; McGready, R; Mu, O; Nosten, F; Phyo, AP; Rijken, MJ; Singhasivanon, P; Tarning, J; Than, HH; White, N; Win, AK, 2011)	0.63
" The pharmacokinetic properties of antimalarial drugs are often affected by pregnancy, resulting in lower drug concentrations and a consequently higher risk of treatment failure."	( Population pharmacokinetics of dihydroartemisinin and piperaquine in pregnant and nonpregnant women with uncomplicated malaria. Day, NP; Hanpithakpong, W; Lindegardh, N; McGready, R; Nosten, F; Phyo, AP; Rijken, MJ; Tarning, J; White, NJ, 2012)	0.63
" The aim of this study was to describe the pharmacokinetic and pharmacodynamic properties of piperaquine in 236 children with uncomplicated falciparum malaria in Burkina Faso."	( Population pharmacokinetics and pharmacodynamics of piperaquine in children with uncomplicated falciparum malaria. Day, NP; Hanpithakpong, W; Jongrak, N; Lindegardh, N; Nosten, F; Ouedraogo, JB; Parikh, S; Rosenthal, PJ; Rouamba, N; Somé, FA; Tarning, J; White, NJ; Zongo, I, 2012)	0.85
"The pharmacokinetic properties of piperaquine were investigated in 12 pregnant and 12 well-matched, non-pregnant women receiving a three-day oral fixed dose combination regimen of dihydroartemisinin and piperaquine for treatment of uncomplicated Plasmodium falciparum at New Halfa Hospital in eastern Sudan."	( Pharmacokinetics of piperaquine in pregnant women in Sudan with uncomplicated Plasmodium falciparum malaria. Adam, I; Lindegardh, N; Mahgoub, H; McGready, R; Nosten, F; Tarning, J, 2012)	0.98
" The pharmacokinetic properties of many anti-malarials are also altered during pregnancy, often resulting in a decreased drug exposure."	( A population pharmacokinetic model of piperaquine in pregnant and non-pregnant women with uncomplicated Plasmodium falciparum malaria in Sudan. Adam, I; Ashton, M; Day, NP; Hanpithakpong, W; Hoglund, RM; Lindegardh, N; Nosten, F; Tarning, J; White, NJ, 2012)	0.65
" A statistically significant decrease in estimated terminal piperaquine half-life in pregnant compared with non-pregnant women was found, but there were no differences in post-hoc estimates of total piperaquine exposure."	( A population pharmacokinetic model of piperaquine in pregnant and non-pregnant women with uncomplicated Plasmodium falciparum malaria in Sudan. Adam, I; Ashton, M; Day, NP; Hanpithakpong, W; Hoglund, RM; Lindegardh, N; Nosten, F; Tarning, J; White, NJ, 2012)	0.89
"The population pharmacokinetic properties of piperaquine were well described by a three-compartment disposition model in pregnant and non-pregnant women with uncomplicated malaria."	( A population pharmacokinetic model of piperaquine in pregnant and non-pregnant women with uncomplicated Plasmodium falciparum malaria in Sudan. Adam, I; Ashton, M; Day, NP; Hanpithakpong, W; Hoglund, RM; Lindegardh, N; Nosten, F; Tarning, J; White, NJ, 2012)	0.91
" Inter- and intra-individual variabilities in the pharmacokinetic parameters were assessed and the contribution of demographic and other covariates was quantified using a nonlinear mixed-effects modelling approach (NONMEM®)."	( Population pharmacokinetics of mefloquine, piperaquine and artemether-lumefantrine in Cambodian and Tanzanian malaria patients. Ariey, F; Beck, HP; Buclin, T; Csajka, C; Decosterd, LA; Duong, S; Genton, B; Guidi, M; Kabanywanyi, AM; Mercier, T; Olliaro, P; Staehli Hodel, EM; Zanolari, B, 2013)	0.65
" From all the covariates tested, only body weight (for all antimalarials) and concomitant treatment (for artemether only) showed a significant influence on these drugs' pharmacokinetic profiles."	( Population pharmacokinetics of mefloquine, piperaquine and artemether-lumefantrine in Cambodian and Tanzanian malaria patients. Ariey, F; Beck, HP; Buclin, T; Csajka, C; Decosterd, LA; Duong, S; Genton, B; Guidi, M; Kabanywanyi, AM; Mercier, T; Olliaro, P; Staehli Hodel, EM; Zanolari, B, 2013)	0.65
" Compartmental pharmacokinetic models for PQ and DHA were developed using a population-based approach."	( Effect of coadministered fat on the tolerability, safety, and pharmacokinetic properties of dihydroartemisinin-piperaquine in Papua New Guinean children with uncomplicated malaria. Batty, KT; Benjamin, JM; Davis, TM; Ginny, E; Griffin, S; Moore, BR; Mueller, I; Page-Sharp, M; Robinson, LJ; Salman, S; Siba, P, 2014)	0.61
" Pharmacokinetic assessment was done with a noncompartmental approach."	( Open-label crossover study of primaquine and dihydroartemisinin-piperaquine pharmacokinetics in healthy adult thai subjects. Ashley, EA; Chotsiri, P; Day, NP; Hanboonkunupakarn, B; Hanpithakpong, W; Jittamala, P; Lee, SJ; Panapipat, S; Pukrittayakamee, S; Tarning, J; Wattanakul, T; White, NJ, 2014)	0.64
" The polymorphic effects of UGT1A9 (I399C>T) and UGT2B7*2 (802C>T), the major enzymes involved in the metabolism of DHA, on the pharmacokinetic profiles of DHA and its metabolite was also studied."	( The effect of UGTs polymorphism on the auto-induction phase II metabolism-mediated pharmacokinetics of dihydroartemisinin in healthy Chinese subjects after oral administration of a fixed combination of dihydroartemisinin-piperaquine. Li, X; Liu, H; Xing, J; Yang, A; Zang, M; Zhao, L; Zhu, F, 2014)	0.59
" No polymorphic effect was found for UGT1A9 (I399C>T) and UGT2B7*2 (802C>T) on the pharmacokinetic profiles of DHA and its metabolite DHA-Glu."	( The effect of UGTs polymorphism on the auto-induction phase II metabolism-mediated pharmacokinetics of dihydroartemisinin in healthy Chinese subjects after oral administration of a fixed combination of dihydroartemisinin-piperaquine. Li, X; Liu, H; Xing, J; Yang, A; Zang, M; Zhao, L; Zhu, F, 2014)	0.59
" Compartmental pharmacokinetic models were developed using a population-based approach."	( Population pharmacokinetics, tolerability, and safety of dihydroartemisinin-piperaquine and sulfadoxine-pyrimethamine-piperaquine in pregnant and nonpregnant Papua New Guinean women. Batty, KT; Benjamin, JM; Davis, TM; Lorry, L; Moore, BR; Mueller, I; Page-Sharp, M; Robinson, LJ; Salman, S; Siba, PM; Tawat, S; Yadi, G, 2015)	0.65
"Piperaquine-dihydroartemisinin combination therapy has established efficacy for the treatment of malaria; however, a more comprehensive understanding of the pharmacokinetic properties and factors contributing to inter- and intra-individual variability is critical to optimize clinical use."	( Effect of food on the pharmacokinetics of piperaquine and dihydroartemisinin. Bacchieri, A; Evans, AM; Francis, B; Lungershausen, Y; Pace, S; Reuter, SE; Shakib, S; Ubben, D; Valentini, G, 2015)	2.12
" Blood samples were collected for analysis of plasma piperaquine and dihydroartemisinin concentrations, which were utilized for calculation of pharmacokinetic parameters, using a standard model-independent approach."	( Effect of food on the pharmacokinetics of piperaquine and dihydroartemisinin. Bacchieri, A; Evans, AM; Francis, B; Lungershausen, Y; Pace, S; Reuter, SE; Shakib, S; Ubben, D; Valentini, G, 2015)	0.93
"The pharmacokinetic compatibility of short-acting CDRI candidate antimalarial trioxane derivative, 99-411, was tested with long-acting prescription antimalarials, lumefantrine and piperaquine."	( Assessment of pharmacokinetic compatibility of short acting CDRI candidate trioxane derivative, 99-411, with long acting prescription antimalarials, lumefantrine and piperaquine. Raju, KS; Singh, SP; Taneja, I; Wahajuddin, M, 2015)	0.8
" Pharmacokinetic analysis was by population-based compartmental models."	( Safety, tolerability and pharmacokinetic properties of coadministered azithromycin and piperaquine in pregnant Papua New Guinean women. Auyeung, SO; Batty, KT; Benjamin, JM; Davis, TM; Griffin, S; Moore, BR; Mueller, I; Page-Sharp, M; Rogerson, SJ; Salman, S; Siba, PM; Yadi, G, 2016)	0.66
"Median parasite clearance half-life was prolonged, and clearance half-life was greater than 5 h in 21% of patients."	( Parasite clearance rates in Upper Myanmar indicate a distinctive artemisinin resistance phenotype: a therapeutic efficacy study. Ashley, EA; Aung, SS; Day, NP; Dhorda, M; Dondorp, AM; Hlaing, TM; Imwong, M; Jeeyapant, A; Promnarate, C; Smithuis, FM; Thein, M; Tun, KM; White, NJ; Woodrow, CJ; Yuentrakul, P, 2016)	0.43
" The pharmacokinetic parameters of tafenoquine, piperaquine, lumefantrine, artemether, and dihydroartemisinin were determined by using noncompartmental methods."	( Pharmacokinetic Interactions between Tafenoquine and Dihydroartemisinin-Piperaquine or Artemether-Lumefantrine in Healthy Adult Subjects. Bouhired, S; Duparc, S; Goyal, N; Green, JA; Hussaini, A; Jones, SW; Koh, GC; Kostov, I; Mohamed, K; Taylor, M; Wolstenholm, A, 2016)	0.92
" This study utilised a population-based pharmacokinetic approach to optimise the antimalarial treatment regimen for piperaquine."	( Population Pharmacokinetic Properties of Piperaquine in Falciparum Malaria: An Individual Participant Data Meta-Analysis. Ashley, EA; Barnes, KI; Borrmann, S; Dahal, P; Day, NP; Edstein, MD; Guerin, PJ; Hoglund, RM; Lwin, KM; McGready, R; Mwai, L; Nosten, F; Nsanzabana, C; Ouedraogo, JB; Parikh, S; Phyo, AP; Price, RN; Quang, NN; Sambol, NC; Tarning, J; Thanh, NX; White, NJ; Workman, L; Zongo, I, 2017)	0.93
"Published pharmacokinetic studies on piperaquine were identified through a systematic literature review of articles published between 1 January 1960 and 15 February 2013."	( Population Pharmacokinetic Properties of Piperaquine in Falciparum Malaria: An Individual Participant Data Meta-Analysis. Ashley, EA; Barnes, KI; Borrmann, S; Dahal, P; Day, NP; Edstein, MD; Guerin, PJ; Hoglund, RM; Lwin, KM; McGready, R; Mwai, L; Nosten, F; Nsanzabana, C; Ouedraogo, JB; Parikh, S; Phyo, AP; Price, RN; Quang, NN; Sambol, NC; Tarning, J; Thanh, NX; White, NJ; Workman, L; Zongo, I, 2017)	0.99
"The derived population pharmacokinetic model was used to develop a revised dose regimen of dihydroartemisinin-piperaquine that is expected to provide equivalent piperaquine exposures safely in all patients, including in small children with malaria."	( Population Pharmacokinetic Properties of Piperaquine in Falciparum Malaria: An Individual Participant Data Meta-Analysis. Ashley, EA; Barnes, KI; Borrmann, S; Dahal, P; Day, NP; Edstein, MD; Guerin, PJ; Hoglund, RM; Lwin, KM; McGready, R; Mwai, L; Nosten, F; Nsanzabana, C; Ouedraogo, JB; Parikh, S; Phyo, AP; Price, RN; Quang, NN; Sambol, NC; Tarning, J; Thanh, NX; White, NJ; Workman, L; Zongo, I, 2017)	0.93
" A population pharmacokinetic model was developed to compare exposure-response relationships between the 2DP and 3DP regimens while accounting for differences in regimen and sample collection times between studies."	( Piperaquine Population Pharmacokinetics and Cardiac Safety in Cambodia. Buathong, N; Cantilena, L; Chann, S; Haigney, M; Ittiverakul, M; Kodchakorn, C; Kuntawunginn, W; Lanteri, C; Lon, C; Manning, J; Milner, E; Pann, ST; Prom, S; Saunders, D; So, M; Sok, S; Spring, M; Sriwichai, S; Ta-Aksorn, W; Vanachayangkul, P; Wojnarski, M; Youdaline, T, 2017)	1.9
"The aims of the present study were to evaluate the pharmacokinetic properties of dihydroartemisinin (DHA) and piperaquine, potential drug-drug interactions with concomitant primaquine treatment, and piperaquine effects on the electrocardiogram in healthy volunteers."	( Population pharmacokinetics and electrocardiographic effects of dihydroartemisinin-piperaquine in healthy volunteers. Blessborn, D; Chotsiri, P; Day, NPJ; Hanboonkunupakarn, B; Hoglund, RM; Jittamala, P; Pukrittayakamee, S; Tarning, J; Wattanakul, T; White, NJ, 2017)	0.89
"The population pharmacokinetic properties of DHA and piperaquine were assessed in 16 healthy Thai adults using an open-label, randomized, crossover study."	( Population pharmacokinetics and electrocardiographic effects of dihydroartemisinin-piperaquine in healthy volunteers. Blessborn, D; Chotsiri, P; Day, NPJ; Hanboonkunupakarn, B; Hoglund, RM; Jittamala, P; Pukrittayakamee, S; Tarning, J; Wattanakul, T; White, NJ, 2017)	0.93
" Concomitant treatment with primaquine did not affect the pharmacokinetic properties of DHA or piperaquine."	( Population pharmacokinetics and electrocardiographic effects of dihydroartemisinin-piperaquine in healthy volunteers. Blessborn, D; Chotsiri, P; Day, NPJ; Hanboonkunupakarn, B; Hoglund, RM; Jittamala, P; Pukrittayakamee, S; Tarning, J; Wattanakul, T; White, NJ, 2017)	0.9
"1% and was clearly associated with parasite clearance half-life (PCt1/2)."	( A randomised, double-blind clinical phase II trial of the efficacy, safety, tolerability and pharmacokinetics of a single dose combination treatment with artefenomel and piperaquine in adults and children with uncomplicated Plasmodium falciparum malaria. Adamy, M; Adoke, Y; Bassat, Q; Biguenet, S; Bouyou-Akotet, M; Demarest, H; Duong, TT; Duparc, S; Foster, C; Issifou, S; Kibuuka, A; Kremsner, PG; Laurijssens, BE; Leipoldt, I; Leroy, D; Macintyre, F; Mombo-Ngoma, G; Ouedraogo, A; Phuc, BQ; Ramharter, M; Smith, M; Tinto, H; Tiono, AB; Tshefu, AK, 2017)	0.65
" Based on in vitro data, a two-way pharmacokinetic interaction was hypothesized for KAF156 use in combination with piperaquine (PPQ) as both drugs are CYP3A4 substrates and inhibitors."	( A phase 1 evaluation of the pharmacokinetic/pharmacodynamic interaction of the anti-malarial agents KAF156 and piperaquine. Feng, Y; Goswami, B; Jain, JP; Leong, FJ; Stein, DS, 2018)	0.9
" Routine safety and pharmacokinetic assessments were carried out up to 61 days."	( A phase 1 evaluation of the pharmacokinetic/pharmacodynamic interaction of the anti-malarial agents KAF156 and piperaquine. Feng, Y; Goswami, B; Jain, JP; Leong, FJ; Stein, DS, 2018)	0.69
" Co-administration of PPQ and KAF156 had no overall effect on AUC of either compound, but the Cmax values of both KAF156 (~ 23%) and piperaquine (~ 70%) increased."	( A phase 1 evaluation of the pharmacokinetic/pharmacodynamic interaction of the anti-malarial agents KAF156 and piperaquine. Feng, Y; Goswami, B; Jain, JP; Leong, FJ; Stein, DS, 2018)	0.9
"Characterization of the pharmacokinetic properties of the enantiomers of primaquine and carboxyprimaquine following administration of racemic primaquine given alone and in combination with commonly used antimalarial drugs."	( Enantiospecific pharmacokinetics and drug-drug interactions of primaquine and blood-stage antimalarial drugs. Blessborn, D; Chairat, K; Day, NPJ; Hanboonkunupakarn, B; Hanpithakpong, W; Jittamala, P; Pukrittayakamee, S; Tarning, J; White, NJ, 2018)	0.48
"Population pharmacokinetic models characterizing the enantiospecific properties of primaquine were developed successfully."	( Enantiospecific pharmacokinetics and drug-drug interactions of primaquine and blood-stage antimalarial drugs. Blessborn, D; Chairat, K; Day, NPJ; Hanboonkunupakarn, B; Hanpithakpong, W; Jittamala, P; Pukrittayakamee, S; Tarning, J; White, NJ, 2018)	0.48

Excerpt	Reference	Relevance
" Competitive uptake of radiolabeled chloroquine and dihydroartemisinin in combination with other antimalarials was observed."	( Effects of piperaquine, chloroquine, and amodiaquine on drug uptake and of these in combination with dihydroartemisinin against drug-sensitive and -resistant Plasmodium falciparum strains. Adagu, IS; Fivelman, QL; Warhurst, DC, 2007)	0.73
"A high prevalence of chloroquine-resistant Plasmodium vivax in Indonesia has shifted first-line treatment to artemisinin-based combination therapies, combined with primaquine (PQ) for radical cure."	( A randomized comparison of dihydroartemisinin-piperaquine and artesunate-amodiaquine combined with primaquine for radical treatment of vivax malaria in Sumatera, Indonesia. Chavez, I; Chokejindachai, W; Dondorp, AM; Imwong, M; Pasaribu, AP; Pasaribu, S; Sirivichayakul, C; Tanomsing, N; Tjitra, E; White, NJ, 2013)	0.65
" This study investigated the safety and pharmacokinetics of KAE609 in combination with the long-acting antimalarial piperaquine (PPQ) in healthy volunteers."	( Open-label, single-dose, parallel-group study in healthy volunteers to determine the drug-drug interaction potential between KAE609 (cipargamin) and piperaquine. Griffin, P; Jain, JP; Kangas, M; Lefèvre, G; Lickliter, J; Machineni, S; Stein, DS, 2015)	0.83
" This study demonstrated that LC-HRMS(n) in combination with multiple data-mining techniques in tandem can be a valuable analytical strategy for rapid metabolite profiling of drugs."	( Metabolite identification of the antimalarial piperaquine in vivo using liquid chromatography-high-resolution mass spectrometry in combination with multiple data-mining tools in tandem. Fan, P; Liu, H; Xing, J; Yang, A; Zang, M, 2016)	0.69
"Characterization of the pharmacokinetic properties of the enantiomers of primaquine and carboxyprimaquine following administration of racemic primaquine given alone and in combination with commonly used antimalarial drugs."	( Enantiospecific pharmacokinetics and drug-drug interactions of primaquine and blood-stage antimalarial drugs. Blessborn, D; Chairat, K; Day, NPJ; Hanboonkunupakarn, B; Hanpithakpong, W; Jittamala, P; Pukrittayakamee, S; Tarning, J; White, NJ, 2018)	0.48
"Enantiomeric pharmacokinetics were evaluated in 49 healthy adult volunteers enrolled in three randomized cross-over studies in which a single dose of primaquine was given alone and then, after a suitable washout period, in combination with chloroquine, dihydroartemisinin/piperaquine or pyronaridine/artesunate."	( Enantiospecific pharmacokinetics and drug-drug interactions of primaquine and blood-stage antimalarial drugs. Blessborn, D; Chairat, K; Day, NPJ; Hanboonkunupakarn, B; Hanpithakpong, W; Jittamala, P; Pukrittayakamee, S; Tarning, J; White, NJ, 2018)	0.66
" No drug-drug interaction effects were seen on the pharmacokinetics of either carboxyprimaquine enantiomer."	( Enantiospecific pharmacokinetics and drug-drug interactions of primaquine and blood-stage antimalarial drugs. Blessborn, D; Chairat, K; Day, NPJ; Hanboonkunupakarn, B; Hanpithakpong, W; Jittamala, P; Pukrittayakamee, S; Tarning, J; White, NJ, 2018)	0.48
" Furthermore, doxycycline has anti-malarial properties and is already recommended as prophylaxis for travellers and for treatment of falciparum malaria in combination with other anti-malarial drugs."	( Has doxycycline, in combination with anti-malarial drugs, a role to play in intermittent preventive treatment of Plasmodium falciparum malaria infection in pregnant women in Africa? Boxberger, M; Gaillard, T; Madamet, M; Pradines, B, 2018)	0.48
" We aimed to establish the efficacy and safety of three single low doses of tafenoquine in combination with dihydroartemisinin-piperaquine for reducing gametocyte density and transmission to mosquitoes."	( Single low-dose tafenoquine combined with dihydroartemisinin-piperaquine to reduce Plasmodium falciparum transmission in Ouelessebougou, Mali: a phase 2, single-blind, randomised clinical trial. Attaher, O; Bousema, T; Bradley, J; Diallo, M; Dicko, A; Dicko, OM; Drakeley, C; Issiaka, D; Keita, S; Lanke, K; Maguiraga, SO; Mahamar, A; McCall, MBB; Niambele, SM; Sacko, A; Samake, S; Sanogo, K; Sinaba, Y; Smit, MJ; Stone, W; Ter Heine, R; Traore, SF, 2022)	1.17
" This study evaluated the efficacy of different dosages of aqueous extract of Strychnos ligustrina combined with dihydroartemisinin and piperaquine phosphate (DHP) against murine Plasmodium berghei infection."	( Antimalarial Efficacy of Aqueous Extract of Strychnos ligustrina and Its Combination with Dihydroartemisinin and Piperaquine Phosphate (DHP) against Plasmodium berghei Infection. Cahyaningsih, U; Maring, AJ; Nugraha, AB; Sa'diah, S; Sari, RK; Syafii, W, 2022)	1.14

Excerpt	Reference	Relevance
" The oral bioavailability of PQ relative to the fasting state was 121% greater after the high-fat meal (95% confidence interval, 26 to 216% increase; P=0."	( Effects of a high-fat meal on the relative oral bioavailability of piperaquine. Davis, TM; Ilett, KF; Sim, IK, 2005)	0.56
" The absolute oral bioavailability was approximately 50%."	( Pharmacokinetics and metabolism of the antimalarial piperaquine after intravenous and oral single doses to the rat. Ashton, M; Day, NJ; Lindegardh, N; Sandberg, S; Tarning, J; White, NJ, 2008)	0.6
" Piperaquine AUC was proportional to the two doses tested and a moderate-fat meal enhanced the bioavailability of piperaquine by 41%, which should improve the therapeutic efficacy of this drug."	( Pharmacokinetics of the antimalarial drug piperaquine in healthy Vietnamese subjects. Bui, D; Edstein, MD; Nguyen, NQ; Nguyen, TC; Nguyen, XT; Travers, T, 2008)	1.52
" In addition, the oral bioavailability of piperaquine improves when given with a high-fat meal, though this does not necessarily translate into a higher efficacy."	( Progress in the development of piperaquine combinations for the treatment of malaria. D'alessandro, U, 2009)	0.9
" The lipophilic characteristic of piperaquine suggests that administration together with fat will increase the oral bioavailability of the drug, and this has been reported for healthy volunteers."	( A small amount of fat does not affect piperaquine exposure in patients with malaria. Annerberg, A; Ashley, E; Day, NP; Khrutsawadchai, S; Lindegardh, N; Lwin, KM; Nosten, F; Singhasivanon, P; Tarning, J; White, NJ, 2011)	0.92
" Piperaquine was best described by a three-compartment disposition model with a 45% higher elimination clearance and a 47% increase in relative bioavailability in pregnant women compared with nonpregnant women."	( Population pharmacokinetics of dihydroartemisinin and piperaquine in pregnant and nonpregnant women with uncomplicated malaria. Day, NP; Hanpithakpong, W; Lindegardh, N; McGready, R; Nosten, F; Phyo, AP; Rijken, MJ; Tarning, J; White, NJ, 2012)	1.54
"Previously published literature reports various impacts of food on the oral bioavailability of piperaquine."	( Population pharmacokinetic assessment of the effect of food on piperaquine bioavailability in patients with uncomplicated malaria. Annerberg, A; Ashley, E; Day, NP; Kiricharoen, L; Lindegardh, N; Lwin, KM; Nosten, F; Tarning, J; White, NJ, 2014)	0.86
" Based on these results, the alternative common three-day regimen for QHS-PQ could probably lead to lower bioavailability of QHS and higher potential of drug-drug interaction caused by the induction of drug-metabolizing enzymes."	( Auto-induction of phase I and phase II metabolism of artemisinin in healthy Chinese subjects after oral administration of a new artemisinin-piperaquine fixed combination. Li, X; Xing, J; Yang, A; Zang, M; Zhu, F, 2014)	0.6
"Coadministration of dihydroartemisinin-piperaquine (DHA-PQ) with fat may improve bioavailability and antimalarial efficacy, but it might also increase toxicity."	( Effect of coadministered fat on the tolerability, safety, and pharmacokinetic properties of dihydroartemisinin-piperaquine in Papua New Guinean children with uncomplicated malaria. Batty, KT; Benjamin, JM; Davis, TM; Ginny, E; Griffin, S; Moore, BR; Mueller, I; Page-Sharp, M; Robinson, LJ; Salman, S; Siba, P, 2014)	0.88
" The metabolic capability could recover after a 12-h dosing interval, which suggested that the alternative common three-day regimen (once daily) for DHA-PQ could probably lead to higher bioavailability of DHA."	( The effect of UGTs polymorphism on the auto-induction phase II metabolism-mediated pharmacokinetics of dihydroartemisinin in healthy Chinese subjects after oral administration of a fixed combination of dihydroartemisinin-piperaquine. Li, X; Liu, H; Xing, J; Yang, A; Zang, M; Zhao, L; Zhu, F, 2014)	0.59
"001) in association with a greater clearance relative to bioavailability (73."	( Population pharmacokinetics, tolerability, and safety of dihydroartemisinin-piperaquine and sulfadoxine-pyrimethamine-piperaquine in pregnant and nonpregnant Papua New Guinean women. Batty, KT; Benjamin, JM; Davis, TM; Lorry, L; Moore, BR; Mueller, I; Page-Sharp, M; Robinson, LJ; Salman, S; Siba, PM; Tawat, S; Yadi, G, 2015)	0.65
" This likely reflects an increase in the oral bioavailability of the drug, directly related to the fat content of the meal."	( Effect of food on the pharmacokinetics of piperaquine and dihydroartemisinin. Bacchieri, A; Evans, AM; Francis, B; Lungershausen, Y; Pace, S; Reuter, SE; Shakib, S; Ubben, D; Valentini, G, 2015)	0.68
" Compared with previous pregnancy studies, the area under the concentration-time curve (AUC0-∞ ) for PQ [38818 (24354-52299) μg h l(-1) ] was similar to published values but there was a 52% increase in relative bioavailability with each dose."	( Safety, tolerability and pharmacokinetic properties of coadministered azithromycin and piperaquine in pregnant Papua New Guinean women. Auyeung, SO; Batty, KT; Benjamin, JM; Davis, TM; Griffin, S; Moore, BR; Mueller, I; Page-Sharp, M; Rogerson, SJ; Salman, S; Siba, PM; Yadi, G, 2016)	0.66
" Based on the present/other data, total AZI doses higher than 3 g for the treatment and prevention of malaria may be unnecessary in pregnant women, while clearance of parasitaemia could improve the relative bioavailability of PQ."	( Safety, tolerability and pharmacokinetic properties of coadministered azithromycin and piperaquine in pregnant Papua New Guinean women. Auyeung, SO; Batty, KT; Benjamin, JM; Davis, TM; Griffin, S; Moore, BR; Mueller, I; Page-Sharp, M; Rogerson, SJ; Salman, S; Siba, PM; Yadi, G, 2016)	0.66
"5%) in piperaquine bioavailability between each piperaquine dose occasion."	( Population Pharmacokinetic Properties of Piperaquine in Falciparum Malaria: An Individual Participant Data Meta-Analysis. Ashley, EA; Barnes, KI; Borrmann, S; Dahal, P; Day, NP; Edstein, MD; Guerin, PJ; Hoglund, RM; Lwin, KM; McGready, R; Mwai, L; Nosten, F; Nsanzabana, C; Ouedraogo, JB; Parikh, S; Phyo, AP; Price, RN; Quang, NN; Sambol, NC; Tarning, J; Thanh, NX; White, NJ; Workman, L; Zongo, I, 2017)	1.18
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51
" They also showed exceptionally better treatment of malaria owing to their sustained release properties and improved bioavailability and are recommended to Pharmaceutical companies for further studies."	( Assessment of the Anti-Malarial Properties of Dihydroartemisinin- Piperaquine Phosphate Solid Lipid-Based Tablets. Amarachi, CS; Attama, AA; Onunkwo, GC, 2022)	0.96

Excerpt	Relevance	Reference
" The total dosage recommended was 2800-3200 mg."	( [Comparative study of artemisinin suppositories and piperaquine phosphate in the treatment of falciparum malaria]. Fu, LC; Guo, XB, 1989)	0.53
"The current dosage of DP (6."	( Randomized, controlled dose-optimization studies of dihydroartemisinin-piperaquine for the treatment of uncomplicated multidrug-resistant falciparum malaria in Thailand. Ashley, EA; Brockman, A; Hutagalung, R; Krudsood, S; Leowattana, W; Looareesuwan, S; McGready, R; Nosten, F; Phaiphun, L; Srivilairit, S; White, NJ; Wilairatana, P, 2004)	0.56
" The dosing regimen has been simplified from four doses to once daily over 3 days."	( Efficacy and safety of dihydroartemisinin-piperaquine. Ashley, EA; Day, NP; Myint, HY; Nosten, F; White, NJ, 2007)	0.6
"The population pharmacokinetics of piperaquine in adults and children with uncomplicated Plasmodium falciparum malaria treated with two different dosage regimens of dihydroartemisinin-piperaquine were characterized."	( Population pharmacokinetics of piperaquine after two different treatment regimens with dihydroartemisinin-piperaquine in patients with Plasmodium falciparum malaria in Thailand. Ashley, EA; Ashton, M; Day, NP; Lindegardh, N; McGready, R; Nosten, F; Phaiphun, L; Stepniewska, K; Tarning, J; White, NJ, 2008)	0.91
" However, AL has several limitations, including a twice-daily dosing regimen, recommendation for administration with fatty food, and a high risk of reinfection soon after therapy in high transmission areas."	( Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treating uncomplicated malaria: a randomized trial to guide policy in Uganda. Bukirwa, H; Dorsey, G; Kamya, MR; Lugemwa, M; Rosenthal, PJ; Rwakimari, JB; Staedke, SG; Talisuna, A; Wabwire-Mangen, F; Yeka, A, 2008)	0.6
"DP is highly efficacious, and operationally preferable to AL because of a less intensive dosing schedule and requirements."	( Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treating uncomplicated malaria: a randomized trial to guide policy in Uganda. Bukirwa, H; Dorsey, G; Kamya, MR; Lugemwa, M; Rosenthal, PJ; Rwakimari, JB; Staedke, SG; Talisuna, A; Wabwire-Mangen, F; Yeka, A, 2008)	0.6
" However, children, compared to the population mean profile, tend to have a smaller central volume of distribution, a shorter distribution half-life and a more rapid fall in early piperaquine plasma concentrations, suggesting that an increase of the weight-adjusted dosage in children may be required."	( Progress in the development of piperaquine combinations for the treatment of malaria. D'alessandro, U, 2009)	0.83
"The dosage recommended for children may need to be reviewed and the usefulness of the coadministration with food should be determined."	( Progress in the development of piperaquine combinations for the treatment of malaria. D'alessandro, U, 2009)	0.64
" falciparum malaria in central Sudan, although treatment with DHA-P (which requires a simpler dosing regimen) might be preferred to treatment with AL."	( Dihydroartemisinin-piperaquine versus artemether-lumefantrine, in the treatment of uncomplicated Plasmodium falciparum malaria in central Sudan. Adam, I; Elhassan, AH; Elmardi, KA; Eltahir, HG; Malik, EM; Salah, MT, 2010)	0.69
" A three-day course of total 8 tablets compound dihydroartemisinin-piperaquine was administered to an adult (each tablet containing 40 mg of dihydroartemisinin and 320 mg of piperaquine phosphate), dosage for children was based on ages (details in the treatment regimen) ."	( [Efficacy of compound dihydroartemisinin/piperaquine in treatment of uncomplicated falciparum malaria in Myanmar]. Li, CF; Liu, H; Nie, RH; Wang, HY; Yang, HL; Zhang, J, 2011)	0.87
"Mechanistic within-host models relating blood anti-malarial drug concentrations with the parasite-time profile help in assessing dosing schedules and partner drugs for new anti-malarial treatments."	( Assessing the utility of an anti-malarial pharmacokinetic-pharmacodynamic model for aiding drug clinical development. Charman, SA; Gamo-Benito, J; Humberstone, A; Jamsen, KM; McCaw, J; Moehrle, J; Price, RN; Simpson, JA; Smith, K; Zaloumis, S, 2012)	0.38
" PQP at the dose of 80 mg/kg, induced prolonged gestation, dystocic delivery and increase perinatal mortality both with interruption of treatment (GD6 to GD17 and LD1-21) and with continuous dosing (GD19-LD21)."	( Piperaquine phosphate: reproduction studies. Brughera, M; Ferraris, L; Longo, M; Mazuè, G; Messina, M; Pace, S; Ubben, D, 2012)	1.82
" The better safety profile of DP and once-daily dosage improves adherence and its fixed co-formulation ensures that both drugs are taken together."	( Efficacy and safety of dihydroartemisinin-piperaquine for treatment of uncomplicated Plasmodium falciparum malaria in endemic countries: meta-analysis of randomised controlled studies. Aung, K; Mak, JW; Naing, C; Wong, JY, 2013)	0.65
" Dosing on body weight appears justified."	( Population pharmacokinetics of mefloquine, piperaquine and artemether-lumefantrine in Cambodian and Tanzanian malaria patients. Ariey, F; Beck, HP; Buclin, T; Csajka, C; Decosterd, LA; Duong, S; Genton, B; Guidi, M; Kabanywanyi, AM; Mercier, T; Olliaro, P; Staehli Hodel, EM; Zanolari, B, 2013)	0.65
"Dihydroartemisinin-piperaquine (DP) is increasingly recommended for antimalarial treatment in many endemic countries; however, concerns have been raised over its potential under dosing in young children."	( The effect of dosing regimens on the antimalarial efficacy of dihydroartemisinin-piperaquine: a pooled analysis of individual patient data. , 2013)	0.94
" The better safety profile of DHP and the once-daily dosage improves adherence, and its fixed co-formulation ensures that both drugs (dihydroartemisinin and piperaquine) are taken together."	( Efficacy and safety of dihydroartemisinin-piperaquine for treatment of Plasmodium vivax malaria in endemic countries: meta-analysis of randomized controlled studies. Aung, K; Mak, JW; Naing, C; Racloz, V; Reid, SA; Tanner, M; Whittaker, MA, 2013)	0.85
" The dosing schedule is simpler with the artenimol + piperaquine combination than with artemether + lumefantrine."	( Artenimol + piperaquine. Very slow piperaquine elimination: cardiovascular risks and interactions. , 2014)	1.03
" However, the optimal drug and dosing regimens for IPT remain to be determined."	( Impact of intermittent preventive treatment with dihydroartemisinin-piperaquine on malaria in Ugandan schoolchildren: a randomized, placebo-controlled trial. Amuge, P; Brooker, SJ; Dorsey, G; Kamya, MR; Kiwanuka, N; Nankabirwa, JI; Rosenthal, PJ; Staedke, SG; Wandera, B, 2014)	0.64
" The development of appropriate pragmatic dosing regimens for low-resource settings or community-based use is not formally regulated, even though these may alter factors which can substantially affect individual patient and population level outcome, such as drug exposure, patient adherence and the spread of drug resistance and can affect a drug's reputation and its eventual therapeutic lifespan."	( Optimizing the programmatic deployment of the anti-malarials artemether-lumefantrine and dihydroartemisinin-piperaquine using pharmacological modelling. Hastings, IM; Hayes, DJ; Hodel, EM; Kay, K; Terlouw, DJ, 2014)	0.62
"An in silico pharmacological model of anti-malarial drug treatment with the pharmacokinetic/pharmacodynamic profiles of artemether-lumefantrine (AM-LF, Coartem®) and dihydroartemisinin-piperaquine (DHA-PPQ, Eurartesim®) was constructed to assess the potential impact of programmatic factors, including regionally optimized, age-based dosing regimens, poor patient adherence, food effects and drug resistance on treatment outcome at population level, and compared both drugs' susceptibility to these factors."	( Optimizing the programmatic deployment of the anti-malarials artemether-lumefantrine and dihydroartemisinin-piperaquine using pharmacological modelling. Hastings, IM; Hayes, DJ; Hodel, EM; Kay, K; Terlouw, DJ, 2014)	0.81
"Compared with DHA-PPQ, therapeutic effectiveness of AM-LF seems more robust to factors affecting drug exposure, such as age- instead of weight-based dosing or poor adherence."	( Optimizing the programmatic deployment of the anti-malarials artemether-lumefantrine and dihydroartemisinin-piperaquine using pharmacological modelling. Hastings, IM; Hayes, DJ; Hodel, EM; Kay, K; Terlouw, DJ, 2014)	0.62
"This study has developed mechanistic models that describe the parasite-time curve after single, multiple or combination dosing of antimalarials to mice."	( Predicting the parasite killing effect of artemisinin combination therapy in a murine malaria model. Batty, KT; Gibbons, PL; Kirkpatrick, CM; Moore, BR; Patel, K, 2014)	0.4
" The cases were given a 2-day course with DHAPIP tablets each containing 40 mg of dihydroartemisinin and 320 mg of piperaquine phosphate, and the total dosage varied with the body weight."	( [Therapeutic efficacy and safety of compound dihydroartemisinin/piperaquine for uncomplicated Plasmodium falciparum infection in Laiza City of Myanmar bordering on China]. Deng, Y; Lasi, JH; Sun, XD; Sun, XY; Wang, H; Wang, J; Yang, YC; Zhang, ZX, 2011)	0.82
" The safety and efficacy of a monthly 2-day dosing regimen of dihydroartemisinin-piperaquine were evaluated in a two-arm, randomized, double-blind, placebo-controlled cohort study with 2:1 treatment allocation."	( Randomized, double-blind, placebo-controlled clinical trial of a two-day regimen of dihydroartemisinin-piperaquine for malaria prevention halted for concern over prolonged corrected QT interval. Auayporn, M; Buathong, N; Cantilena, L; Chann, S; Chour, CM; Haigney, M; Kaewkungwal, J; Kuntawunginn, W; Lanteri, C; Lon, C; Manning, J; Mitprasat, M; Phann, ST; Prom, S; Saunders, D; Se, Y; Sea, D; Siripokasupkul, R; So, M; Soh, E; Somethy, S; Spring, M; Sriwichai, S; Tang, D; Teja-Isavadharm, P; Timmermans, A; Vanachayangkul, P, 2014)	0.84
" However, the optimal chemoprevention drug and dosing strategy is unclear in areas of year-round transmission and resistance to many antimalarial drugs."	( Protective efficacy and safety of three antimalarial regimens for the prevention of malaria in young Ugandan children: a randomized controlled trial. Achan, J; Aweeka, FT; Bigira, V; Clark, TD; Dorsey, G; Havlir, DV; Huang, L; Kamya, MR; Kapisi, J; Kinara, S; Muhindo, MK; Mwangwa, F; Osterbauer, B; Rosenthal, PJ, 2014)	0.4
" This result relies on the assumption that compliance to treatment with DhP is higher than that with AL due to its relatively simple once-a-day dosage regimen."	( Cost-effectiveness of dihydroartemisinin-piperaquine compared with artemether-lumefantrine for treating uncomplicated malaria in children at a district hospital in Tanzania. Mori, AT; Ngalesoni, F; Norheim, OF; Robberstad, B, 2014)	0.67
" Simulations of monthly dosing, based on the final model and published pharmacokinetic data, suggested that the incidence of malaria infections over 1 year could be reduced by 70% with a recently suggested dosing regimen compared to the current manufacturer's recommendations for small children (8 to 12 kg)."	( Characterization of an in vivo concentration-effect relationship for piperaquine in malaria chemoprevention. Bergstrand, M; Karlsson, MO; Lwin, KM; Nosten, F; Tarning, J; White, NJ, 2014)	0.64
" Due to auto-induction metabolism, declining plasma concentrations after the repeated dosing have been reported for artemisinin (Qing-hao-su) and artemether."	( The effect of UGTs polymorphism on the auto-induction phase II metabolism-mediated pharmacokinetics of dihydroartemisinin in healthy Chinese subjects after oral administration of a fixed combination of dihydroartemisinin-piperaquine. Li, X; Liu, H; Xing, J; Yang, A; Zang, M; Zhao, L; Zhu, F, 2014)	0.59
" The metabolic capability could recover after a 12-h dosing interval, which suggested that the alternative common three-day regimen (once daily) for DHA-PQ could probably lead to higher bioavailability of DHA."	( The effect of UGTs polymorphism on the auto-induction phase II metabolism-mediated pharmacokinetics of dihydroartemisinin in healthy Chinese subjects after oral administration of a fixed combination of dihydroartemisinin-piperaquine. Li, X; Liu, H; Xing, J; Yang, A; Zang, M; Zhao, L; Zhu, F, 2014)	0.59
"Adherence to anti-malarial dosing schedules is essential to ensure effective treatment."	( Perceptions and utilization of the anti-malarials artemether-lumefantrine and dihydroartemisinin-piperaquine in young children in the Chikhwawa District of Malawi: a mixed methods study. Ewing, VL; Kapinda, A; Lalloo, DG; Pace, C; Richards, E; Terlouw, DJ; Tolhurst, R, 2015)	0.63
" While the sweet taste of dispersible AL may have reduced conflict between the child and caregiver, sub-optimal dosing due to medication loss remained a problem and overall adherence was greater among those receiving DHA-PPQ, which requires fewer doses."	( Perceptions and utilization of the anti-malarials artemether-lumefantrine and dihydroartemisinin-piperaquine in young children in the Chikhwawa District of Malawi: a mixed methods study. Ewing, VL; Kapinda, A; Lalloo, DG; Pace, C; Richards, E; Terlouw, DJ; Tolhurst, R, 2015)	0.63
" Current weight-based dosing does not adequately address physiological changes in early childhood."	( Population Pharmacokinetics of Piperaquine in Young Ugandan Children Treated With Dihydroartemisinin-Piperaquine for Uncomplicated Malaria. Arinaitwe, E; Aweeka, FT; Bigira, V; Creek, DJ; Kakuru, A; Lindegardh, N; McCormack, SA; Nosten, F; Parikh, S; Sambol, NC; Tappero, JW; Tarning, J; Wanzira, H; Yan, L, 2015)	0.7
" Subjects were randomized to four parallel dosing arms with five cohorts (2:2:2:2:1), receiving 75 mg KAE609 plus 320 mg PPQ, 25 mg KAE609 plus 1,280 mg PPQ, 25 mg KAE609 alone, 320 mg PPQ alone, or 1,280 mg PPQ alone."	( Open-label, single-dose, parallel-group study in healthy volunteers to determine the drug-drug interaction potential between KAE609 (cipargamin) and piperaquine. Griffin, P; Jain, JP; Kangas, M; Lefèvre, G; Lickliter, J; Machineni, S; Stein, DS, 2015)	0.62
" In particular, the malaria community may be missing the opportunity to dramatically increase ACT effectiveness through regimen changes, particularly through a switch to twice-daily regimens and/or increases in artemisinin dosing levels."	( How Robust Are Malaria Parasite Clearance Rates as Indicators of Drug Effectiveness and Resistance? Hastings, IM; Hodel, EM; Kay, K, 2015)	0.42
" Children were randomized at 6 months of age to no chemoprevention (n = 89) or monthly DHA/PQ (n = 87) and followed through 24 months of age, with pharmacokinetic sampling performed at variable times following monthly dosing of DHA/PQ."	( Variable piperaquine exposure significantly impacts protective efficacy of monthly dihydroartemisinin-piperaquine for the prevention of malaria in Ugandan children. Aweeka, F; Bigira, V; Dorsey, G; Huang, L; Jagannathan, P; Kakuru, MM; Kamya, MR; Kapisi, J; Savic, R; Sundell, K, 2015)	0.83
" Strategies to ensure good adherence to monthly dosing and optimize drug exposure are critical to maximize the efficacy of this promising malaria control strategy."	( Variable piperaquine exposure significantly impacts protective efficacy of monthly dihydroartemisinin-piperaquine for the prevention of malaria in Ugandan children. Aweeka, F; Bigira, V; Dorsey, G; Huang, L; Jagannathan, P; Kakuru, MM; Kamya, MR; Kapisi, J; Savic, R; Sundell, K, 2015)	0.83
" Candidate regimens that were tested included monthly administration of standard therapeutic doses, bimonthly dosing, and weekly dosing (with and without a loading dose)."	( Rethinking Dosing Regimen Selection of Piperaquine for Malaria Chemoprevention: A Simulation Study. Arinaitwe, E; Parikh, S; Sambol, NC; Tappero, JW, 2016)	0.7
" In contrast, weekly dosing of 320 mg (i."	( Rethinking Dosing Regimen Selection of Piperaquine for Malaria Chemoprevention: A Simulation Study. Arinaitwe, E; Parikh, S; Sambol, NC; Tappero, JW, 2016)	0.7
" This therapeutic failure with DP by under-dosing highlighted the importance of appropriate dosing guidelines and the need of research data (efficacy, pharmacokinetics and pharmacodynamics) in over-weight patient group."	( Failure of dihydroartemisinin plus piperaquine treatment of falciparum malaria by under-dosing in an overweight patient. Javelle, E; Madamet, M; Paleiron, N; Pradines, B; Roseau, JB; Simon, F; Vedy, S, 2016)	0.71
" This study explored alternative DHA-PQ adult dosing regimens compared to the monthly adult dosing regimen currently being studied in clinical trials."	( Prediction of Improved Antimalarial Chemoprevention with Weekly Dosing of Dihydroartemisinin-Piperaquine. Bergstrand, M; Karlsson, MO; Nosten, F; Permala, J; Tarning, J; White, NJ, 2017)	0.67
" This may soon change to recommending artemisinin-based combination therapies (standard duration of dosing = 3 days)."	( Animal Embryotoxicity Studies of Key Non-Artemisinin Antimalarials and Use in Women in the First Trimester. Clark, RL, 2017)	0.46
"5 mg can make dosing convenient in children."	( Assessment of Efficacy and Safety of Arterolane Maleate-Piperaquine Phosphate Dispersible Tablets in Comparison With Artemether-Lumefantrine Dispersible Tablets in Pediatric Patients With Acute Uncomplicated Plasmodium falciparum Malaria: A Phase 3, Rando Anvikar, AR; Behra, N; Das, RR; Gaye, O; Jalali, RK; Maheshwar, AV; Mishra, P; Mwapasa, V; Nasa, A; Roy, A; Sagara, I; Sharma, P; Sharma, SK; Thompson, R; Toure, OA; Tshefu, AK; Valecha, N, 2017)	0.7
"For HIV-infected pregnant women receiving efavirenz, low daily DHA-PQ dosing was predicted to improve protection against parasitemia and reduce risk of toxicity compared to monthly dosing."	( Predicting Optimal Dihydroartemisinin-Piperaquine Regimens to Prevent Malaria During Pregnancy for Human Immunodeficiency Virus-Infected Women Receiving Efavirenz. Aweeka, F; Dorsey, G; Havlir, D; Huang, L; Jagannathan, P; Kakuru, A; Kamya, M; Muhindo, M; Nakalembe, M; Natureeba, P; Rosenthal, PJ; Savic, RM; Vucicevic, K; Wallender, E, 2018)	0.75
" Determining associations between piperaquine (PQ) exposure, malaria risk, and adverse birth outcomes informs optimal dosing strategies."	( Intermittent Preventive Treatment for Malaria in Pregnancy: Optimization of Target Concentrations of Dihydroartemisinin-Piperaquine. Aweeka, FT; Clark, TD; Dorsey, G; Havlir, DV; Huang, L; Jagannathan, P; Kajubi, R; Kakuru, A; Kamya, M; Muhindo, MK; Mwebaza, N; Opira, B; Rosenthal, PJ; Savic, RM; Wallender, E; Were, M; Zhang, N, 2018)	0.97
" Simulations of new dosing scenarios were performed."	( Intermittent Preventive Treatment for Malaria in Pregnancy: Optimization of Target Concentrations of Dihydroartemisinin-Piperaquine. Aweeka, FT; Clark, TD; Dorsey, G; Havlir, DV; Huang, L; Jagannathan, P; Kajubi, R; Kakuru, A; Kamya, M; Muhindo, MK; Mwebaza, N; Opira, B; Rosenthal, PJ; Savic, RM; Wallender, E; Were, M; Zhang, N, 2018)	0.69
" Studies of the efficacy and safety of alternative DHA-PQ IPTp dosing strategies are warranted."	( Intermittent Preventive Treatment for Malaria in Pregnancy: Optimization of Target Concentrations of Dihydroartemisinin-Piperaquine. Aweeka, FT; Clark, TD; Dorsey, G; Havlir, DV; Huang, L; Jagannathan, P; Kajubi, R; Kakuru, A; Kamya, M; Muhindo, MK; Mwebaza, N; Opira, B; Rosenthal, PJ; Savic, RM; Wallender, E; Were, M; Zhang, N, 2018)	0.69
" All treatments were once-daily or twice-daily tablets or granules given orally and dosed by bodyweight over 3 days at the study centre."	( Pyronaridine-artesunate or dihydroartemisinin-piperaquine versus current first-line therapies for repeated treatment of uncomplicated malaria: a randomised, multicentre, open-label, longitudinal, controlled, phase 3b/4 trial. , 2018)	0.74
" Isolates exhibit a bimodal dose-response curve when exposed to PPQ, with the area under the curve quantifying their survival in vitro."	( Plasmepsin II-III copy number accounts for bimodal piperaquine resistance among Cambodian Plasmodium falciparum. Amaratunga, C; Ariey, F; Ashley, EA; Bopp, S; Dhorda, M; Dondorp, AM; Fairhurst, RM; Lim, P; Magistrado, P; Menard, D; Mukherjee, A; Schaffner, SF; Volkman, SK; White, NJ; Wirth, DF; Wong, W; Woodrow, CJ, 2018)	0.73
" We provide published data supporting the use of a higher dosage regimen of ivermectin in malaria and difficult-to-treat head lice, and announce an ongoing randomized clinical trial in severe scabies."	( High-dose ivermectin in malaria and other parasitic diseases: a new step in the development of a neglected drug. Bernigaud, C; Chosidow, O; Do-Pham, G, 2018)	0.48
"Nous soulignons l’absence de données probantes de haut niveau sur les études de dosage concernant l’utilisation de l’ivermectine par voie orale dans les maladies parasitaires sensibles."	( High-dose ivermectin in malaria and other parasitic diseases: a new step in the development of a neglected drug. Bernigaud, C; Chosidow, O; Do-Pham, G, 2018)	0.48
" Future studies are needed to better understand the biological mechanisms of in utero drug exposure on drug metabolism and how this may affect the dosing of antimalarial drugs for treatment and prevention during infancy."	( Dihydroartemisinin-piperaquine for intermittent preventive treatment of malaria during pregnancy and risk of malaria in early childhood: A randomized controlled trial. Aweeka, F; Beeson, J; Charlebois, ED; Clark, TD; Dorsey, G; Drakeley, C; Feeney, ME; Greenhouse, B; Havlir, DV; Jagannathan, P; Kakuru, A; Kamya, MR; Muhindo, MK; Nakalembe, M; Nankya, F; Natureeba, P; Okiring, J; Olwoch, P; Opira, B; Prahl, M; Reiling, L; Rodriguez-Barraquer, I; Ssewanyana, I; Tetteh, K; Wallender, E, 2018)	0.81
" falciparum to artemisinin, chloroquine and piperaquine by both a standard dose-response analysis and a piperaquine survival assay."	( Overexpression of plasmepsin II and plasmepsin III does not directly cause reduction in Plasmodium falciparum sensitivity to artesunate, chloroquine and piperaquine. Ansbro, MR; Chookajorn, T; Chotivanich, K; de Cozar, C; Gamo, FJ; Kochakarn, T; Kotanan, N; Kümpornsin, K; Lee, MCS; Loesbanluechai, D; Sanz, LM; White, NJ; Wilairat, P, 2019)	0.97
"Dihydroartemisinin (DHA)-piperaquine is being evaluated as intermittent preventive therapy for malaria, but dosing has not been optimized for children."	( Reduced Exposure to Piperaquine, Compared to Adults, in Young Children Receiving Dihydroartemisinin-Piperaquine as Malaria Chemoprevention. Aweeka, FT; Chamankhah, N; Dorsey, G; Huang, L; Jagannathan, P; Kajubi, R; Kamya, MR; Mwebaza, N; Orukan, F; Rosenthal, PJ; Wallender, E; Whalen, ME, 2019)	1.14
" However, the optimal dosing strategy is unclear and conflicting evidence exists regarding the risk of malaria after cessation of chemoprevention."	( Intermittent preventive treatment with dihydroartemisinin-piperaquine and risk of malaria following cessation in young Ugandan children: a double-blind, randomised, controlled trial. Charlebois, E; Clark, TD; Dorsey, G; Feeney, ME; Havlir, DV; Jagannathan, P; Kakuru, A; Kamya, MR; Muhindo, MK; Nalugo, N; Okiring, J; Olwoch, P; Opira, B; Ruel, T, 2019)	0.76
"Considering the low day 7 concentrations of piperaquine reported in the patients studied here, we suggest to adopt the recently recommended higher dose of DP in young children or a prolonged 5-day dosing in children living in malaria endemic areas who have suffered an initial episode of severe malaria in order to achieve adequate drug exposures for effective post-treatment prophylactic effects."	( Piperaquine concentration and malaria treatment outcomes in Ugandan children treated for severe malaria with intravenous Artesunate or quinine plus Dihydroartemisinin-Piperaquine. Blessborn, D; Byakika-Kibwika, P; Lamorde, M; Ssenyonga, R; Tarning, J, 2019)	2.22
" Nineteen percent of HCPs thought that dihydroartemisinin/piperaquine gave the most satisfactory patient treatment outcomes, while 80% HCPs thought that artemether/lumefantrine gave the least satisfactory patient treatment outcomes, possibly due to dosing schedule and pill burden."	( Healthcare professionals' perspective can guide post-marketing surveillance of artemisinin-based combination therapy in Uganda. D'Hoore, W; Kiguba, R; Kirabira, E; Manirakiza, L; Mukonzo, J; Nabirye, L; Ndagije, HB; Olsson, S; Speybroeck, N; Spinewine, A; Sserwanga, A, 2020)	0.8
" Participants in the intermittent preventive malaria treatment arm will receive dihydroartemisinin/piperaquine (DP) dosed by weight, 1 month apart, prior to the first immunisation, followed by monthly treatment thereafter."	( Effect of intermittent preventive treatment for malaria with dihydroartemisinin-piperaquine on immune responses to vaccines among rural Ugandan adolescents: randomised controlled trial protocol B for the ' Akello, F; Amongi, S; Amongin, R; Cose, S; Elliott, AM; Kabuubi, PN; Kiwanuka, S; Kiwudhu, F; Kizindo, R; Mutebe, A; Nakazibwe, E; Nassuuna, J; Natukunda, A; Nkurunungi, G; Nsubuga, D; Oduru, G; Onen, C; Sewankambo, M; Staedke, SG; Webb, E; Zirimenya, L, 2021)	1.06
" Additionally, these models are able to identify patient characteristics that cause alterations in the expected PK/PD profiles and through simulations can recommend changes to dosing which compensate for the differences."	( Malaria PK/PD and the Role Pharmacometrics Can Play in the Global Health Arena: Malaria Treatment Regimens for Vulnerable Populations. Hughes, E; Jagannathan, P; Mohamed Ali, A; Savic, RM; Wallender, E, 2021)	0.62
" Optimal DP dosing regimens will maximize efficacy and reduce toxicity and resistance selection."	( Identifying an optimal dihydroartemisinin-piperaquine dosing regimen for malaria prevention in young Ugandan children. Ali, AM; Aweeka, F; Dorsey, G; Duvalsaint, M; Huang, L; Hughes, E; Jagannathan, P; Kakuru, A; Kamya, MR; Legac, J; Muhindo, MK; Opira, B; Rosenthal, PJ; Savic, RM; Wallender, E; Whalen, M, 2021)	0.89
" Piperaquine prolongs the corrected QT interval (QTc), and it is possible that repeated monthly dosing could lead to progressive QTc prolongation."	( Piperaquine-Induced QTc Prolongation Decreases With Repeated Monthly Dihydroartemisinin-Piperaquine Dosing in Pregnant Ugandan Women. Aweeka, F; Clark, TD; Dorsey, G; Hughes, E; Jagannathan, P; Kajubi, R; Kakuru, A; Kamya, MR; Ochieng, T; Rosenthal, PJ; Savic, RM; Wallender, E, 2022)	3.07
"Repeated DHA-PQ dosing did not result in increased risk of QTc prolongation and the postdose QTc intervals progressively decreased."	( Piperaquine-Induced QTc Prolongation Decreases With Repeated Monthly Dihydroartemisinin-Piperaquine Dosing in Pregnant Ugandan Women. Aweeka, F; Clark, TD; Dorsey, G; Hughes, E; Jagannathan, P; Kajubi, R; Kakuru, A; Kamya, MR; Ochieng, T; Rosenthal, PJ; Savic, RM; Wallender, E, 2022)	2.16
" Drug sensitivity against a panel of antimalarials, the ring-stage survival assay (RSA), the PPQ survival assay (PSA), and bimodal dose-response curves were used to evaluate antimalarial susceptibility."	( A single point mutation in the Plasmodium falciparum 3'-5' exonuclease does not alter piperaquine susceptibility. Boonyalai, N; Griesenbeck, JS; Kirativanich, K; Praditpol, C; Thamnurak, C; Vesely, BA; Waters, NC; Wojnarski, M, 2022)	0.94
" Participants were randomly assigned (1:1:1:1) to standard treatment with dihydroartemisinin-piperaquine, or dihydroartemisinin-piperaquine plus a single dose of tafenoquine (in solution) at a final dosage of 0·42 mg/kg, 0·83 mg/kg, or 1·66 mg/kg."	( Single low-dose tafenoquine combined with dihydroartemisinin-piperaquine to reduce Plasmodium falciparum transmission in Ouelessebougou, Mali: a phase 2, single-blind, randomised clinical trial. Attaher, O; Bousema, T; Bradley, J; Diallo, M; Dicko, A; Dicko, OM; Drakeley, C; Issiaka, D; Keita, S; Lanke, K; Maguiraga, SO; Mahamar, A; McCall, MBB; Niambele, SM; Sacko, A; Samake, S; Sanogo, K; Sinaba, Y; Smit, MJ; Stone, W; Ter Heine, R; Traore, SF, 2022)	1.18
" We will also assess toxicity from cumulative DP dosing and the development of resistance."	( Dihydroartemisinin-piperaquine or sulphadoxine-pyrimethamine for the chemoprevention of malaria in children with sickle cell anaemia in eastern and southern Africa (CHEMCHA): a protocol for a multi-centre, two-arm, double-blind, randomised, placebo-contro Akun, P; Galileya, LT; Idro, R; Kalibbala, D; Nambatya, W; Nkosi-Gondwe, T; Opoka, R; Phiri, K; Robberstad, B; Rujumba, J; Ssenkusu, J; TerKuile, F, 2023)	1.24

Role	Description
antimalarial	A drug used in the treatment of malaria. Antimalarials are usually classified on the basis of their action against Plasmodia at different stages in their life cycle in the human.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
N-arylpiperazine
organochlorine compound	An organochlorine compound is a compound containing at least one carbon-chlorine bond.
aminoquinoline	Any member of the class of quinolines in which the quinoline skeleton is substituted by one or more amino or substituted-amino groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Cytochrome P450 3A4	Homo sapiens (human)	Ki	0.0900	0.0001	1.4162	9.9000	AID1579733
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
lipid hydroxylation	Cytochrome P450 3A4	Homo sapiens (human)
lipid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
steroid catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
xenobiotic metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
steroid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
cholesterol metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
androgen metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
estrogen metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
alkaloid catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
monoterpenoid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
calcitriol biosynthetic process from calciol	Cytochrome P450 3A4	Homo sapiens (human)
xenobiotic catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
retinol metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
retinoic acid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
long-chain fatty acid biosynthetic process	Cytochrome P450 3A4	Homo sapiens (human)
aflatoxin metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
oxidative demethylation	Cytochrome P450 3A4	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
monooxygenase activity	Cytochrome P450 3A4	Homo sapiens (human)
steroid binding	Cytochrome P450 3A4	Homo sapiens (human)
iron ion binding	Cytochrome P450 3A4	Homo sapiens (human)
protein binding	Cytochrome P450 3A4	Homo sapiens (human)
steroid hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
retinoic acid 4-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
oxidoreductase activity	Cytochrome P450 3A4	Homo sapiens (human)
oxygen binding	Cytochrome P450 3A4	Homo sapiens (human)
enzyme binding	Cytochrome P450 3A4	Homo sapiens (human)
heme binding	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D3 25-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
caffeine oxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
quinine 3-monooxygenase activity	Cytochrome P450 3A4	Homo sapiens (human)
testosterone 6-beta-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
1-alpha,25-dihydroxyvitamin D3 23-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
anandamide 8,9 epoxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
anandamide 11,12 epoxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
anandamide 14,15 epoxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
aromatase activity	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D 24-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
estrogen 16-alpha-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
estrogen 2-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
1,8-cineole 2-exo-monooxygenase activity	Cytochrome P450 3A4	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
cytoplasm	Cytochrome P450 3A4	Homo sapiens (human)
endoplasmic reticulum membrane	Cytochrome P450 3A4	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 3A4	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (277)

Assay ID	Title	Year	Journal	Article
AID1347092	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347095	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347106	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347101	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347411	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347098	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347089	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID1347103	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID748935	Antimalarial activity against multidrug-resistant Plasmodium falciparum W2 infected in ip dosed mouse assessed as reduction in parasitemia administered on day 64 post-infection	2013	Bioorganic & medicinal chemistry letters, May-15, Volume: 23, Issue:10	Recent advances in malaria drug discovery.
AID561061	Half life in Plasmodium falciparum-infected patient at 320 mg/kg, po	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Pharmacokinetics and ex vivo pharmacodynamic antimalarial activity of dihydroartemisinin-piperaquine in patients with uncomplicated falciparum malaria in Vietnam.
AID547315	Antimalarial activity against Plasmodium falciparum	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	In vitro activities of quinine and other antimalarials and pfnhe polymorphisms in Plasmodium isolates from Kenya.
AID561064	Antiplasmodial activity against Plasmodium falciparum D6	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Pharmacokinetics and ex vivo pharmacodynamic antimalarial activity of dihydroartemisinin-piperaquine in patients with uncomplicated falciparum malaria in Vietnam.
AID428119	Terminal half life in human children	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Pharmacokinetics and pharmacodynamics of piperaquine in a murine malaria model.
AID428115	Antiparasitic activity as parasitaemia against Plasmodium berghei ANKA infected Swiss mice (Mus musculus) at 30 mg/kg intraperitoneal dose 64 hrs post infection	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Pharmacokinetics and pharmacodynamics of piperaquine in a murine malaria model.
AID519196	Antimicrobial activity against Plasmodium vivax at the ring stage measured after 30 hrs by microscopy	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Determinants of in vitro drug susceptibility testing of Plasmodium vivax.
AID563112	Antimalarial activity against Plasmodium falciparum 3D7 harboring Ppcrt I371R mutant gene and Pfnhe-1 ms4760 microsatellite mutant assessed as incorporation of [3]H hypoxanthine after 48 hrs by scintillation counter	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID545363	Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum C3 harboring Dd2 pfcrt allele infected in erythrocytes assessed as [3H]hypoxanthine incorporation	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Role of known molecular markers of resistance in the antimalarial potency of piperaquine and dihydroartemisinin in vitro.
AID521748	Terminal half-life in healthy human at 25 mg/kg, po after 29 days	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Population pharmacokinetics of piperaquine after two different treatment regimens with dihydroartemisinin-piperaquine in patients with Plasmodium falciparum malaria in Thailand.
AID521760	Apparent oral clearance in human with uncomplicated malaria at 35 mg/kg, perorally after 35 days	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Population pharmacokinetics of piperaquine after two different treatment regimens with dihydroartemisinin-piperaquine in patients with Plasmodium falciparum malaria in Thailand.
AID545381	Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum TM6 infected in erythrocytes assessed as [3H]hypoxanthine incorporation in presence of dihydroartimisinin	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Role of known molecular markers of resistance in the antimalarial potency of piperaquine and dihydroartemisinin in vitro.
AID586608	Antimalarial activity against trophozoites stage of Plasmodium falciparum assessed as parasites growth inhibition using giemsa staining after 24 to 56 hrs by microscopic analysis in presence of 10% human serum	2011	Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3	Ex vivo activity of histone deacetylase inhibitors against multidrug-resistant clinical isolates of Plasmodium falciparum and P. vivax.
AID423738	Apparent clearance with respect to bioavailability in human after fasting using non-compartmental analysis	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Pharmacokinetics and efficacy of piperaquine and chloroquine in Melanesian children with uncomplicated malaria.
AID521745	Plasma concentration in human with uncomplicated malaria at 31 mg/kg, perorally at day 28	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Population pharmacokinetics of piperaquine after two different treatment regimens with dihydroartemisinin-piperaquine in patients with Plasmodium falciparum malaria in Thailand.
AID576573	Antimalarial activity against Plasmodium vivax at the ring stage infected in human erythrocytes assessed as growth inhibition by microscopic analysis using giemsa staining	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	In vitro activity of pyronaridine against multidrug-resistant Plasmodium falciparum and Plasmodium vivax.
AID1638537	Antimalarial activity against chloroquine-resistant Plasmodium falciparum K1 infected in human RBC assessed as reduction in parasite growth after 35 to 56 hrs by nucleic acid staining based flow cytometry	2019	Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5	3,3'-Disubstituted 5,5'-Bi(1,2,4-triazine) Derivatives with Potent in Vitro and in Vivo Antimalarial Activity.
AID423743	Volume of distribution at steady state with respect to bioavailability in Vietnamese human	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Pharmacokinetics and efficacy of piperaquine and chloroquine in Melanesian children with uncomplicated malaria.
AID423741	Absorption half life in Vietnamese human by three-compartmental analysis	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Pharmacokinetics and efficacy of piperaquine and chloroquine in Melanesian children with uncomplicated malaria.
AID564300	Antimalarial activity against Plasmodium falciparum IMT 10500 assessed as inhibition of [3H] incorporation after 48 hrs by scintillation counter	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID545384	Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum C2 infected in erythrocytes assessed as [3H]hypoxanthine incorporation in presence of dihydroartimisinin	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Role of known molecular markers of resistance in the antimalarial potency of piperaquine and dihydroartemisinin in vitro.
AID323678	Reduction of [3H]chloroquine uptake in chloroquine-sensitive Plasmodium falciparum FC27 infected erythrocytes after 90 min	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Effects of piperaquine, chloroquine, and amodiaquine on drug uptake and of these in combination with dihydroartemisinin against drug-sensitive and -resistant Plasmodium falciparum strains.
AID564295	Antimalarial activity against Plasmodium falciparum IMT 31 assessed as inhibition of [3H] incorporation after 48 hrs by scintillation counter	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID1649452	Ratio of AUC (0 to infinity) in ICR mouse liver to plasma at 80 mg/kg, po administered as single dose	2020	Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11	Lead Optimization of Second-Generation Acridones as Broad-Spectrum Antimalarials.
AID563102	Antimalarial activity against Plasmodium falciparum IMT 9881 harboring Ppcrt I371R mutant gene assessed as incorporation of [3]H hypoxanthine after 48 hrs by scintillation counter	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID323683	Reduction of [3H]dihydroartemisinin uptake in chloroquine-resistant Plasmodium falciparum K1 infected erythrocytes after 90 min	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Effects of piperaquine, chloroquine, and amodiaquine on drug uptake and of these in combination with dihydroartemisinin against drug-sensitive and -resistant Plasmodium falciparum strains.
AID323682	Reduction of [3H]dihydroartemisinin uptake in chloroquine-sensitive Plasmodium falciparum FC27 infected erythrocytes after 90 min	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Effects of piperaquine, chloroquine, and amodiaquine on drug uptake and of these in combination with dihydroartemisinin against drug-sensitive and -resistant Plasmodium falciparum strains.
AID323684	Reduction of [3H]dihydroartemisinin uptake in chloroquine-sensitive Plasmodium falciparum 3D7 infected erythrocytes after 90 min	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Effects of piperaquine, chloroquine, and amodiaquine on drug uptake and of these in combination with dihydroartemisinin against drug-sensitive and -resistant Plasmodium falciparum strains.
AID423714	Tlag in Paua New Guinean children with uncomplicated malaria at 20 mg/kg daily for 3 days	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Pharmacokinetics and efficacy of piperaquine and chloroquine in Melanesian children with uncomplicated malaria.
AID423713	Distribution half life in Paua New Guinean children with uncomplicated malaria at 20 mg/kg daily for 3 days	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Pharmacokinetics and efficacy of piperaquine and chloroquine in Melanesian children with uncomplicated malaria.
AID564316	Antimalarial activity against Plasmodium falciparum IMT A4 harboring Ppcrt M74I, N75E, K76T, A220H, Q271E, N326S and I356T mutant gene, Pmdr1 Y184F, N1042D, D1246Y mutant gene assessed as incorporation of [3]H hypoxanthine after 48 hrs by scintillation co	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID1593289	Antimalarial activity against drug-resistant Plasmodium falciparum Dd2 harboring M133I mutant infected in human erythrocytes after 72 hrs by SYBR green 1-based fluorescence assay	2019	Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7	Discovery and Structural Optimization of Acridones as Broad-Spectrum Antimalarials.
AID423712	Elimination half life in Paua New Guinean children with uncomplicated malaria at 20 mg/kg daily for 3 days	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Pharmacokinetics and efficacy of piperaquine and chloroquine in Melanesian children with uncomplicated malaria.
AID545389	Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum 7G8 harboring parental pfcrt allele infected in erythrocytes assessed as [3H]hypoxanthine incorporation in presence of dihydroartimisinin	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Role of known molecular markers of resistance in the antimalarial potency of piperaquine and dihydroartemisinin in vitro.
AID564302	Antimalarial activity against Plasmodium falciparum IMT K14 assessed as inhibition of [3H] incorporation after 48 hrs by scintillation counter	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID564313	Antimalarial activity against Plasmodium falciparum 106/1 harboring Ppcrt M74I, N75E, K76T, A220S, Q271E, N326S and I356T mutant gene, Pmdr1 N86Y mutant gene and Pfmrp H191Y and S437A mutant gene assessed as incorporation of [3]H hypoxanthine after 48 hrs	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID521762	Terminal half-life in human with uncomplicated malaria at 31 mg/kg, perorally	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Population pharmacokinetics of piperaquine after two different treatment regimens with dihydroartemisinin-piperaquine in patients with Plasmodium falciparum malaria in Thailand.
AID521764	Apparent steady-state volume of distribution with respect to bioavailability in human with uncomplicated malaria at 31 mg/kg, perorally	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Population pharmacokinetics of piperaquine after two different treatment regimens with dihydroartemisinin-piperaquine in patients with Plasmodium falciparum malaria in Thailand.
AID428111	Plasma concentration in Swiss mice (Mus musculus) infected with Plasmodium berghei ANKA at 90 mg/kg, intraperitoneally administered 64 hrs after infection measured after 30 days	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Pharmacokinetics and pharmacodynamics of piperaquine in a murine malaria model.
AID521746	Plasma concentration in human with uncomplicated malaria at 31 mg/kg, perorally four-dose treatment regimen measured at day 20	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Population pharmacokinetics of piperaquine after two different treatment regimens with dihydroartemisinin-piperaquine in patients with Plasmodium falciparum malaria in Thailand.
AID521755	Apparent steady-state volume of distribution with respect to bioavailability in human with uncomplicated malaria at 35 mg/kg, perorally after 35 days	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Population pharmacokinetics of piperaquine after two different treatment regimens with dihydroartemisinin-piperaquine in patients with Plasmodium falciparum malaria in Thailand.
AID564231	Antiplasmodial activity against multidrug-sensitive Plasmodium falciparum 3D7 after 18 hrs by [3H]hypoxanthine incorporation assay	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	In vitro activities of piperaquine, lumefantrine, and dihydroartemisinin in Kenyan Plasmodium falciparum isolates and polymorphisms in pfcrt and pfmdr1.
AID561065	Antiplasmodial activity against Plasmodium falciparum K1 isolated from po dosed patient with malaria after 7 days	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Pharmacokinetics and ex vivo pharmacodynamic antimalarial activity of dihydroartemisinin-piperaquine in patients with uncomplicated falciparum malaria in Vietnam.
AID428093	Apparent clearance in Swiss mice (Mus musculus) infected with Plasmodium berghei ANKA at 90 mg/kg, intraperitoneally administered 64 hrs after infection	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Pharmacokinetics and pharmacodynamics of piperaquine in a murine malaria model.
AID521770	AUC (3 to 20 days) in children with uncomplicated malaria at 31 mg/kg, perorally	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Population pharmacokinetics of piperaquine after two different treatment regimens with dihydroartemisinin-piperaquine in patients with Plasmodium falciparum malaria in Thailand.
AID563108	Antimalarial activity against Plasmodium falciparum IMT K2 harboring Ppcrt M74I, N75E, K76T, A220S, Q271E, N326S mutant gene, Pmdr1 S1034C, N1042D mutant gene and Pfmrp H191Y and S437A mutant gene assessed as incorporation of [3]H hypoxanthine after 48 hr	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID1688325	Antimalarial activity against Plasmodium falciparum infected in human erythrocytes assessed as inhibition of [G-3H]hypoxanthine uptake incubated for 42 hrs by liquid scintillation spectrometry	2020	European journal of medicinal chemistry, Feb-15, Volume: 188	Current progress in antimalarial pharmacotherapy and multi-target drug discovery.
AID423716	Apparent clearance with respect to bioavailability in Paua New Guinean children with uncomplicated malaria at 20 mg/kg daily for 3 days	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Pharmacokinetics and efficacy of piperaquine and chloroquine in Melanesian children with uncomplicated malaria.
AID564293	Antimalarial activity against Plasmodium falciparum IMT Guy assessed as inhibition of [3H] incorporation after 48 hrs by scintillation counter	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID564298	Antimalarial activity against Plasmodium falciparum IMT 10336 assessed as inhibition of [3H] incorporation after 48 hrs by scintillation counter	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID564307	Antimalarial activity against Plasmodium falciparum W2 harboring Ppcrt M74I, N75E, K76T, A220S, Q271E, N326S and I356T mutant gene, Pmdr1 N86Y mutant gene and Pfmrp H191Y and S437A mutant gene assessed as incorporation of [3]H hypoxanthine after 48 hrs by	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID423732	Volume of distribution at steady state with respect to bioavailability in Cambodian children with malaria	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Pharmacokinetics and efficacy of piperaquine and chloroquine in Melanesian children with uncomplicated malaria.
AID423731	Elimination half life in Cambodian children with malaria	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Pharmacokinetics and efficacy of piperaquine and chloroquine in Melanesian children with uncomplicated malaria.
AID428121	Antiparasitic activity as survival at day 30 against Plasmodium berghei ANKA infected Swiss mice (Mus musculus) at 10 mg/kg intraperitoneal dose 64 hrs post infection	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Pharmacokinetics and pharmacodynamics of piperaquine in a murine malaria model.
AID586610	Antimalarial activity against Plasmodium vivax assessed as parasites growth inhibition using giemsa staining after 24 to 56 hrs by microscopic analysis in presence of 20% human serum	2011	Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3	Ex vivo activity of histone deacetylase inhibitors against multidrug-resistant clinical isolates of Plasmodium falciparum and P. vivax.
AID496886	Antimalarial activity against chloroquine-resistant Plasmodium falciparum	2010	European journal of medicinal chemistry, Aug, Volume: 45, Issue:8	Quinolines and structurally related heterocycles as antimalarials.
AID563103	Antimalarial activity against Plasmodium falciparum IMT 10336 harboring Pfcrt Q271E mutant gene and Ppcrt I371R mutant gene assessed as incorporation of [3]H hypoxanthine after 48 hrs by scintillation counter	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID562110	Antiplasmodial activity against multidrug-resistant Plasmodium falciparum VS/1 by [3H]hypoxanthine incorporation assay	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	In vitro chemosensitization of Plasmodium falciparum to antimalarials by verapamil and probenecid.
AID545361	Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum 3D7 infected in erythrocytes assessed as [3H]hypoxanthine incorporation	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Role of known molecular markers of resistance in the antimalarial potency of piperaquine and dihydroartemisinin in vitro.
AID545390	Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum 7G8 harboring D10 pfcrt allele infected in erythrocytes assessed as [3H]hypoxanthine incorporation in presence of dihydroartimisinin	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Role of known molecular markers of resistance in the antimalarial potency of piperaquine and dihydroartemisinin in vitro.
AID323672	Antimalarial activity against chloroquine-sensitive Plasmodium falciparum 3D7	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Effects of piperaquine, chloroquine, and amodiaquine on drug uptake and of these in combination with dihydroartemisinin against drug-sensitive and -resistant Plasmodium falciparum strains.
AID423717	AUC (0 to 42 days) in Paua New Guinean children with uncomplicated malaria at 20 mg/kg daily for 3 days	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Pharmacokinetics and efficacy of piperaquine and chloroquine in Melanesian children with uncomplicated malaria.
AID545388	Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum D10 harboring 7G8 pfcrt allele infected in erythrocytes assessed as [3H]hypoxanthine incorporation in presence of dihydroartimisinin	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Role of known molecular markers of resistance in the antimalarial potency of piperaquine and dihydroartemisinin in vitro.
AID545391	Selectivity ratio of IC50 for chloroquine-resistant Plasmodium falciparum C3 harboring Dd2 pfcrt allele to IC50 for chloroquine-sensitive Plasmodium falciparum C2	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Role of known molecular markers of resistance in the antimalarial potency of piperaquine and dihydroartemisinin in vitro.
AID323674	Antimalarial activity against chloroquine-resistant Plasmodium falciparum K1	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Effects of piperaquine, chloroquine, and amodiaquine on drug uptake and of these in combination with dihydroartemisinin against drug-sensitive and -resistant Plasmodium falciparum strains.
AID521769	Apparent oral clearance in human with uncomplicated malaria at 31 mg/kg, perorally	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Population pharmacokinetics of piperaquine after two different treatment regimens with dihydroartemisinin-piperaquine in patients with Plasmodium falciparum malaria in Thailand.
AID576574	Antimalarial activity against Plasmodium vivax trophozoites infected in human erythrocytes assessed as growth inhibition by microscopic analysis using giemsa staining	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	In vitro activity of pyronaridine against multidrug-resistant Plasmodium falciparum and Plasmodium vivax.
AID576571	Antimalarial activity against Plasmodium falciparum at the ring stage infected in human erythrocytes assessed as growth inhibition by microscopic analysis using giemsa staining	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	In vitro activity of pyronaridine against multidrug-resistant Plasmodium falciparum and Plasmodium vivax.
AID423739	Apparent clearance with respect to bioavailability in human after fat meal using non-compartmental analysis	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Pharmacokinetics and efficacy of piperaquine and chloroquine in Melanesian children with uncomplicated malaria.
AID564314	Antimalarial activity against Plasmodium falciparum IMT Bres harboring Ppcrt M74I, N75E, K76T, A220S, Q271E, N326S and I356T mutant gene, Pmdr1 N86Y mutant gene and Pfmrp H191Y and S437A mutant gene assessed as incorporation of [3]H hypoxanthine after 48	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID1593296	Inhibition of Plasmodium falciparum cytochrome b-c1	2019	Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7	Discovery and Structural Optimization of Acridones as Broad-Spectrum Antimalarials.
AID561052	Cmax in Plasmodium falciparum-infected patient at 320 mg/kg, po	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Pharmacokinetics and ex vivo pharmacodynamic antimalarial activity of dihydroartemisinin-piperaquine in patients with uncomplicated falciparum malaria in Vietnam.
AID564296	Antimalarial activity against Plasmodium falciparum IMT 8425 assessed as inhibition of [3H] incorporation after 48 hrs by scintillation counter	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID521768	AUC (3 to 20 days) in human adult with uncomplicated malaria at 31 mg/kg, perorally	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Population pharmacokinetics of piperaquine after two different treatment regimens with dihydroartemisinin-piperaquine in patients with Plasmodium falciparum malaria in Thailand.
AID428090	Terminal half life in healthy Swiss mouse at 90 mg/kg, ip by two compartment model assay	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Pharmacokinetics and pharmacodynamics of piperaquine in a murine malaria model.
AID428089	Initial half life in healthy Swiss mouse at 90 mg/kg, ip by two compartment model assay	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Pharmacokinetics and pharmacodynamics of piperaquine in a murine malaria model.
AID1579733	Inhibition of CYP3A4 (unknown origin)	2019	Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23	The Development Process for Discovery and Clinical Advancement of Modern Antimalarials.
AID576576	Antimalarial activity against Plasmodium vivax infected in human erythrocytes assessed as growth inhibition by microscopic analysis using giemsa staining	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	In vitro activity of pyronaridine against multidrug-resistant Plasmodium falciparum and Plasmodium vivax.
AID1593287	Antimalarial activity against drug-resistant Plasmodium falciparum Dd2 harboring V259L mutant infected in human erythrocytes after 72 hrs by SYBR green 1-based fluorescence assay	2019	Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7	Discovery and Structural Optimization of Acridones as Broad-Spectrum Antimalarials.
AID555962	Antimalarial activity against chloroquine-resistant Plasmodium vivax by Giemsa staining	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vivo and in vitro efficacy of amodiaquine monotherapy for treatment of infection by chloroquine-resistant Plasmodium vivax.
AID428122	Antimalarial activity against chloroquine-resistant Plasmodium falciparum by Peters 4 day test	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Pharmacokinetics and pharmacodynamics of piperaquine in a murine malaria model.
AID1579735	Cardiotoxicity in human assessed as effect on QT parameters at 1280 mg	2019	Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23	The Development Process for Discovery and Clinical Advancement of Modern Antimalarials.
AID519198	Antimicrobial activity against Plasmodium vivax at the ring stage measured within 30 hrs by microscopy	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Determinants of in vitro drug susceptibility testing of Plasmodium vivax.
AID561071	Antiplasmodial activity against Plasmodium falciparum D6 isolated from patient with malaria at 25 ng/ml after 28 days	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Pharmacokinetics and ex vivo pharmacodynamic antimalarial activity of dihydroartemisinin-piperaquine in patients with uncomplicated falciparum malaria in Vietnam.
AID519197	Antimicrobial activity against Plasmodium vivax trophozoites measured within 30 hrs by microscopy	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Determinants of in vitro drug susceptibility testing of Plasmodium vivax.
AID748940	Half life in human	2013	Bioorganic & medicinal chemistry letters, May-15, Volume: 23, Issue:10	Recent advances in malaria drug discovery.
AID586613	Antimalarial activity against chloroquine-resistant Plasmodium falciparum K1 assessed as inhibition of [3H]hypoxanthine incorporation	2011	Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3	Ex vivo activity of histone deacetylase inhibitors against multidrug-resistant clinical isolates of Plasmodium falciparum and P. vivax.
AID772515	Antimalarial activity against gametocytic stage of Plasmodium berghei infected in blood assessed as inhibition of ookinete formation at 10 uM after 24 hrs by Giemsa staining-based microscopic analysis relative to control	2013	Journal of medicinal chemistry, Oct-24, Volume: 56, Issue:20	Using genetic methods to define the targets of compounds with antimalarial activity.
AID428087	Apparent clearance in healthy Swiss mouse at 90 mg/kg, ip	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Pharmacokinetics and pharmacodynamics of piperaquine in a murine malaria model.
AID545366	Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum D10 harboring 7G8 pfcrt allele infected in erythrocytes assessed as [3H]hypoxanthine incorporation	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Role of known molecular markers of resistance in the antimalarial potency of piperaquine and dihydroartemisinin in vitro.
AID545368	Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum 7G8 harboring D10 pfcrt allele infected in erythrocytes assessed as [3H]hypoxanthine incorporation	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Role of known molecular markers of resistance in the antimalarial potency of piperaquine and dihydroartemisinin in vitro.
AID428094	Apparent volume of distribution in Swiss mice (Mus musculus) infected with Plasmodium berghei ANKA at 90 mg/kg, intraperitoneally administered 64 hrs after infection	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Pharmacokinetics and pharmacodynamics of piperaquine in a murine malaria model.
AID545360	Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum 7G8 infected in erythrocytes assessed as [3H]hypoxanthine incorporation	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Role of known molecular markers of resistance in the antimalarial potency of piperaquine and dihydroartemisinin in vitro.
AID564308	Antimalarial activity against Plasmodium falciparum D6 harboring Ppcrt I371R mutant gene assessed as incorporation of [3]H hypoxanthine after 48 hrs by scintillation counter	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID564285	Antimalarial activity against Plasmodium falciparum W2 assessed as inhibition of [3H] incorporation after 48 hrs by scintillation counter	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID511256	Antimicrobial activity against Plasmodium falciparum harboring mdr1 N86Y/D1246Y/Y184F mutant gene by ELISA	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	In vitro sensitivities of Plasmodium falciparum to different antimalarial drugs in Uganda.
AID423718	AUC (0 to infinity) in Paua New Guinean children with uncomplicated malaria at 20 mg/kg daily for 3 days	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Pharmacokinetics and efficacy of piperaquine and chloroquine in Melanesian children with uncomplicated malaria.
AID545365	Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum D10 infected in erythrocytes assessed as [3H]hypoxanthine incorporation	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Role of known molecular markers of resistance in the antimalarial potency of piperaquine and dihydroartemisinin in vitro.
AID428123	Toxicity in mouse	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Pharmacokinetics and pharmacodynamics of piperaquine in a murine malaria model.
AID151200	In vitro activity against Plasmodium falciparum D6	1992	Journal of medicinal chemistry, May-29, Volume: 35, Issue:11	Bisquinolines. 1. N,N-bis(7-chloroquinolin-4-yl)alkanediamines with potential against chloroquine-resistant malaria.
AID586606	Antimalarial activity against trophozoites stage of Plasmodium vivax assessed as parasites growth inhibition using giemsa staining after 24 to 56 hrs by microscopic analysis in presence of 20% human serum	2011	Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3	Ex vivo activity of histone deacetylase inhibitors against multidrug-resistant clinical isolates of Plasmodium falciparum and P. vivax.
AID521763	Apparent oral clearance in human with uncomplicated malaria at 31 mg/kg, perorally after 63 days	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Population pharmacokinetics of piperaquine after two different treatment regimens with dihydroartemisinin-piperaquine in patients with Plasmodium falciparum malaria in Thailand.
AID521771	AUC (0 to 60 days) in children with uncomplicated malaria at 31 mg/kg, perorally	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Population pharmacokinetics of piperaquine after two different treatment regimens with dihydroartemisinin-piperaquine in patients with Plasmodium falciparum malaria in Thailand.
AID428086	AUC in healthy Swiss mouse at 90 mg/kg, ip	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Pharmacokinetics and pharmacodynamics of piperaquine in a murine malaria model.
AID423737	Volume of distribution at steady state with respect to bioavailability in human after fat meal using non-compartmental analysis	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Pharmacokinetics and efficacy of piperaquine and chloroquine in Melanesian children with uncomplicated malaria.
AID561070	Antiplasmodial activity against Plasmodium falciparum D6 isolated from po dosed patient with malaria after 7 days	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Pharmacokinetics and ex vivo pharmacodynamic antimalarial activity of dihydroartemisinin-piperaquine in patients with uncomplicated falciparum malaria in Vietnam.
AID561072	Antiplasmodial activity against Plasmodium falciparum K1 isolated from patient with malaria at 25 ng/ml after 28 days	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Pharmacokinetics and ex vivo pharmacodynamic antimalarial activity of dihydroartemisinin-piperaquine in patients with uncomplicated falciparum malaria in Vietnam.
AID1638536	Antimalarial activity against chloroquine-sensitive Plasmodium falciparum FC27 infected in human RBC assessed as reduction in parasite growth after 35 to 56 hrs by nucleic acid staining based flow cytometry	2019	Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5	3,3'-Disubstituted 5,5'-Bi(1,2,4-triazine) Derivatives with Potent in Vitro and in Vivo Antimalarial Activity.
AID561073	Plasma concentration in Plasmodium falciparum-infected patient at 320 mg/kg, po after 28 days	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Pharmacokinetics and ex vivo pharmacodynamic antimalarial activity of dihydroartemisinin-piperaquine in patients with uncomplicated falciparum malaria in Vietnam.
AID1638539	Antimalarial activity against multidrug-resistant Plasmodium vivax clinical isolates assessed as reduction in parasite growth after 35 to 56 hrs by nucleic acid staining based flow cytometry	2019	Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5	3,3'-Disubstituted 5,5'-Bi(1,2,4-triazine) Derivatives with Potent in Vitro and in Vivo Antimalarial Activity.
AID521766	Apparent intercompartmental clearance with respect to bioavailability in human with uncomplicated malaria at 31 mg/kg, perorally	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Population pharmacokinetics of piperaquine after two different treatment regimens with dihydroartemisinin-piperaquine in patients with Plasmodium falciparum malaria in Thailand.
AID428118	Terminal half life in adult human	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Pharmacokinetics and pharmacodynamics of piperaquine in a murine malaria model.
AID1593253	Antimalarial activity against multidrug-resistant Plasmodium falciparum Dd2 infected in human erythrocytes by SYBR green 1-based fluorescence assay	2019	Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7	Discovery and Structural Optimization of Acridones as Broad-Spectrum Antimalarials.
AID521776	Apparent oral clearance in high-fat fed healthy human at 4.2 mg/kg, po after 42 days	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Population pharmacokinetics of piperaquine after two different treatment regimens with dihydroartemisinin-piperaquine in patients with Plasmodium falciparum malaria in Thailand.
AID563111	Antimalarial activity against Plasmodium falciparum IMT Vol harboring Ppcrt M74I, N75E, K76T, A220S, Q271E, N326S mutant gene, Pmdr1 N86Y mutant gene and Pfmrp H191Y and S437A mutant gene assessed as incorporation of [3]H hypoxanthine after 48 hrs by scin	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID748942	Antiplasmodial activity against multidrug-resistant Plasmodium falciparum W2 infected in human erythrocytes after 72 hrs by ELISA	2013	Bioorganic & medicinal chemistry letters, May-15, Volume: 23, Issue:10	Recent advances in malaria drug discovery.
AID521744	AUC (0 to 63 days) in human with uncomplicated malaria at 31 mg/kg, perorally once daily for 3 days	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Population pharmacokinetics of piperaquine after two different treatment regimens with dihydroartemisinin-piperaquine in patients with Plasmodium falciparum malaria in Thailand.
AID1593288	Antimalarial activity against drug-resistant Plasmodium falciparum Dd2 harboring M133I/A138T double mutant infected in human erythrocytes after 72 hrs by SYBR green 1-based fluorescence assay	2019	Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7	Discovery and Structural Optimization of Acridones as Broad-Spectrum Antimalarials.
AID561055	Tmax in Plasmodium falciparum-infected patient at 320 mg/kg, po	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Pharmacokinetics and ex vivo pharmacodynamic antimalarial activity of dihydroartemisinin-piperaquine in patients with uncomplicated falciparum malaria in Vietnam.
AID423748	Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Pharmacokinetics and efficacy of piperaquine and chloroquine in Melanesian children with uncomplicated malaria.
AID323673	Antimalarial activity against chloroquine-sensitive Plasmodium falciparum 106/1	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Effects of piperaquine, chloroquine, and amodiaquine on drug uptake and of these in combination with dihydroartemisinin against drug-sensitive and -resistant Plasmodium falciparum strains.
AID428091	Half life in Swiss mice (Mus musculus) infected with Plasmodium berghei ANKA at 90 mg/kg, intraperitoneally administered 64 hrs after infection	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Pharmacokinetics and pharmacodynamics of piperaquine in a murine malaria model.
AID521754	Apparent steady-state volume of distribution with respect to bioavailability in healthy human at 4.2 mg/kg, po after 42 days	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Population pharmacokinetics of piperaquine after two different treatment regimens with dihydroartemisinin-piperaquine in patients with Plasmodium falciparum malaria in Thailand.
AID564290	Antimalarial activity against Plasmodium falciparum HB3 assessed as inhibition of [3H] incorporation after 48 hrs by scintillation counter	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID511251	Antimicrobial activity against Plasmodium falciparum by ELISA	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	In vitro sensitivities of Plasmodium falciparum to different antimalarial drugs in Uganda.
AID564230	Antiplasmodial activity against multidrug-resistant Plasmodium falciparum VS/1 after 18 hrs by [3H]hypoxanthine incorporation assay	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	In vitro activities of piperaquine, lumefantrine, and dihydroartemisinin in Kenyan Plasmodium falciparum isolates and polymorphisms in pfcrt and pfmdr1.
AID586612	Antimalarial activity against chloroquine-sensitive Plasmodium falciparum 3D7 assessed as inhibition of [3H]hypoxanthine incorporation	2011	Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3	Ex vivo activity of histone deacetylase inhibitors against multidrug-resistant clinical isolates of Plasmodium falciparum and P. vivax.
AID564294	Antimalarial activity against Plasmodium falciparum IMT A4 assessed as inhibition of [3H] incorporation after 48 hrs by scintillation counter	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID423715	Volume of distribution at steady state with respect to bioavailability in Paua New Guinean children with uncomplicated malaria at 20 mg/kg daily for 3 days	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Pharmacokinetics and efficacy of piperaquine and chloroquine in Melanesian children with uncomplicated malaria.
AID563105	Antimalarial activity against Plasmodium falciparum IMT 10500 harboring Pfcrt Q271E mutant gene and Ppcrt I371R mutant gene and Pfnhe-1 ms4760 microsatellite mutant assessed as incorporation of [3]H hypoxanthine after 48 hrs by scintillation counter	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID564286	Antimalarial activity against Plasmodium falciparum D6 assessed as inhibition of [3H] incorporation after 48 hrs by scintillation counter	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID521778	Terminal half-life in high-fat fed healthy human at 4.2 mg/kg, po after 42 days	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Population pharmacokinetics of piperaquine after two different treatment regimens with dihydroartemisinin-piperaquine in patients with Plasmodium falciparum malaria in Thailand.
AID545386	Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum C6harboring 7G8 pfcrt allele infected in erythrocytes assessed as [3H]hypoxanthine incorporation in presence of dihydroartimisinin	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Role of known molecular markers of resistance in the antimalarial potency of piperaquine and dihydroartemisinin in vitro.
AID521757	Apparent steady-state volume of distribution with respect to bioavailability in human with uncomplicated malaria at 31 mg/kg, perorally after 63 days	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Population pharmacokinetics of piperaquine after two different treatment regimens with dihydroartemisinin-piperaquine in patients with Plasmodium falciparum malaria in Thailand.
AID323680	Reduction of [3H]chloroquine uptake in chloroquine-resistant Plasmodium falciparum RSA11 infected erythrocytes after 90 min	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Effects of piperaquine, chloroquine, and amodiaquine on drug uptake and of these in combination with dihydroartemisinin against drug-sensitive and -resistant Plasmodium falciparum strains.
AID561066	Antiplasmodial activity against Plasmodium falciparum K1	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Pharmacokinetics and ex vivo pharmacodynamic antimalarial activity of dihydroartemisinin-piperaquine in patients with uncomplicated falciparum malaria in Vietnam.
AID423742	Apparent clearance with respect to bioavailability in Vietnamese human	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Pharmacokinetics and efficacy of piperaquine and chloroquine in Melanesian children with uncomplicated malaria.
AID564311	Antimalarial activity against Plasmodium falciparum PA harboring Ppcrt M74I, N75E, K76T, A220S, Q271E, N326S and I356T mutant gene, Pmdr1 N86Y mutant gene and Pfmrp H191Y and S437A mutant gene assessed as incorporation of [3]H hypoxanthine after 48 hrs by	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID323677	Antimalarial activity against chloroquine-resistant Plasmodium falciparum 34-1/E	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Effects of piperaquine, chloroquine, and amodiaquine on drug uptake and of these in combination with dihydroartemisinin against drug-sensitive and -resistant Plasmodium falciparum strains.
AID564304	Antimalarial activity against Plasmodium falciparum IMT K4 assessed as inhibition of [3H] incorporation after 48 hrs by scintillation counter	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID423733	Apparent clearance with respect to bioavailability in Cambodian children with malaria	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Pharmacokinetics and efficacy of piperaquine and chloroquine in Melanesian children with uncomplicated malaria.
AID564312	Antimalarial activity against Plasmodium falciparum HB3 harboring Ppcrt I371R mutant gene and Pfmdr1 Y184F mutant gene assessed as incorporation of [3]H hypoxanthine after 48 hrs by scintillation counter	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID428125	Antiparasitic activity as survival at day 30 against Plasmodium berghei ANKA infected Swiss mice (Mus musculus) at 20-30 mg/kg intraperitoneal dose 64 hrs post infection	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Pharmacokinetics and pharmacodynamics of piperaquine in a murine malaria model.
AID323675	Antimalarial activity against chloroquine-resistant Plasmodium falciparum RSA11	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Effects of piperaquine, chloroquine, and amodiaquine on drug uptake and of these in combination with dihydroartemisinin against drug-sensitive and -resistant Plasmodium falciparum strains.
AID564235	Antiplasmodial activity against Plasmodium falciparum harboring mutant pfcrt-76 gene after 18 hrs by [3H]hypoxanthine incorporation assay	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	In vitro activities of piperaquine, lumefantrine, and dihydroartemisinin in Kenyan Plasmodium falciparum isolates and polymorphisms in pfcrt and pfmdr1.
AID564301	Antimalarial activity against Plasmodium falciparum IMT 16332 assessed as inhibition of [3H] incorporation after 48 hrs by scintillation counter	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID428095	Initial half life in Swiss mice (Mus musculus) infected with Plasmodium berghei ANKA at 90 mg/kg, intraperitoneally by two compartment model assay	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Pharmacokinetics and pharmacodynamics of piperaquine in a murine malaria model.
AID564284	Antimalarial activity against Plasmodium falciparum 3D7 assessed as inhibition of [3H] incorporation after 48 hrs by scintillation counter	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID545380	Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum K1 infected in erythrocytes assessed as [3H]hypoxanthine incorporation in presence of dihydroartimisinin	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Role of known molecular markers of resistance in the antimalarial potency of piperaquine and dihydroartemisinin in vitro.
AID423740	Absorption half life in Vietnamese human by two-compartmental analysis	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Pharmacokinetics and efficacy of piperaquine and chloroquine in Melanesian children with uncomplicated malaria.
AID521774	AUC (3 to 20 days) in uncomplicated malaria patient at 31 mg/kg, perorally once daily for 3 days	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Population pharmacokinetics of piperaquine after two different treatment regimens with dihydroartemisinin-piperaquine in patients with Plasmodium falciparum malaria in Thailand.
AID586609	Antimalarial activity against ring stage of Plasmodium falciparum assessed as parasites growth inhibition using giemsa staining after 24 to 56 hrs by microscopic analysis in presence of 10% human serum	2011	Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3	Ex vivo activity of histone deacetylase inhibitors against multidrug-resistant clinical isolates of Plasmodium falciparum and P. vivax.
AID323685	Reduction of [3H]dihydroartemisinin uptake in chloroquine-resistant Plasmodium falciparum RSA11 infected erythrocytes after 90 min	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Effects of piperaquine, chloroquine, and amodiaquine on drug uptake and of these in combination with dihydroartemisinin against drug-sensitive and -resistant Plasmodium falciparum strains.
AID585012	Antimalarial activity against Plasmodium ovale ring stage infected in red blood cells in presence of AB+ human serum by drug susceptibility assay	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	In vivo and in vitro efficacy of chloroquine against Plasmodium malariae and P. ovale in Papua, Indonesia.
AID563110	Antimalarial activity against Plasmodium falciparum IMT L1 harboring Ppcrt M74I, N75E, K76T, A220S, Q271E mutant gene, Pmdr1 N86Y mutant gene and Pfmrp H191Y and S437A mutant gene assessed as incorporation of [3]H hypoxanthine after 48 hrs by scintillatio	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID561057	AUC in Plasmodium falciparum-infected patient at 320 mg/kg, po	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Pharmacokinetics and ex vivo pharmacodynamic antimalarial activity of dihydroartemisinin-piperaquine in patients with uncomplicated falciparum malaria in Vietnam.
AID564288	Antimalarial activity against Plasmodium falciparum FCR3 assessed as inhibition of [3H] incorporation after 48 hrs by scintillation counter	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID511255	Antimicrobial activity against chloroquine-resistant Plasmodium falciparum K1 by ELISA	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	In vitro sensitivities of Plasmodium falciparum to different antimalarial drugs in Uganda.
AID423735	Absorption half life in human after fat meal using non-compartmental analysis	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Pharmacokinetics and efficacy of piperaquine and chloroquine in Melanesian children with uncomplicated malaria.
AID545359	Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum TM6 infected in erythrocytes assessed as [3H]hypoxanthine incorporation	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Role of known molecular markers of resistance in the antimalarial potency of piperaquine and dihydroartemisinin in vitro.
AID521765	Apparent peripheral volume of distribution with respect to bioavailability in human with uncomplicated malaria at 31 mg/kg, perorally	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Population pharmacokinetics of piperaquine after two different treatment regimens with dihydroartemisinin-piperaquine in patients with Plasmodium falciparum malaria in Thailand.
AID317969	Antiparasitic activity against chloroquine-sensitive Plasmodium falciparum by [3H]hypoxanthine incorporation	2008	Journal of medicinal chemistry, Mar-13, Volume: 51, Issue:5	Antimalarial dual drugs based on potent inhibitors of glutathione reductase from Plasmodium falciparum.
AID521772	AUC (0 to 60 days) in human adult with uncomplicated malaria at 31 mg/kg, perorally	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Population pharmacokinetics of piperaquine after two different treatment regimens with dihydroartemisinin-piperaquine in patients with Plasmodium falciparum malaria in Thailand.
AID521759	Apparent oral clearance in healthy human at 4.2 mg/kg, po after 42 days	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Population pharmacokinetics of piperaquine after two different treatment regimens with dihydroartemisinin-piperaquine in patients with Plasmodium falciparum malaria in Thailand.
AID521749	Terminal half-life in healthy human at 4.2 mg/kg, po after 42 days	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Population pharmacokinetics of piperaquine after two different treatment regimens with dihydroartemisinin-piperaquine in patients with Plasmodium falciparum malaria in Thailand.
AID545382	Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum 7G8 infected in erythrocytes assessed as [3H]hypoxanthine incorporation in presence of dihydroartimisinin	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Role of known molecular markers of resistance in the antimalarial potency of piperaquine and dihydroartemisinin in vitro.
AID521747	Plasma concentration in human with uncomplicated malaria at 31 mg/kg, perorally once daily for 3 days measured at day 20	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Population pharmacokinetics of piperaquine after two different treatment regimens with dihydroartemisinin-piperaquine in patients with Plasmodium falciparum malaria in Thailand.
AID428124	Plasma concentration in Swiss mouse at 90 mg/kg, ip administered 64 hrs after infection measured after 60 days	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Pharmacokinetics and pharmacodynamics of piperaquine in a murine malaria model.
AID576575	Antimalarial activity against Plasmodium falciparum infected in human erythrocytes assessed as growth inhibition by microscopic analysis using giemsa staining	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	In vitro activity of pyronaridine against multidrug-resistant Plasmodium falciparum and Plasmodium vivax.
AID521753	Apparent steady-state volume of distribution with respect to bioavailability in healthy human at 25 mg/kg, po after 29 days	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Population pharmacokinetics of piperaquine after two different treatment regimens with dihydroartemisinin-piperaquine in patients with Plasmodium falciparum malaria in Thailand.
AID428088	Apparent volume of distribution in healthy Swiss mouse at 90 mg/kg, ip	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Pharmacokinetics and pharmacodynamics of piperaquine in a murine malaria model.
AID521756	Apparent steady-state volume of distribution with respect to bioavailability in human with uncomplicated malaria at 32 mg/kg, perorally after 35 days	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Population pharmacokinetics of piperaquine after two different treatment regimens with dihydroartemisinin-piperaquine in patients with Plasmodium falciparum malaria in Thailand.
AID585009	Antimalarial activity against Plasmodium malariae trophozoite stage infected in red blood cells in presence of AB+ human serum by drug susceptibility assay	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	In vivo and in vitro efficacy of chloroquine against Plasmodium malariae and P. ovale in Papua, Indonesia.
AID423734	Absorption half life in human after fasting using non-compartmental analysis	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Pharmacokinetics and efficacy of piperaquine and chloroquine in Melanesian children with uncomplicated malaria.
AID511254	Antimicrobial activity against chloroquine-resistant Plasmodium falciparum HB3 by ELISA	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	In vitro sensitivities of Plasmodium falciparum to different antimalarial drugs in Uganda.
AID323670	Antimalarial activity against chloroquine-sensitive Plasmodium falciparum FC27	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Effects of piperaquine, chloroquine, and amodiaquine on drug uptake and of these in combination with dihydroartemisinin against drug-sensitive and -resistant Plasmodium falciparum strains.
AID521775	AUC (0 to 63 days) in uncomplicated malaria patient at 31 mg/kg, perorally four-dose treatment regimen	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Population pharmacokinetics of piperaquine after two different treatment regimens with dihydroartemisinin-piperaquine in patients with Plasmodium falciparum malaria in Thailand.
AID586611	Antimalarial activity against Plasmodium falciparum assessed as parasites growth inhibition using giemsa staining after 24 to 56 hrs by microscopic analysis in presence of 10% human serum	2011	Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3	Ex vivo activity of histone deacetylase inhibitors against multidrug-resistant clinical isolates of Plasmodium falciparum and P. vivax.
AID521773	AUC (3 to 20 days) in uncomplicated malaria patient at 31 mg/kg, perorally four-dose treatment regimen	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Population pharmacokinetics of piperaquine after two different treatment regimens with dihydroartemisinin-piperaquine in patients with Plasmodium falciparum malaria in Thailand.
AID564292	Antimalarial activity against Plasmodium falciparum IMT Bres assessed as inhibition of [3H] incorporation after 48 hrs by scintillation counter	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID563109	Antimalarial activity against Plasmodium falciparum IMT K4 harboring Ppcrt M74I, N75E, K76T, A220S, Q271E, N326S mutant gene, Pmdr1 S1034C, N1042D mutant gene and Pfmrp H191Y and S437A mutant gene assessed as incorporation of [3]H hypoxanthine after 48 hr	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID585011	Antimalarial activity against Plasmodium ovale trophozoite stage infected in red blood cells in presence of AB+ human serum by drug susceptibility assay	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	In vivo and in vitro efficacy of chloroquine against Plasmodium malariae and P. ovale in Papua, Indonesia.
AID496885	Antimalarial activity against chloroquine-sensitive Plasmodium falciparum	2010	European journal of medicinal chemistry, Aug, Volume: 45, Issue:8	Quinolines and structurally related heterocycles as antimalarials.
AID564297	Antimalarial activity against Plasmodium falciparum IMT 9881 assessed as inhibition of [3H] incorporation after 48 hrs by scintillation counter	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID564287	Antimalarial activity against Plasmodium falciparum FCM29 assessed as inhibition of [3H] incorporation after 48 hrs by scintillation counter	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID521761	Apparent oral clearance in human with uncomplicated malaria at 32 mg/kg, perorally after 35 days	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Population pharmacokinetics of piperaquine after two different treatment regimens with dihydroartemisinin-piperaquine in patients with Plasmodium falciparum malaria in Thailand.
AID511253	Antimicrobial activity against chloroquine-sensitive Plasmodium falciparum D6 by ELISA	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	In vitro sensitivities of Plasmodium falciparum to different antimalarial drugs in Uganda.
AID323681	Reduction of [3H]chloroquine uptake in chloroquine-resistant Plasmodium falciparum RSA11 infected erythrocytes after 90 min	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Effects of piperaquine, chloroquine, and amodiaquine on drug uptake and of these in combination with dihydroartemisinin against drug-sensitive and -resistant Plasmodium falciparum strains.
AID1593291	Antimalarial activity against drug-resistant Plasmodium falciparum 3D7 harboring A82T/V259L double mutant infected in human erythrocytes after 72 hrs by SYBR green 1-based fluorescence assay	2019	Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7	Discovery and Structural Optimization of Acridones as Broad-Spectrum Antimalarials.
AID428112	Plasma concentration in Swiss mice (Mus musculus) infected with Plasmodium berghei ANKA at 90 mg/kg, intraperitoneally administered 64 hrs after infection measured after 60 days	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Pharmacokinetics and pharmacodynamics of piperaquine in a murine malaria model.
AID564305	Antimalarial activity against Plasmodium falciparum IMT L1 assessed as inhibition of [3H] incorporation after 48 hrs by scintillation counter	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID564232	Antiplasmodial activity against Plasmodium falciparum clinical isolate after 18 hrs by [3H]hypoxanthine incorporation assay	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	In vitro activities of piperaquine, lumefantrine, and dihydroartemisinin in Kenyan Plasmodium falciparum isolates and polymorphisms in pfcrt and pfmdr1.
AID428109	Plasma concentration in Swiss mice (Mus musculus) infected with Plasmodium berghei ANKA at 90 mg/kg, intraperitoneally administered 64 hrs after infection measured after 2 to 7 days	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Pharmacokinetics and pharmacodynamics of piperaquine in a murine malaria model.
AID576572	Antimalarial activity against Plasmodium falciparum trophozoites infected in human erythrocytes assessed as growth inhibition by microscopic analysis using giemsa staining	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	In vitro activity of pyronaridine against multidrug-resistant Plasmodium falciparum and Plasmodium vivax.
AID423711	Absorption half life in Papua New Guinean children with uncomplicated malaria at 20 mg/kg daily for 3 days	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Pharmacokinetics and efficacy of piperaquine and chloroquine in Melanesian children with uncomplicated malaria.
AID428092	AUC in Swiss mice (Mus musculus) infected with Plasmodium berghei ANKA at 90 mg/kg, intraperitoneally administered 64 hrs after infection	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Pharmacokinetics and pharmacodynamics of piperaquine in a murine malaria model.
AID564317	Antimalarial activity against Plasmodium falciparum IMT 31 harboring Ppcrt I371R mutant gene assessed as incorporation of [3]H hypoxanthine after 48 hrs by scintillation counter	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID521767	Apparent volume of distribution with respect to bioavailability in human with uncomplicated malaria at 31 mg/kg, perorally	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Population pharmacokinetics of piperaquine after two different treatment regimens with dihydroartemisinin-piperaquine in patients with Plasmodium falciparum malaria in Thailand.
AID564318	Antimalarial activity against Plasmodium falciparum IMT 8425 harboring Ppcrt I371R mutant gene and Pfnhe-1 ms4760 microsatellite mutant assessed as incorporation of [3]H hypoxanthine after 48 hrs by scintillation counter	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID561067	Antiplasmodial activity against Plasmodium falciparum K1 assessed as inhibition of [3H]hypoxanthine incorporation by beta counting	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Pharmacokinetics and ex vivo pharmacodynamic antimalarial activity of dihydroartemisinin-piperaquine in patients with uncomplicated falciparum malaria in Vietnam.
AID545364	Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum C6harboring 7G8 pfcrt allele infected in erythrocytes assessed as [3H]hypoxanthine incorporation	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Role of known molecular markers of resistance in the antimalarial potency of piperaquine and dihydroartemisinin in vitro.
AID561059	AUC (0 to infinity) in Plasmodium falciparum-infected patient at 320 mg/kg, po	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Pharmacokinetics and ex vivo pharmacodynamic antimalarial activity of dihydroartemisinin-piperaquine in patients with uncomplicated falciparum malaria in Vietnam.
AID511252	Antimicrobial activity against chloroquine-sensitive Plasmodium falciparum W2 by ELISA	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	In vitro sensitivities of Plasmodium falciparum to different antimalarial drugs in Uganda.
AID563106	Antimalarial activity against Plasmodium falciparum IMT 16332 harboring Ppcrt M74I, N75E, K76T, A220S, Q271E mutant gene, Pmdr1 N86Y mutant gene assessed as incorporation of [3]H hypoxanthine after 48 hrs by scintillation counter	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID323679	Reduction of [3H]chloroquine uptake in chloroquine-sensitive Plasmodium falciparum 3D7 infected erythrocytes after 90 min	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Effects of piperaquine, chloroquine, and amodiaquine on drug uptake and of these in combination with dihydroartemisinin against drug-sensitive and -resistant Plasmodium falciparum strains.
AID545383	Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum 3D7 infected in erythrocytes assessed as [3H]hypoxanthine incorporation in presence of dihydroartimisinin	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Role of known molecular markers of resistance in the antimalarial potency of piperaquine and dihydroartemisinin in vitro.
AID1593290	Antimalarial activity against Plasmodium falciparum 3D7 infected in human erythrocytes after 72 hrs by SYBR green 1-based fluorescence assay	2019	Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7	Discovery and Structural Optimization of Acridones as Broad-Spectrum Antimalarials.
AID323671	Antimalarial activity against chloroquine-sensitive Plasmodium falciparum T996	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Effects of piperaquine, chloroquine, and amodiaquine on drug uptake and of these in combination with dihydroartemisinin against drug-sensitive and -resistant Plasmodium falciparum strains.
AID428084	Plasma concentration in Swiss mice (Mus musculus) infected with Plasmodium berghei ANKA at 90 mg/kg, intraperitoneally administered 64 hrs after infection measured after 36 hrs	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Pharmacokinetics and pharmacodynamics of piperaquine in a murine malaria model.
AID428096	Terminal half life in Swiss mice (Mus musculus) infected with Plasmodium berghei ANKA at 90 mg/kg, intraperitoneally by two compartment model assay	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Pharmacokinetics and pharmacodynamics of piperaquine in a murine malaria model.
AID564303	Antimalarial activity against Plasmodium falciparum IMT K2 assessed as inhibition of [3H] incorporation after 48 hrs by scintillation counter	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID521750	Terminal half-life in human with uncomplicated malaria at 35 mg/kg, perorally after 35 days	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Population pharmacokinetics of piperaquine after two different treatment regimens with dihydroartemisinin-piperaquine in patients with Plasmodium falciparum malaria in Thailand.
AID1638538	Antimalarial activity against multidrug-resistant Plasmodium falciparum clinical isolates infected assessed as reduction in parasite growth after 35 to 56 hrs by nucleic acid staining based flow cytometry	2019	Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5	3,3'-Disubstituted 5,5'-Bi(1,2,4-triazine) Derivatives with Potent in Vitro and in Vivo Antimalarial Activity.
AID545367	Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum 7G8 harboring parental pfcrt allele infected in erythrocytes assessed as [3H]hypoxanthine incorporation	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Role of known molecular markers of resistance in the antimalarial potency of piperaquine and dihydroartemisinin in vitro.
AID586607	Antimalarial activity against ring stage of Plasmodium vivax assessed as parasites growth inhibition using giemsa staining after 24 to 56 hrs by microscopic analysis in presence of 20% human serum	2011	Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3	Ex vivo activity of histone deacetylase inhibitors against multidrug-resistant clinical isolates of Plasmodium falciparum and P. vivax.
AID423730	Absorption half life in Cambodian children with malaria	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Pharmacokinetics and efficacy of piperaquine and chloroquine in Melanesian children with uncomplicated malaria.
AID564233	Antiplasmodial activity against Plasmodium falciparum harboring wild type pfcrt-76 gene after 18 hrs by [3H]hypoxanthine incorporation assay	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	In vitro activities of piperaquine, lumefantrine, and dihydroartemisinin in Kenyan Plasmodium falciparum isolates and polymorphisms in pfcrt and pfmdr1.
AID423736	Volume of distribution at steady state with respect to bioavailability in human after fasting using non-compartmental analysis	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Pharmacokinetics and efficacy of piperaquine and chloroquine in Melanesian children with uncomplicated malaria.
AID521752	Terminal half-life in human with uncomplicated malaria at 32 mg/kg, perorally after 35 days	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Population pharmacokinetics of piperaquine after two different treatment regimens with dihydroartemisinin-piperaquine in patients with Plasmodium falciparum malaria in Thailand.
AID545385	Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum C3 harboring Dd2 pfcrt allele infected in erythrocytes assessed as [3H]hypoxanthine incorporation in presence of dihydroartimisinin	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Role of known molecular markers of resistance in the antimalarial potency of piperaquine and dihydroartemisinin in vitro.
AID545387	Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum D10 infected in erythrocytes assessed as [3H]hypoxanthine incorporation in presence of dihydroartimisinin	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Role of known molecular markers of resistance in the antimalarial potency of piperaquine and dihydroartemisinin in vitro.
AID521777	Apparent steady-state volume of distribution with respect to bioavailability in high-fat fed healthy human at 4.2 mg/kg, po after 42 days	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Population pharmacokinetics of piperaquine after two different treatment regimens with dihydroartemisinin-piperaquine in patients with Plasmodium falciparum malaria in Thailand.
AID563107	Antimalarial activity against Plasmodium falciparum IMT K14 harboring Ppcrt M74I, N75E, K76T, A220S, Q271E, N326S mutant gene, Pmdr1 Y184F, S1034C, N1042D, D1246Y mutant gene and Pfmrp H191Y and S437A mutant gene assessed as incorporation of [3]H hypoxant	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID428083	Plasma concentration in Swiss mice (Mus musculus) infected with Plasmodium berghei ANKA at 90 mg/kg, intraperitoneally administered 64 hrs after infection measured after 2 hrs	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Pharmacokinetics and pharmacodynamics of piperaquine in a murine malaria model.
AID576577	Antimalarial activity against Plasmodium vivax with >50% parasites at ring stage infected in human erythrocytes assessed as growth inhibition after 30 to 50 hrs by microscopic analysis using giemsa staining	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	In vitro activity of pyronaridine against multidrug-resistant Plasmodium falciparum and Plasmodium vivax.
AID519195	Antimicrobial activity against Plasmodium vivax trophozoites measured after 30 hrs by microscopy	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Determinants of in vitro drug susceptibility testing of Plasmodium vivax.
AID564299	Antimalarial activity against Plasmodium falciparum IMT 10354 assessed as inhibition of [3H] incorporation after 48 hrs by scintillation counter	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID585010	Antimalarial activity against Plasmodium malariae ring stage infected in red blood cells in presence of AB+ human serum by drug susceptibility assay	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	In vivo and in vitro efficacy of chloroquine against Plasmodium malariae and P. ovale in Papua, Indonesia.
AID564289	Antimalarial activity against Plasmodium falciparum PA assessed as inhibition of [3H] incorporation after 48 hrs by scintillation counter	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID521758	Apparent oral clearance in healthy human at 25 mg/kg, po after 29 days	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Population pharmacokinetics of piperaquine after two different treatment regimens with dihydroartemisinin-piperaquine in patients with Plasmodium falciparum malaria in Thailand.
AID564309	Antimalarial activity against Plasmodium falciparum FCM29 harboring Ppcrt M74I, N75E, K76T, A220S, Q271E, N326S and I356T mutant gene, Pmdr1 N86Y mutant gene and Pfmrp H191Y and S437A mutant gene assessed as incorporation of [3]H hypoxanthine after 48 hrs	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID428110	Antiparasitic activity as parasitaemia after 36 hrs against Plasmodium berghei ANKA infected Swiss mice (Mus musculus) at 90 mg/kg intraperitoneal dose 64 hrs post infection	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Pharmacokinetics and pharmacodynamics of piperaquine in a murine malaria model.
AID564291	Antimalarial activity against Plasmodium falciparum 106/1 assessed as inhibition of [3H] incorporation after 48 hrs by scintillation counter	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID545362	Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum C2 infected in erythrocytes assessed as [3H]hypoxanthine incorporation	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Role of known molecular markers of resistance in the antimalarial potency of piperaquine and dihydroartemisinin in vitro.
AID564306	Antimalarial activity against Plasmodium falciparum IMT Vol assessed as inhibition of [3H] incorporation after 48 hrs by scintillation counter	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID235122	Resistance index was measured as the ratio of IC50 of Plasmodium falciparum W-2 clone / IC50 of P. falciparum D-6 clone	1992	Journal of medicinal chemistry, May-29, Volume: 35, Issue:11	Bisquinolines. 1. N,N-bis(7-chloroquinolin-4-yl)alkanediamines with potential against chloroquine-resistant malaria.
AID423747	Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Pharmacokinetics and efficacy of piperaquine and chloroquine in Melanesian children with uncomplicated malaria.
AID323676	Antimalarial activity against chloroquine-resistant Plasmodium falciparum 7G8-mdr7G8	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Effects of piperaquine, chloroquine, and amodiaquine on drug uptake and of these in combination with dihydroartemisinin against drug-sensitive and -resistant Plasmodium falciparum strains.
AID1649432	Antimalarial activity against Plasmodium falciparum clinical isolates measured after 72 hrs by SYBR green dye based fluorescence assay	2020	Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11	Lead Optimization of Second-Generation Acridones as Broad-Spectrum Antimalarials.
AID564315	Antimalarial activity against Plasmodium falciparum IMT Guy harboring Ppcrt K76T, A220S, N326D and I371R mutant gene, Pmdr1 T184FN, 1042D and D1246Y, mutant gene and Pfmrp H191Y and S437A mutant gene and Pfnhe-1 ms4760 microsatellite mutant assessed as in	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID521751	Terminal half-life in human with uncomplicated malaria at 31 mg/kg, perorally after 63 days	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Population pharmacokinetics of piperaquine after two different treatment regimens with dihydroartemisinin-piperaquine in patients with Plasmodium falciparum malaria in Thailand.
AID151201	In vitro activity against Plasmodium falciparum W-2	1992	Journal of medicinal chemistry, May-29, Volume: 35, Issue:11	Bisquinolines. 1. N,N-bis(7-chloroquinolin-4-yl)alkanediamines with potential against chloroquine-resistant malaria.
AID428085	Half life in healthy Swiss mouse at 90 mg/kg, ip	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Pharmacokinetics and pharmacodynamics of piperaquine in a murine malaria model.
AID564310	Antimalarial activity against Plasmodium falciparum FCR3 harboring Ppcrt M74I, N75E, K76T, A220S, Q271E, N326S and I356T mutant gene, Pmdr1 N86Y mutant gene and Pfmrp H191Y and S437A mutant gene assessed as incorporation of [3]H hypoxanthine after 48 hrs	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID563104	Antimalarial activity against Plasmodium falciparum IMT 10354 harboring Ppcrt M74I, N75E, K76T, A220S mutant gene, Pmdr1 D1246Y mutant gene assessed as incorporation of [3]H hypoxanthine after 48 hrs by scintillation counter	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID428120	Antiparasitic activity as survival at day 30 against Plasmodium berghei ANKA infected Swiss mice (Mus musculus) at 30 mg/kg intraperitoneal dose 64 hrs post infection	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Pharmacokinetics and pharmacodynamics of piperaquine in a murine malaria model.
AID549354	Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum K1 infected in erythrocytes assessed as [3H]hypoxanthine incorporation	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Role of known molecular markers of resistance in the antimalarial potency of piperaquine and dihydroartemisinin in vitro.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	23 (3.62)	18.7374
1990's	8 (1.26)	18.2507
2000's	88 (13.86)	29.6817
2010's	371 (58.43)	24.3611
2020's	145 (22.83)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	227 (35.58%)	5.53%
Reviews	43 (6.74%)	6.00%
Case Studies	16 (2.51%)	4.05%
Observational	9 (1.41%)	0.25%
Other	343 (53.76%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (132)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
School-based Malaria Control: Impact of Intermittent Preventive Treatment on Malaria Morbidity and Cognitive Function in Ugandan School Children [NCT01231880]	Phase 3	740 participants (Actual)	Interventional	2011-02-28	Completed
An Active Malaria Epidemiology Cohort Study With Evaluation of a 2 Day Versus 3 Day Treatment Regimen of Dihydroartemisinin (DHA)-Piperaquine for Patients With Uncomplicated Malaria [NCT01280162]		222 participants (Actual)	Interventional	2010-09-30	Completed
Comparison of the Efficacy and Safety of Two ACTs Plus Primaquine for Uncomplicated Plasmodium Vivax Malaria in North Sumatera, Indonesia: 1 Year Followup [NCT01288820]	Phase 3	331 participants (Actual)	Interventional	2011-01-31	Completed
Efficacy, Safety and Tolerability of Dihydroartemisinin-Piperaquine for Treatment of Uncomplicated Falciparum Malaria in Pregnancy: an Open-label, Randomised Controlled, Non-inferiority Trial [NCT01231113]	Phase 3	417 participants (Actual)	Interventional	2011-07-31	Completed
A Randomised, Double-blind, Placebo Controlled, Parallel Group Study in Healthy Adult Volunteers to Determine the Tolerability and Safety of Pyronaridine (PYR) Co-administered With Piperaquine (PQP) Under Fasted Conditions [NCT05160363]	Phase 1	37 participants (Actual)	Interventional	2022-02-18	Active, not recruiting
An Open-label Randomized Trial to Assess the Therapeutic Efficacy of Arterolane-piperaquine Versus Dihydroartemisinin-piperaquine for the Treatment of Uncomplicated Falciparum Malaria in Eastern Myanmar, an Area of Emerging Artemisinin-resistant Falciparu [NCT02461186]	Phase 2/Phase 3	0 participants (Actual)	Interventional	2015-06-30	Withdrawn(stopped due to Change of the study site due to the current political climate in Myanmar.)
Triple Antimalarial Combination (Imatinib-DHA-PPQ) to Accelerate the Parasite Clearance and to Prevent the Selection of Resistant Parasites [NCT03697668]	Phase 2	50 participants (Anticipated)	Interventional	2017-09-17	Recruiting
Prevention of Malaria in HIV-uninfected Pregnant Women and Infants [NCT02793622]	Phase 3	782 participants (Actual)	Interventional	2016-09-30	Completed
Proof of Concept Study of Eurartesim® in Patients With Imported Uncomplicated Plasmodium Vivax Malaria [NCT02110784]	Phase 2	27 participants (Actual)	Interventional	2014-06-18	Terminated(stopped due to Low recruitment)
Clinical Trial to Evaluate Intermittent Screening and Treatment and Intermittent Preventive Treatment of Malaria in Asymptomatic Schoolchildren to Decrease P. Falciparum Infection and Transmission: Phase 2 Comparing Drug Regimens [NCT05980156]	Phase 4	646 participants (Actual)	Interventional	2023-02-13	Completed
Clinical Investigation of In-vivo Susceptibility of P. Falciparum to Artesunate in Phuoc Long Hospital, Binh Phuoc Province, Vietnam [NCT01165372]	Phase 2	166 participants (Actual)	Interventional	2010-08-31	Completed
Evaluation of the Safety of Primaquine in Combination With Dihydroartemisinin-piperaquine in G6PD Deficient Males in The Gambia [NCT02654730]	Phase 2/Phase 3	61 participants (Actual)	Interventional	2015-12-31	Terminated(stopped due to Enrollment took longer than anticipated; it was financially and logistically impossible to recruit the final cohort (G6PDd 0.4mg/kg PQ).)
Defining Effective, Appropriate, Implementable Strategies for Malaria Elimination in Military Forces in Cambodia as a Model for Mobile Populations [NCT02653898]	Phase 4	1,050 participants (Actual)	Interventional	2016-01-31	Active, not recruiting
Effects of Metronidazole Plus Intermittent Preventive Treatment of Malaria in Pregnancy on Birth Outcomes: a Randomised Controlled Trial in Zambia [NCT04189744]	Phase 3	5,436 participants (Actual)	Interventional	2019-12-15	Completed
Clinical Efficacy of Artemisinin-based Combination Therapy for Treatment of Uncomplicated Plasmodium Falciparum Malaria in North Sumatera, Indonesia and the Association of Molecular Markers With Treatment Outcomes [NCT02325180]	Phase 4	338 participants (Actual)	Interventional	2015-01-31	Completed
Combination Momordica Charantia Extract and Primaquine Againts Plasmodium Falciparum Uncomplicated and Plasmodium Vivax Uncomplicated Treatment in Manokwari, West Papua [NCT06036030]	Phase 2	50 participants (Actual)	Interventional	2019-01-11	Completed
Dihydroartemisinin-Piperaquine or Sulphadoxine-Pyrimethamine for the Chemoprevention of Malaria in Children With Sickle Cell Anaemia in Eastern and Southern Africa: a Double Blind Randomised Trial (CHEMCHA) [NCT04844099]	Phase 3	723 participants (Actual)	Interventional	2021-04-09	Completed
Observational Study to Evaluate the Clinical Safety After Introduction of the Fixed Dose Artemisinin-based Combination Therapy Eurartesim® (Dihydroartemisinin/Piperaquine [Dha/Pqp]) in Public Health Districts in Sub-Saharan Africa. [NCT02199951]		10,000 participants (Anticipated)	Observational	2013-09-30	Recruiting
Clinical Trial to Evaluate Efficacy and Safety of Sulfadoxine/Pyrimethamine-Amodiaquine and Dihydroartemsinin-Piperaquine Plus Ivermectin Administered Monthly as Intermittent Preventive Treatment in School-aged Children in Burkina Faso [NCT05946642]	Phase 3	13,000 participants (Anticipated)	Interventional	2023-07-15	Recruiting
A Randomised, Single-blinded Controlled Treatment Trial of Subclinical Vivax Infections With Primaquine in Nong Province, Laos [NCT02802813]	Phase 1/Phase 2	41 participants (Actual)	Interventional	2016-06-14	Completed
DPART Study: Dihydroartemisinin-Piperaquine in the Context of Antiretroviral Therapy [NCT04487145]	Phase 4	190 participants (Actual)	Interventional	2020-11-23	Completed
The Tolerability and Safety of Low Dose Primaquine for Transmission Blocking in Symptomatic Falciparum Infected Cambodians [NCT02434952]	Phase 4	109 participants (Actual)	Interventional	2014-10-31	Completed
An Open-label Randomised Trial to Assess the Therapeutic Efficacy and Tolerability of Arterolane-piperaquine Plus Single Low Dose Primaquine Versus Arterolane-piperaquine Plus Mefloquine and Single Low Dose Primaquine Versus Artemether-lumefantrine Plus S [NCT03452475]	Phase 3	219 participants (Actual)	Interventional	2018-03-07	Completed
Effectiveness and Safety of Intermittent Preventive Treatment for Malaria Using Either Dihydroartemisinin-piperaquine or Artesunate-amodiaquine in Reducing Malaria Related Morbidities and Improving Cognitive Ability in School-aged Children in Tanzania: A [NCT03640403]	Phase 3	1,555 participants (Actual)	Interventional	2019-03-26	Active, not recruiting
Optimal Chemopreventive Regimens to Prevent Malaria and Improve Birth Outcomes in Uganda [NCT04336189]	Phase 3	2,757 participants (Anticipated)	Interventional	2020-12-28	Recruiting
Evaluating the Effectiveness and Feasibility of Reactive Focal Mass Drug Administration vs. Reactive Case Detection as a Community Level Intervention in Response to a Passively Identified Index Malaria Case in Swaziland [NCT02315690]	Phase 3	4,000 participants (Actual)	Interventional	2015-09-30	Completed
Open-Label Study to Evaluate Potential Pharmacokinetic and Pharmacodynamic Interactions of Orally Administered Mefloquine and Dihydroartemisinin-Piperaquine in Healthy Adult Subjects [NCT02324738]	Phase 4	16 participants (Actual)	Interventional	2015-01-31	Completed
Evaluation of the Efficacy of Artemether-lumefantrine and Dihydroartemisinin-piperaquine in Children With Uncomplicated Clinical Malaria in Rural Rwanda [NCT04767217]	Phase 4	528 participants (Anticipated)	Interventional	2021-06-14	Recruiting
A Double Blind Randomized Controlled Trial of Dihydroartemisinin-piperaquine Alone and in Combination With Single Dose Primaquine to Reduce Post-treatment Malaria Transmission. [NCT02259426]	Phase 3	120 participants (Actual)	Interventional	2014-10-31	Completed
Safety and Feasibility of a Malaria Transmission Model in Semi-immune Kenyan Adults Using Plasmodium Falciparum Sporozoites [NCT04280692]	Phase 1/Phase 2	44 participants (Actual)	Interventional	2022-08-22	Active, not recruiting
Efficacy and Safety of Artesunate-amodiaquine and Dihydroartemisinin-piperaquine for the Treatment of Uncomplicated Falciparum Malaria in Mainland Tanzania [NCT03431714]	Phase 4	333 participants (Actual)	Interventional	2017-07-14	Completed
Phase I, Randomized, Parallel Group Study to Evaluate the Effect of Multiple Oral Doses of Eurartesim on the QT/QTc Interval Compared to Riamet, Placebo and Moxifloxacin in Healthy Male and Female Volunteers [NCT01103830]	Phase 1	287 participants (Actual)	Interventional	2010-02-28	Completed
Comparison of the Electrocardiographic Effects in Relation to Pharmacokinetic Profile of Chloroquine and Piperaquine in Healthy Thai Subjects [NCT02192944]	Phase 4	16 participants (Actual)	Interventional	2014-07-31	Completed
Impact Tanzania in Vivo Efficacy 2010: Assessing the Efficacy of Artemisinin Combination Therapies for Treatment of Uncomplicated Malaria Infection in Children Aged 6-59 Months [NCT01082705]	Phase 3	323 participants (Actual)	Interventional	2010-04-30	Completed
Mass Drug Administration of Ivermectin and Dihydroartemisinin-piperaquine as an Additional Intervention for Malaria Elimination [NCT03576313]	Phase 3	4,939 participants (Actual)	Interventional	2018-08-11	Completed
Effectiveness of Mass Drug Administration (MDA) for Reducing Seasonal Malaria Transmission Towards Its Elimination in Hotspot Areas in Zanzibar - a Cluster-randomised Controlled Trial [NCT02721186]		22,500 participants (Actual)	Interventional	2016-04-30	Completed
A Randomized Controlled Trial of Monthly Dihydroartemisinin-piperaquine Versus Monthly Sulfadoxine-pyrimethamine Versus Daily Trimethoprim-sulfamethoxazole Versus No Therapy for the Prevention of Malaria [NCT00948896]	Phase 3	600 participants (Actual)	Interventional	2010-06-30	Completed
'Controlled Human Malaria Infection Study to Assess Gametocytaemia and Mosquito Transmissibility in Participants Challenged With Plasmodium Falciparum by Sporozoite Challenge to Establish a Model for the Evaluation of Transmission-blocking Interventions' [NCT02836002]	Phase 1/Phase 2	29 participants (Actual)	Interventional	2016-06-30	Completed
[NCT00845533]	Phase 4	0 participants	Interventional	2007-08-31	Completed
[NCT00868465]		600 participants (Anticipated)	Interventional	2009-04-30	Completed
A Phase II, Open-label, Multicentre, Pharmacokinetic, Pharmacodynamics and Safety Study of a New Paediatric Eurartesim Dispersible Formulation and Crushed Film Coated Eurartesim Tablet, in Infant Patients With P. Falciparum Malaria [NCT01992900]	Phase 2	300 participants (Actual)	Interventional	2013-11-30	Completed
Open Label Randomized Study Evaluating the in Vivo Efficacies of Artemether-lumefantrine and Dihydroartemisinin-piperaquine in the Treatment of Uncomplicated Plasmodium Falciparum Malaria in Children Under Five Years of Age in Western Kenya [NCT05060198]		340 participants (Actual)	Interventional	2016-06-17	Completed
Phase 1b to Assess Safety, Tolerability, Pharmacokinetic Profile, and Antimalarial Activity of Single Doses of Co-administered OZ439and PQP Against Early Plasmodium Falciparum Blood Stage Infection in Healthy Adult Volunteers [NCT03542149]	Phase 1	24 participants (Actual)	Interventional	2018-04-23	Completed
Adaptation of Blood-stage Controlled Human Malaria Infection for Evaluation of Transmission Blocking Malaria Interventions in Malaria Endemic Countries [NCT06172686]	Phase 1	24 participants (Anticipated)	Interventional	2024-01-09	Not yet recruiting
A Five-cohort, Randomized, Open-label, Parallel-group Study to Evaluate the Pharmacokinetics of a Single Dose of Tafenoquine (SB252263) 300mg When Co-administered With the Artemisinin-based Combination Therapies (ACT) Artemether + Lumefantrine (AL) and Di [NCT02184637]	Phase 1	120 participants (Actual)	Interventional	2014-07-31	Completed
Malaria Chemoprevention With Monthly Treatment With Dihydroartemisinin-Piperaquine for the Post-discharge Management of Severe Anaemia in Children Less Than 5 Years in Malawi [NCT02721420]	Phase 3	375 participants (Anticipated)	Interventional	2016-03-24	Recruiting
A Multi-site Cohort Observational Study for Molecular Assessment of Artemisinin Resistance Falciparum Malaria in Myanmar [NCT02792816]		550 participants (Actual)	Observational	2009-06-30	Completed
Chemoprevention With Monthly IPTp With Dihydroartemisinin-piperaquine for Malaria in HIV-infected Pregnant Participants on Daily Cotrimoxazole in Kenya and Malawi: a Multi-centre Placebo-controlled Trial [NCT04158713]	Phase 3	898 participants (Actual)	Interventional	2019-11-11	Completed
Intermittent Preventive Treatment in Pregnancy With Sulfadoxine-pyrimethamine Plus Dihydroartemisinin-piperaquine to Prevent Malaria Infection and Reduce Adverse Pregnancy Outcomes in Papua New Guinea - a Randomised Controlled Trial [NCT05426434]	Phase 3	1,172 participants (Anticipated)	Interventional	2022-08-31	Recruiting
Randomized Clinical Trial of the Efficacy and Safety of Dihydroartimisinine+Papiraquine (Artekin) Compared With First Line Drugs for Treatment of Vivax and Uncomplicated Falciparum Malaria in Afghanistan [NCT00682578]	Phase 3	1,086 participants (Actual)	Interventional	2007-07-31	Completed
IPT in Schoolchildren: Comparison of the Efficacy, Safety, and Tolerability of Antimalarial Regimens in Uganda [NCT00852371]	Phase 3	760 participants (Actual)	Interventional	2008-02-29	Completed
Effectiveness and Safety of Artemether + Lumefantrine and Dihydroartemisinin + Piperaquine for the Treatment of Uncomplicated Malaria in Guinea-Bissau [NCT04897919]	Phase 4	474 participants (Actual)	Interventional	2015-08-01	Completed
Malaria Chemoprevention With Monthly Treatment With Dihydroartemisinin-piperaquine for the Post-discharge Management of Severe Anaemia in Children Aged Less Than 5 Years in Uganda and Kenya: A Two-arm Randomised Placebo Controlled Trial [NCT02671175]	Phase 3	1,049 participants (Actual)	Interventional	2016-05-20	Completed
A Safety, Tolerability, Pharmacokinetic and Efficacy Study of Azithromycin Plus Piperaquine as Presumptive Treatment in Pregnant Papua New Guinean Women [NCT02575755]	Phase 4	150 participants (Anticipated)	Interventional	2012-10-31	Recruiting
Enhancing Immunity to Malaria in Young Children With Effective Chemoprevention [NCT04978272]	Phase 3	924 participants (Actual)	Interventional	2022-02-08	Active, not recruiting
A Phase1 Interventional Sequential Single Site Study to Characterize the Effectiveness of Oral KAE609 in Reducing Asexual & Sexual Blood-stage P. Falciparum Following Inoculation in Healthy-volunteers & Subsequent Infectivity to Mosquitoes [NCT02543086]	Phase 1	8 participants (Actual)	Interventional	2015-07-31	Terminated
A Randomized, Placebo-controlled, Double-blind Trial Using Dihydroartemisinine+Piperaquine (DP) to Protect Forest Workers From Malaria in Bu Gia Map National Park [NCT02788864]	Phase 4	150 participants (Actual)	Interventional	2016-05-20	Completed
A Multi-Site, Open-Label, Randomized Trial to Assess the Efficacy, Safety, and Tolerability of Dihydroartemisinin-Piperaquine Plus Mefloquine Compared to Dihydroartemisinin-Piperaquine or Artesunate-Mefloquine in Patients With Uncomplicated Falciparum Mal [NCT02612545]	Phase 1	216 participants (Actual)	Interventional	2015-11-20	Completed
Safe and Efficacious Artemisinin-based Combination Treatments for African Pregnant Women With Malaria [NCT00852423]	Phase 3	3,428 participants (Actual)	Interventional	2010-06-30	Completed
The Efficacy and Safety of Pyronaridine-artesunate Combined With Low Dose Primaquine for Preventing Transmission of P. Falciparum Gametocytes in Sub-Saharan Africa [NCT04049916]	Phase 2/Phase 3	100 participants (Actual)	Interventional	2019-09-12	Completed
A Multi-centre Randomised Controlled Non-inferiority Trial to Compare the Efficacy, Safety and Tolerability of Triple Artemisinin-based Combination Therapies Versus First-line ACTs + Placebo for the Treatment of Uncomplicated Plasmodium Falciparum Malaria [NCT03939104]	Phase 3	1,368 participants (Anticipated)	Interventional	2021-06-30	Recruiting
A Multi-centre Randomised Controlled Non-inferiority Trial to Compare the Efficacy, Safety and Tolerability of Triple Artemisinin-based Combination Therapies Versus First-line ACTs + Placebo for the Treatment of Uncomplicated Plasmodium Falciparum Malaria [NCT03923725]	Phase 3	3,240 participants (Anticipated)	Interventional	2020-09-01	Recruiting
Evaluation of 4 Artemisinin-based Combinations for Treating Uncomplicated Malaria in African Children [NCT00393679]	Phase 3	4,112 participants (Actual)	Interventional	2007-07-31	Completed
[NCT01075945]	Phase 4	140 participants (Anticipated)	Interventional	2010-02-28	Recruiting
Efficacy and Safety of Artemether-Lumefantrine and Dihydroartemisinin-Piperaquine for the Treatment of Uncomplicated Plasmodium Falciparum Malaria Among Children in the North Region of Cameroon [NCT05340153]	Phase 4	184 participants (Anticipated)	Interventional	2022-04-11	Not yet recruiting
Electrocardiographic Safety Evaluation of Monthly Dihydroartemisinin-Piperaquine for the Use in Mass Treatment Campaigns to Block Malaria Transmission [NCT02605720]	Phase 3	78 participants (Actual)	Interventional	2015-09-30	Completed
In-vivo Efficacy and Safety of Artemether/Lumefantrine Vs Dihydroartemisinin-piperaquine for Treatment of Uncomplicated Malaria and Assessment of Parasite Genetic Factors Associated With Parasite Clearance or Treatment Failure [NCT02590627]	Phase 4	509 participants (Actual)	Interventional	2014-05-31	Completed
Targeted Chemo-elimination (TCE) to Eradicate Malaria in Areas of Suspected or Proven Artemisinin Resistance in Southeast Asia and South Asia [NCT01872702]		8,000 participants (Actual)	Interventional	2013-04-30	Completed
Impact of Mass Screening and Selective Treatment With Dihydroartemisinin-piperaquine Plus Primaquine on Malaria Transmission in High Endemic Area, Belu Regency, Nusa Tenggara Timur Province, Indonesia: a Randomized Cluster Trial [NCT01878357]	Phase 4	1,488 participants (Actual)	Interventional	2013-06-30	Completed
Safety, Tolerability, Pharmacokinetics and Efficacy, Phase Iv, Open Label Study of Fixed Arco® and Eurartesim® Therapies in Adults and Children With Uncomplicated P. Falciparum Malaria in Tanzania [NCT01930331]	Phase 4	60 participants (Actual)	Interventional	2014-01-07	Completed
Interactions Between HIV and Malaria in African Children [NCT00527800]	Phase 3	351 participants (Actual)	Interventional	2007-08-31	Completed
Efficacy and Safety of the Dispersible Formulation of Artemether-lumefantrine, Co-formulated Artesunate-amodiaquine and Co-formulated Dihydroartemisinin-piperaquine for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in Machinga District, Mal [NCT01326754]		498 participants (Actual)	Interventional	2011-08-31	Completed
A Phase IIa Proof of Concept Study to Explore the Efficacy, Tolerability and Safety of Fosmidomycin Sodium When Administered With Piperaquine Tetraphosphate to Adults and Older Children With Acute Uncomplicated Plasmodium Falciparum Malaria [NCT02198807]	Phase 2	100 participants (Actual)	Interventional	2014-03-31	Active, not recruiting
A Randomised Controlled Trial to Assess the Antimalarial Drug Susceptibility and Molecular Characterization of Plasmodium Vivax Isolates in Vietnam [NCT01887821]	Phase 4	330 participants (Actual)	Interventional	2013-02-28	Completed
Single Low Dose Tafenoquine to Reduce P. Falciparum Transmission in Mali (NECTAR2) [NCT04609098]	Phase 2	80 participants (Actual)	Interventional	2020-10-29	Completed
Effectiveness of Dihydroartemisinin-piperaquine as Seasonal Malaria Chemoprophylaxis in Extended High Transmission Settings of Tanzania: an Open Cluster Randomized Clinical Trial. [NCT05874869]		13,800 participants (Actual)	Interventional	2020-07-01	Completed
A Randomized, Open Label, Two-part, Parallel-group, Phase I Study to Evaluate the Pharmacokinetics of Piperaquine Oral Dispersible Granules Formulation Compared to Piperaquine Hard Tablets Administered as a Single Dose in Fasting Condition (Part 1) and of [NCT05930782]	Phase 1	60 participants (Anticipated)	Interventional	2023-07-24	Active, not recruiting
Intermittent Screening and Treatment for the Control of Malaria in the First Year of Life in Papua, Indonesia: A Cluster Randomized Controlled Trial [NCT02001428]		757 participants (Actual)	Interventional	2014-07-21	Completed
'SCHOOL-BASED TREATMENT WITH ACT TO REDUCE TRANSMISSION' (START-IPT): Evaluation of the Community Impact of Intermittent Preventive Treatment for Malaria in Ugandan Children: a Cluster Randomised Trial [NCT02009215]	Phase 4	10,746 participants (Actual)	Interventional	2014-02-28	Completed
Comparison of Safety, Tolerability and Efficacy of Three Drug Combinations for Intermittent Preventive Treatment in Children Aged 1-5 Years in an Area of Seasonal Malaria Transmission in Upper River Division, The Gambia [NCT00561899]	Phase 2/Phase 3	1,295 participants (Actual)	Interventional	2007-08-31	Completed
Randomised Parallel Open Label Comparison Between 7 and 14 Day Primaquine Combined With 3-day Dihydroartemisinin-piperaquine or 3-day Chloroquine Regimens for Radical Cure of Plasmodium Vivax [NCT01640574]	Phase 3	680 participants (Actual)	Interventional	2012-02-29	Completed
Effect of Imatinib on Suppression of Malaria Parasites in Patients With Uncomplicated Plasmodium Falciparum Malaria [NCT02614404]	Phase 1	15 participants (Actual)	Interventional	2015-11-30	Completed
Reactive Household-based Self-administered Treatment Against Residual Malaria Transmission: a Cluster Randomized Trial [NCT02878200]		2,236 participants (Actual)	Interventional	2016-11-04	Completed
Acceptability and Feasibility of IPTp With Dihydroartemisinin-piperaquine With or Without Azithromycin to Prevent Malaria, Sexually Transmitted and Reproductive Tract Infections in HIV-uninfected Pregnant Women (IMPROVE) in Kenya. [NCT04160026]	Phase 4	1,600 participants (Actual)	Interventional	2019-11-11	Completed
Efficacy, Safety, and Pharmacokinetics of Sulphadoxine-pyrimethamine-amodiaquine (SP-AQ), SP-AQ Plus Primaquine, Dihydroartemisinin-piperaquine (DP), DP Plus Methylene Blue for Preventing Transmission of P. Falciparum Gametocytes in Mali [NCT02831023]	Phase 2	80 participants (Actual)	Interventional	2016-07-31	Completed
Evaluation of the Household-level Impact of a Single Round of Intermittent Preventive Treatment of Malaria in Schoolchildren: A Randomized Study [NCT04660110]	Phase 3	1,500 participants (Anticipated)	Interventional	2021-01-28	Recruiting
Evaluation of Impact Dihydroartemisinin-piperaquine Plus Primaquine on Malaria Transmission in Lempasing Village, Lampung Province, Southern Sumatra [NCT01389557]	Phase 4	77 participants (Actual)	Interventional	2011-02-28	Completed
Effectiveness of Dihydroartemisinin-piperaquine With or Without Primaquine on Gametocytes Plasmodium Falciparum in Mesoendemic Area of Indonesia [NCT01392014]	Phase 4	374 participants (Actual)	Interventional	2008-12-31	Completed
Evaluation of the Implementation and Effectiveness of Intermittent Preventive Treatment for Malaria Using Dihydroartemisinin-piperaquine on Reducing Malaria Burden in School Aged Children in Tanzania [NCT04245033]	Phase 4	4,100 participants (Actual)	Interventional	2020-07-20	Active, not recruiting
A Randomised Open Label Trial Comparing Standard Dose of Dihydroartemisinin-piperaquine, Standard Fixed Artesunate-mefloquine Regimen and a Longer Regimen of Artemether-lumefantrine in the Treatment of Uncomplicated Malaria in Pregnancy [NCT01054248]	Phase 3	511 participants (Actual)	Interventional	2010-02-16	Completed
Effectiveness of Momordica Charantia Extract Compared to the Standard Antimalarial Drug Combination Dihydroartemisinin Piperaquine-primaquine in Patients With Uncomplicated Falciparum Malaria, in Sumba Barat Daya District of Indonesia [NCT05829187]	Phase 2	36 participants (Actual)	Interventional	2022-11-01	Completed
Active Surveillance for P. Falciparum Drug Resistance With Assessment of Transmission Blocking Activity of Single Dose Primaquine in Cambodia [NCT01849640]		150 participants (Anticipated)	Interventional	2012-12-31	Suspended(stopped due to Poor efficacy of DHA-piperaquine due to likely drug resistance.)
Does Artemisinin Combination Treatment Reduce the Radical Curative Efficacy of High Dose Tafenoquine for Plasmodium Vivax Malaria? [NCT05788094]	Phase 4	388 participants (Anticipated)	Interventional	2023-06-26	Recruiting
Mass Drug Administration of Monthly DHA-PQP to Accelerate Towards Malaria Elimination in Magude District, Southern Mozambique [NCT02914145]		240,502 participants (Actual)	Interventional	2015-11-30	Completed
Randomized Trial of Effectiveness and Acceptability of Three Alternative Regimens for Malaria Seasonal Intermittent Preventive Treatment in Senegal [NCT00529620]	Phase 3	1,833 participants (Actual)	Interventional	2007-09-30	Completed
Cardiac Safety of Dihydroartemisinin-Piperaquine Amongst Pregnant Women in Tanzania [NCT02909712]	Phase 2	201 participants (Actual)	Interventional	2016-09-30	Completed
Evaluation of a Pilot Implementation of Intermittent Preventive Treatment With Dihydroartemisinin-piperaquine to Prevent Adverse Birth Outcomes in Papua, Indonesia [NCT05294406]	Phase 4	1,420 participants (Anticipated)	Interventional	2022-02-07	Active, not recruiting
Evaluation of the Safety and Efficacy of Dihydroartemisinin-piperaquine for Intermittent Preventive Treatment of Malaria in HIV-infected Pregnant Women [NCT03671109]	Phase 3	666 participants (Actual)	Interventional	2019-09-18	Completed
Randomised Phase IIb Study of Efficacy, Safety, Tolerability & Pharmacokinetics of a Single Dose Regimen of Artefenomel (OZ439) in Loose Combination With Piperaquine in Adults and Children With Uncomplicated Plasmodium Falciparum Malaria. [NCT02083380]	Phase 2/Phase 3	448 participants (Actual)	Interventional	2014-07-31	Completed
A Cluster-randomised, Open-label Trial to Compare the Impact of Combined Mass Vaccine and Drug Administrations, Mass Drug Administration, Mass Vaccinations, or no Intervention on Plasmodium Falciparum Malaria Transmission [NCT06068530]	Phase 4	10,000 participants (Anticipated)	Interventional	2023-11-01	Not yet recruiting
Efficacy and Safety of Artesunate-amodiaquine, Artemether-lumefantrine and Dihydroartemisinine-piperaquine in the Treatment of Uncomplicated Plasmodium Falciparum Malaria in the Democratic Republic of Congo: a Randomized Controlled Trial [NCT02940756]	Phase 4	1,615 participants (Actual)	Interventional	2017-03-15	Completed
IPTp With Dihydroartemisinin-piperaquine and Azithromycin for Malaria, Sexually Transmitted and Reproductive Tract Infections in Pregnancy in High Sulphadoxine-pyrimethamine Resistance Areas in Kenya, Malawi and Tanzania [NCT03208179]	Phase 3	4,680 participants (Actual)	Interventional	2018-03-29	Completed
Preventing Malaria in School Children to Protect the Whole Community in Rural Blantyre District, Malawi [NCT06083688]	Phase 4	1,000 participants (Anticipated)	Interventional	2024-10-31	Not yet recruiting
A Randomized, Double Blind, Placebo-controlled Clinical Trial of Monthly DHA-piperaquine for Malaria Prevention in Cambodia. [NCT01624337]		231 participants (Anticipated)	Interventional	2012-05-31	Terminated(stopped due to Medication safety concern)
An Individually Randomised Trial of Seasonal Malaria Chemoprevention Versus a Long-acting Artemisinin Combination Therapy for the Prevention of Malaria and Anaemia in Children Living in an Area of Extended Seasonal Transmission in Ghana. [NCT01651416]	Phase 4	2,400 participants (Actual)	Interventional	2012-07-31	Completed
Efficacy and Safety of Artemether + Lumefantrine and Dihydroartemisinin + Piperaquine for the Treatment of Uncomplicated Malaria in Guinea-Bissau. [NCT01704508]	Phase 4	346 participants (Actual)	Interventional	2012-11-30	Completed
Phase 2a Dose Escalation Study of the Efficacy, Safety, and Pharmacokinetics of Low Dose Primaquine for Gametocytocidal Activity Against P. Falciparum in Sub-Saharan Africa and South East Asia [NCT01743820]	Phase 2	81 participants (Actual)	Interventional	2013-09-30	Completed
Efficacy of Artesunate-amodiaquine, Dihydroartemisinin-piperaquine and Artemether-lumefantrine Combination Therapies for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in Children Aged 6 to 59 Months in Maradi, Niger 2012-13 [NCT01755559]	Phase 4	663 participants (Actual)	Interventional	2013-06-30	Completed
Phase III Study to Study the Clinical Response to ACT Fixed Dose Combination in 42 Days in Uncomplicated Malaria in Cameroon [NCT01845701]	Phase 3	720 participants (Actual)	Interventional	2010-03-31	Completed
Study 200894: A Double-blind, Double-dummy, Randomized, Parallel Group, Placebo-controlled Superiority Study to Evaluate the Efficacy and Safety of Tafenoquine (SB-252263, WR238605) Co-administered With Dihydroartemisinin-piperaquine (DHA-PQP) for the Rad [NCT02802501]	Phase 3	150 participants (Actual)	Interventional	2018-04-08	Completed
Evaluation of Community-based Screening and Treatment for Malaria in the KEMRI/CDC Health and Demographic Surveillance System (HDSS) in Western Kenya [NCT02987270]	Phase 3	90,000 participants (Actual)	Interventional	2013-04-30	Completed
Controlled Human Malaria Infection Study to Assess Gametocytemia and Mosquito Transmissibility in Participants Challenged With Plasmodium Falciparum by Sporozoite or Blood Stage Challenge to Establish a Model for the Evaluation of Transmission-blocking In [NCT03454048]		24 participants (Actual)	Interventional	2018-05-07	Completed
Adjunctive Ivermectin Mass Drug Administration for Malaria Control on the Bijagos Archipelago of Guinea Bissau: A Cluster-randomized Placebo-controlled Trial [NCT04844905]	Phase 3	24,000 participants (Anticipated)	Interventional	2021-05-03	Recruiting
Assessment of Antimalaria Drugs Susceptibility Testing for an Effective Management of Infected Patients in Sub-Sahara Africa [NCT02974348]	Phase 3	300 participants (Actual)	Interventional	2013-01-31	Completed
Randomized Open-label Trial of Comparison Between DHA-Piperaquine and Mefloquine Artesunate Combinations 3 Day-regimens for the Treatment of Uncomplicated Plasmodium Falciparum Malaria on the Thai-Myanmar Border (RDM) [NCT01640587]		76 participants (Actual)	Interventional	2013-11-30	Terminated(stopped due to No adequate malaria patient)
Efficacy and Safety of Sulfadoxine-pyrimethamine or Sulfadoxine-pyrimethamine Plus Piperaquine Regimens Delivered Through Intermittent Preventive Treatment in Schoolchildren of Democratic Republic of Congo: A Randomised Control Trial [NCT01722539]	Phase 3	616 participants (Actual)	Interventional	2012-11-30	Completed
Clinical Trial to Evaluate Intermittent Screening and Treatment and Intermittent Preventive Treatment of Malaria in Asymptomatic Schoolchildren to Decrease P. Falciparum Infection and Transmission [NCT05244954]	Phase 4	746 participants (Actual)	Interventional	2022-02-01	Completed
A Prospective Randomized Open-Label Study on the Efficacy and Safety of Intermittent Preventive Treatment in Pregnancy (IPTp) With Dihydroartemisinin-Piperaquine (DP) Versus IPTp With Sulfadoxine-Pyrimethamine (SP) in Malawi [NCT03009526]	Phase 3	602 participants (Actual)	Interventional	2017-01-17	Completed
Reducing the Burden of Malaria in HIV-uninfected Pregnant Women and Infants (PROMOTE Birth Cohort 1) [NCT02163447]	Phase 3	300 participants (Actual)	Interventional	2014-06-23	Completed
Reducing the Burden of Malaria in HIV-Infected Pregnant Women and Their HIV-Exposed Children (PROMOTE Birth Cohort 2) [NCT02282293]	Phase 3	200 participants (Actual)	Interventional	2014-12-09	Completed
Blood Stage Challenge Study to Asses Mosquito Transmissibility in Participants Inoculated With Plasmodium Falciparum [NCT02431637]	Phase 1	6 participants (Actual)	Interventional	2015-04-30	Completed
Phase 3a: Efficacy, Safety, and Tolerability of Dihydroartemisinin/Piperaquine (Artekin®) for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in the Peruvian Amazon Region [NCT00373607]	Phase 3	522 participants (Actual)	Interventional	2003-07-31	Completed
Mass Drug Administration With Dihydroartemisinin-piperaquine and Primaquine to Reduce Malaria in a Moderate-low Transmission Setting in Senegal: A Cluster Randomized Controlled Trial [NCT04864444]		10,715 participants (Actual)	Interventional	2021-06-19	Completed
Efficacy and Safety of Dihydroartemisinin-piperaquine for the Treatment of Uncomplicated Plasmodium Falciparum and Plasmodium Vivax Malaria in Timika, Indonesia [NCT02353494]		130 participants (Actual)	Observational	2015-03-31	Completed
Boosting the Impact of Seasonal Malaria Chemoprevention (SMC) Through Simultaneous Screening and Treatment of SMC-Children's Roommates in Burkina Faso [NCT04816461]	Phase 4	789 participants (Anticipated)	Interventional	2021-07-31	Not yet recruiting
Enhancing Preventive Therapy of Malaria In Children With Sickle Cell Anemia in East Africa (EPiTOMISE) [NCT03178643]	Phase 4	246 participants (Actual)	Interventional	2018-01-23	Completed
Evaluation of the Efficacy of Artemisinin Combination Therapy in Kenya [NCT01899820]	Phase 3	2,100 participants (Anticipated)	Interventional	2013-04-30	Active, not recruiting
A Hybrid Effectiveness-implementation Study to Assess the Effectiveness and Chemoprevention Efficacy of Implementing Seasonal Malaria Chemoprevention in Five Districts in Karamoja Region, Uganda [NCT05323721]	Phase 4	6,805 participants (Actual)	Interventional	2022-06-01	Active, not recruiting
Efficacy of Artemether Lumefantrine (AL) and Dihydroartemisinin-Piperaquine (DHP) for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in Siaya and Bungoma Counties, Kenya [NCT04767191]	Phase 4	400 participants (Actual)	Interventional	2021-03-15	Completed
A Phase I Study to Investigate the Safety, Tolerability & Pharmacokinetics of Co-administered Single Doses of OZ439 and Piperaquine to Healthy Subjects [NCT01660022]	Phase 1	59 participants (Actual)	Interventional	2012-09-30	Completed
Field Study of the Pharmacokinetics and Pharmacodynamics of Artemisinin-based Combination Therapy for Gametocyte Clearance and Post-treatment Chemoprotection in Zambian Children With Uncomplicated Falciparum Malaria [NCT04009343]	Phase 2/Phase 3	182 participants (Anticipated)	Interventional	2019-06-19	Active, not recruiting
Efficacy and Safety of High-dose Ivermectin for Reducing Malaria Transmission: A Dose Finding Study (IVERMAL) [NCT02511353]	Phase 2	141 participants (Actual)	Interventional	2015-07-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT00948896 (4) [back to overview]	Incident Malaria Cases Per Person Year at Risk in HIV-unexposed Participants
NCT00948896 (4) [back to overview]	Incident Malaria Cases Per Person Year at Risk in HIV-exposed Participants
NCT00948896 (4) [back to overview]	Rebound Incidence of Malaria Defined as the Number of Treatments for New Episodes of Malaria Per Time at Risk
NCT00948896 (4) [back to overview]	Incidence of Any Adverse Events Defined as Severity Grade 3-4 That Are Possibly, Probably, or Definitely Related to Study Drugs
NCT01660022 (6) [back to overview]	OZ439 AUC(0-168)
NCT01660022 (6) [back to overview]	OZ439 t1/2
NCT01660022 (6) [back to overview]	Piperaquine t1/2
NCT01660022 (6) [back to overview]	OZ439 Cmax
NCT01660022 (6) [back to overview]	Piperaquine AUC(0-168)
NCT01660022 (6) [back to overview]	Piperaquine Cmax
NCT02083380 (32) [back to overview]	PCR-adjusted ACPR at Day 42 in the ITT Population
NCT02083380 (32) [back to overview]	PCR-adjusted ACPR at Day 63 in the ITT Population
NCT02083380 (32) [back to overview]	PCR-adjusted ACPR at Day 63 in the PP Population
NCT02083380 (32) [back to overview]	Piperaquine: Cday7 Africa (> 5 Years)
NCT02083380 (32) [back to overview]	Piperaquine: Cday7 Africa (>=0.5 to <= 2 Years)
NCT02083380 (32) [back to overview]	Crude ACPR at Day 63 in the ITT Population
NCT02083380 (32) [back to overview]	Piperaquine: Cday7 Asia (All Ages)
NCT02083380 (32) [back to overview]	PRR48
NCT02083380 (32) [back to overview]	Piperaquine: Cday7 Africa (>2 to <= 5 Years)
NCT02083380 (32) [back to overview]	Artefenomel Cday7 African Patients (> 5 Years)
NCT02083380 (32) [back to overview]	Artefenomel Cday7 African Patients (>=0.5 to <= 2 Years)
NCT02083380 (32) [back to overview]	Artefenomel Cday7 African Patients (>2 to <= 5 Years)
NCT02083380 (32) [back to overview]	Artefenomel Cday7 Asian Patients (All Ages)
NCT02083380 (32) [back to overview]	Crude ACPR at Day 28 in the ITT Population
NCT02083380 (32) [back to overview]	Crude ACPR at Day 28 in the PP Population
NCT02083380 (32) [back to overview]	Crude ACPR at Day 42 in the ITT Population
NCT02083380 (32) [back to overview]	Crude ACPR at Day 42 in the PP Population
NCT02083380 (32) [back to overview]	Crude ACPR at Day 63 in the PP Population
NCT02083380 (32) [back to overview]	Fever Clearance Time
NCT02083380 (32) [back to overview]	Kaplan-Meier Estimate of New Infection Rate
NCT02083380 (32) [back to overview]	Kaplan-Meier Estimate of Recrudescence
NCT02083380 (32) [back to overview]	Kaplan-Meier Estimate of Recurrence
NCT02083380 (32) [back to overview]	Parasite Clearance Time
NCT02083380 (32) [back to overview]	PCR - Adjusted ACPR at Day 42 in the PP Population
NCT02083380 (32) [back to overview]	PCR-adjusted ACPR at Day 28 in the ITT Population
NCT02083380 (32) [back to overview]	PCR-adjusted ACPR at Day 28 in the PP Population (All Patients)
NCT02083380 (32) [back to overview]	PCR-adjusted ACPR at Day 28 in the PP Population: Africa (< = 5 Years)
NCT02083380 (32) [back to overview]	PCR-adjusted ACPR at Day 28 in the PP Population: Africa (> Than 5 Years)
NCT02083380 (32) [back to overview]	PCR-adjusted ACPR at Day 28 in the PP Population: Africa (>= 0.5 to <= 2 Years)
NCT02083380 (32) [back to overview]	PCR-adjusted ACPR at Day 28 in the PP Population: Africa (>2 to <= 5 Years)
NCT02083380 (32) [back to overview]	PCR-adjusted ACPR at Day 28 in the PP Population: Africa (All Ages)
NCT02083380 (32) [back to overview]	PCR-adjusted ACPR at Day 28 in the PP Population: Asia (All Ages)
NCT02163447 (14) [back to overview]	Number of Participants With One or More Birth Outcomes: Congenital Malformations, Spontaneous Abortion, LBW (<2500g), Still Birth, Pre-term Delivery
NCT02163447 (14) [back to overview]	Prevalence of Anemia in Pregnant Women
NCT02163447 (14) [back to overview]	Prevalence of Gametocytemia in Infants
NCT02163447 (14) [back to overview]	Prevalence of Gametocytemia in Pregnant Women
NCT02163447 (14) [back to overview]	Prevalence of Parasitemia at the Time of Monthly Routine Visits During Pregnancy
NCT02163447 (14) [back to overview]	Prevalence of Parasitemia in Infants
NCT02163447 (14) [back to overview]	Prevalence of Placental Malaria
NCT02163447 (14) [back to overview]	Number of Participants With Blood Samples Positive for Parasites by Microscopy or LAMP
NCT02163447 (14) [back to overview]	Number of Participants With Maternal Blood Samples Positive for Parasites by Microscopy and LAMP at Delivery
NCT02163447 (14) [back to overview]	Incidence of Complicated Malaria in Infants
NCT02163447 (14) [back to overview]	Incidence of Hospital Admissions in Infants
NCT02163447 (14) [back to overview]	Incidence of Malaria in Infants
NCT02163447 (14) [back to overview]	Incidence of Malaria in Infants
NCT02163447 (14) [back to overview]	Incidence of Malaria in Pregnant Women
NCT02282293 (7) [back to overview]	Incidence of Malaria, Pregnant Women
NCT02282293 (7) [back to overview]	Number of Monthly Routine Visits With Positive Blood Samples for Parasites
NCT02282293 (7) [back to overview]	Number of Participants With Placental Malaria
NCT02282293 (7) [back to overview]	Number of Routine Visits Measured Every 8 Weeks During Pregnancy for Which the Participants Had Anemia
NCT02282293 (7) [back to overview]	Maternal Parasitemia at Delivery by Microscopy and LAMP
NCT02282293 (7) [back to overview]	Placental Parasitemia (Number of Women With Placental Blood Samples Positive for Malaria by Microscopy or PCR)
NCT02282293 (7) [back to overview]	Composite Adverse Birth Outcome (Proportion With Low Birth Weight (<2500 gm), Spontaneous Abortion (<28 Weeks), Stillbirth (Fetal Demise ≥28 Weeks), Congenital Anomaly, or Preterm Delivery (<37 Weeks)
NCT02431637 (1) [back to overview]	Safety: Number of AEs
NCT02793622 (14) [back to overview]	Prevalence of Maternal Malaria
NCT02793622 (14) [back to overview]	Prevalence of Placental Malaria by Histology
NCT02793622 (14) [back to overview]	Prevalence of Placental Parasitemia
NCT02793622 (14) [back to overview]	Incidence of Complicated Malaria in Infants
NCT02793622 (14) [back to overview]	Incidence of Hospital Admissions in Infants
NCT02793622 (14) [back to overview]	Incidence of Malaria in Infants
NCT02793622 (14) [back to overview]	Infant Mortality Rate
NCT02793622 (14) [back to overview]	Mean Gestational Age in Weeks at Birth
NCT02793622 (14) [back to overview]	Number of Participants Who Deliver With a Composite Adverse Birth Outcome
NCT02793622 (14) [back to overview]	Number of Participants With Adverse Events
NCT02793622 (14) [back to overview]	Prevalence of Anemia in Infants
NCT02793622 (14) [back to overview]	Prevalence of Anemia in Pregnant Women
NCT02793622 (14) [back to overview]	Prevalence of Asymptomatic Parasitemia in Infants
NCT02793622 (14) [back to overview]	Prevalence of Asymptomatic Parasitemia in Pregnant Women
NCT02802501 (20) [back to overview]	Percentage of Participants With Relapse-free Efficacy at Four Months After Administration of Tafenoquine With DHA-PQP and DHA-PQP Alone
NCT02802501 (20) [back to overview]	Number of Participants With Recrudescence
NCT02802501 (20) [back to overview]	Number of Participants With Electrocardiogram (ECG) Values Outside Clinical Concern Range-QT Interval Corrected Using Fredericia's Formula (QTcF)
NCT02802501 (20) [back to overview]	Percentage of Participants With Relapse-free Efficacy at Six Months After Administration of Tafenoquine With DHA-PQP and DHA-PQP Alone
NCT02802501 (20) [back to overview]	Percentage of Participants With Relapse-free Efficacy at Six Months After Administration of Tafenoquine With DHA-PQP and Primaquine+DHA-PQP
NCT02802501 (20) [back to overview]	Time to Fever Clearance
NCT02802501 (20) [back to overview]	Time to Parasite Clearance
NCT02802501 (20) [back to overview]	Time to Relapse of P. Vivax Malaria
NCT02802501 (20) [back to overview]	Change From Baseline in Methemoglobin/ Total Hemoglobin
NCT02802501 (20) [back to overview]	Change From Baseline in QT Interval Corrected by Fridericia's Formula (QTcF)
NCT02802501 (20) [back to overview]	Number of Participants With Any Adverse Events (AEs) and Serious Adverse Events (SAEs) During the Double-blind Treatment Phase
NCT02802501 (20) [back to overview]	Number of Participants With Chemistry Values Outside Clinical Concern Range
NCT02802501 (20) [back to overview]	Number of Participants With Gastrointestinal AEs
NCT02802501 (20) [back to overview]	Number of Participants With Hematology Values Outside Clinical Concern Range
NCT02802501 (20) [back to overview]	Percentage of Participants With Relapse-free Efficacy at Six Months After Administration of Primaquine With DHA-PQP and DHA-PQP Alone
NCT02802501 (20) [back to overview]	Number of Participants With Protocol-defined SAE (Hemoglobin Drop)
NCT02802501 (20) [back to overview]	Number of Participants With Worst Case Body Temperature Results Relative to Normal Range Post-Baseline Relative to Baseline
NCT02802501 (20) [back to overview]	Number of Participants With Worst Case Pulse Rate Results Relative to Normal Range Post-Baseline Relative to Baseline
NCT02802501 (20) [back to overview]	Number of Participants With Worst Case Respiratory Rate Results Relative to Normal Range Post-Baseline Relative to Baseline
NCT02802501 (20) [back to overview]	Number of Participants With Worst Case Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Results Relative to Normal Range Post-Baseline Relative to Baseline
NCT03454048 (8) [back to overview]	AUC Gametocytes
NCT03454048 (8) [back to overview]	Frequency of Adverse Events in the CHMI-trans Model
NCT03454048 (8) [back to overview]	Gametocyte Commitment
NCT03454048 (8) [back to overview]	Gametocyte Prevalence
NCT03454048 (8) [back to overview]	Gametocyte Sex-ratio
NCT03454048 (8) [back to overview]	Number of Participants Infectious for Mosquitoes Through DFA
NCT03454048 (8) [back to overview]	Peak Density Gametocytes
NCT03454048 (8) [back to overview]	Magnitude of Adverse Events in the CHMI-trans Model

Incident Malaria Cases Per Person Year at Risk in HIV-unexposed Participants

The incidence of malaria, defined as the number of incident episodes per time at risk, during the period the intervention was given (6-24 mo of age). Treatments within 14d of a prior episode were not considered incident events. Time at risk was from the day following the initiation of study drugs to the last day of observation, minus 14 d after each treatment for malaria. (NCT00948896)
Timeframe: 6 to 24 months of age

,,,

Intervention	Episode per person year at risk (Number)
	6-24 mo. of Age	6-11 mo. of Age	12-24 mo. of Age
HIV-unexposed & Daily TS	5.21	3.27	6.32
HIV-unexposed & Monthly DP	3.02	1.49	3.88
HIV-unexposed & Monthly SP	6.73	5.51	7.41
HIV-unexposed & no Chemoprevention	6.95	6.41	7.24

Intervention	Episodes per person year at risk (Number)
	Randomization - 24 mo. of Age	Randomization -16 mo. of Age	17-24 mo. of Age
HIV-exposed & Daily TS	2.86	1.70	3.79
HIV-exposed & Monthly DP	1.83	0.90	2.67
HIV-exposed & Monthly SP	4.50	3.72	5.22
HIV-exposed & no Chemoprevention	6.28	5.42	7.04

Intervention	Incidence per person year at risk (Number)
	All incident episodes of malaria	Complicated malaria	All-cause hospital admissions
HIV-exposed & Daily TS	8.13	0.116	0.186
HIV-exposed & Monthly DP	6.78	0.044	0.089
HIV-exposed & Monthly SP	6.75	0.147	0.318
HIV-exposed & no Chemoprevention	9.08	0.161	0.459
HIV-unexposed & Daily TS	10.90	0.046	0.091
HIV-unexposed & Monthly DP	10.77	0	0.023
HIV-unexposed & Monthly SP	11.98	0.132	0.452
HIV-unexposed & no Chemoprevention	10.85	0.046	0.046

Intervention	incidence per person-year at risk (Number)
	All grade 3-4 adverse events	Grade 3-4 AEs possibly related to study drugs	All serious adverse events	Elevated Temperature	Anemia	Thrombocytopenia	Elevated aspartate aminotransferase	Elevated alanine aminotransferase	Neutropenia	Malnutrition
HIV-exposed & Daily TS	0.659	0.062	0.330	0.206	0.206	0	0.041	0	0	0.021
HIV-exposed & Monthly DP	0.678	0.097	0.194	0.174	0.291	0.058	0.039	0	0	0.039
HIV-exposed & Monthly SP	1.478	0	0.453	0.532	0.631	0.118	0.020	0	0	0.020
HIV-exposed & no Chemoprevention	1.214	NA	0.411	0.431	0.705	0	0.039	0	0	0.020
HIV-unexposed & Daily TS	0.914	0.054	0.196	0.393	0.318	0.061	0.041	0.027	0.014	0
HIV-unexposed & Monthly DP	0.611	0.021	0.091	0.323	0.168	0.035	0.021	0.021	0.007	0
HIV-unexposed & Monthly SP	1.415	0.056	0.364	0.546	0.602	0.119	0.056	0.028	0.042	0
HIV-unexposed & no Chemoprevention	1.159	NA	0.178	0.542	0.384	0.123	0.048	0.027	0.021	0

Intervention	ng.h/mL (Geometric Mean)
Cohort 1 - OZ439 100mg	862
Cohort 1 - OZ439 100mg / PQP 160mg	920
Cohort 2 - OZ439 100mg	1130
Cohort 2 - OZ439 100mg / PQP 480mg	1390
Cohort 3 - OZ439 100mg	909
Cohort 3 - OZ439 100mg / PQP 1440mg	1520
Cohort 4 - OZ439 300mg	5740
Cohort 4 - OZ439 300mg / PQP 1440mg	7410
Cohort 5 - OZ439 800mg	15300
Cohort 5 - OZ439 800mg / PQP 1440mg	18600

Intervention	hour (Geometric Mean)
OZ439 100mg / PQP 160mg	294
OZ439 100mg / PQP 480mg	283
OZ439 100mg / PQP 1440mg	515
OZ439 300mg / PQP 1440mg	632
OZ439 800mg / PQP 1440mg	509

Intervention	ng.h/mL (Geometric Mean)
OZ439 100mg / PQP 160mg	1340
OZ439 100mg / PQP 480mg	3420
OZ439 100mg / PQP 1440mg	17500
OZ439 300mg / PQP 1440mg	17200
OZ439 800mg / PQP 1440mg	13200

Intervention	ng/mL (Geometric Mean)
OZ439 100mg / PQP 160mg	8.59
OZ439 100mg / PQP 480mg	46.6
OZ439 100mg / PQP 1440mg	393
OZ439 300mg / PQP 1440mg	271
OZ439 800mg / PQP 1440mg	356

Intervention	% ACPR PCR-adjusted (Number)
A) Artefenomel 800mg: Piperaquine 640mg	46.9
B) Artefenomel 800mg: Piperaquine 960mg	48.6
C) Artefenomel 800mg: Piperaquine 1440mg	50.0

Intervention	% ACPR PCR-adjusted (Number)
A) Artefenomel 800mg: Piperaquine 640mg	36.8
B) Artefenomel 800mg: Piperaquine 960mg	38.6
C) Artefenomel 800mg: Piperaquine 1440mg	43.7

Intervention	% ACPR PCR-adjusted (Number)
A) Artefenomel 800mg: Piperaquine 640mg	57.8
B) Artefenomel 800mg: Piperaquine 960mg	58.9
C) Artefenomel 800mg: Piperaquine 1440mg	69.0

Intervention	ratio (Median)
A) Artefenomel 800mg: Piperaquine 640mg	9.120
B) Artefenomel 800mg: Piperaquine 960mg	9.300
C) Artefenomel 800mg: Piperaquine 1440mg	8.690

Intervention	% ACPR unadjusted (crude) (Number)
A) Artefenomel 800mg: Piperaquine 640mg	53.1
B) Artefenomel 800mg: Piperaquine 960mg	53.4
C) Artefenomel 800mg: Piperaquine 1440mg	63.0

Intervention	% ACPR unadjusted (crude) (Number)
A) Artefenomel 800mg: Piperaquine 640mg	57.4
B) Artefenomel 800mg: Piperaquine 960mg	56.6
C) Artefenomel 800mg: Piperaquine 1440mg	66.9

Intervention	% ACPR unadjusted (crude) (Number)
A) Artefenomel 800mg: Piperaquine 640mg	44.1
B) Artefenomel 800mg: Piperaquine 960mg	44.6
C) Artefenomel 800mg: Piperaquine 1440mg	46.6

Intervention	% ACPR unajusted (crude) (Number)
A) Artefenomel 800mg: Piperaquine 640mg	48.0
B) Artefenomel 800mg: Piperaquine 960mg	48.5
C) Artefenomel 800mg: Piperaquine 1440mg	51.5

Intervention	% ACPR unadjusted (crude) (Number)
A) Artefenomel 800mg: Piperaquine 640mg	42.1
B) Artefenomel 800mg: Piperaquine 960mg	39.3
C) Artefenomel 800mg: Piperaquine 1440mg	49.1

Intervention	% population with new infection (Number)
A) Artefenomel 800mg: Piperaquine 640mg	11.3
B) Artefenomel 800mg: Piperaquine 960mg	16.3
C) Artefenomel 800mg: Piperaquine 1440mg	13.6

Intervention	% patients with recrudescence (Number)
A) Arttefenomel 800mg: Piperaquine 640mg	22.7
B) Artefenomel 800mg: Piperaquine 960mg	29.1
C) Artefenomel 800mg: Piperaquine 1440mg	18.6

Intervention	% population recurring (Number)
A) Artefenomel 800mg: Piperaquine 640mg	44.7
B) Artefenomel 800mg: Piperaquine 960mg	54.6
C) Artefenomel 800mg: Piperaquine 1440mg	43.6

Intervention	hours (Median)
A) Artefenomel 800mg: Piperaquine 640mg	36.1
B) Artefenomel 800mg: Piperaquine 960mg	36.0
C) Artefenomel 800mg: Piperaquine 1440mg	36.1

piperaquine

Description

Cross-References

Synonyms (40)

Research Excerpts

Overview

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Roles (1)

Drug Classes (3)

Protein Targets (1)

Inhibition Measurements

Biological Processes (19)

Molecular Functions (23)

Ceullar Components (3)

Bioassays (277)

Research

Studies (635)

Market Indicators

Research Demand Index: 56.93

Study Types

Clinical Trials (132)

Trial Overview

Trial Outcomes

Incident Malaria Cases Per Person Year at Risk in HIV-unexposed Participants

Incident Malaria Cases Per Person Year at Risk in HIV-exposed Participants

Rebound Incidence of Malaria Defined as the Number of Treatments for New Episodes of Malaria Per Time at Risk

Incidence of Any Adverse Events Defined as Severity Grade 3-4 That Are Possibly, Probably, or Definitely Related to Study Drugs

OZ439 AUC(0-168)

OZ439 t1/2

Piperaquine t1/2

OZ439 Cmax

Piperaquine AUC(0-168)

Piperaquine Cmax

PCR-adjusted ACPR at Day 42 in the ITT Population

PCR-adjusted ACPR at Day 63 in the ITT Population

PCR-adjusted ACPR at Day 63 in the PP Population

Piperaquine: Cday7 Africa (> 5 Years)

Piperaquine: Cday7 Africa (>=0.5 to <= 2 Years)

Crude ACPR at Day 63 in the ITT Population

Piperaquine: Cday7 Asia (All Ages)

PRR48

Piperaquine: Cday7 Africa (>2 to <= 5 Years)

Artefenomel Cday7 African Patients (> 5 Years)

Artefenomel Cday7 African Patients (>=0.5 to <= 2 Years)

Artefenomel Cday7 African Patients (>2 to <= 5 Years)

Artefenomel Cday7 Asian Patients (All Ages)

Crude ACPR at Day 28 in the ITT Population

Crude ACPR at Day 28 in the PP Population

Crude ACPR at Day 42 in the ITT Population

Crude ACPR at Day 42 in the PP Population

Crude ACPR at Day 63 in the PP Population

Fever Clearance Time

Kaplan-Meier Estimate of New Infection Rate

Kaplan-Meier Estimate of Recrudescence

Kaplan-Meier Estimate of Recurrence

Parasite Clearance Time

PCR - Adjusted ACPR at Day 42 in the PP Population

PCR-adjusted ACPR at Day 28 in the ITT Population

PCR-adjusted ACPR at Day 28 in the PP Population (All Patients)

PCR-adjusted ACPR at Day 28 in the PP Population: Africa (< = 5 Years)

PCR-adjusted ACPR at Day 28 in the PP Population: Africa (> Than 5 Years)

PCR-adjusted ACPR at Day 28 in the PP Population: Africa (>= 0.5 to <= 2 Years)

PCR-adjusted ACPR at Day 28 in the PP Population: Africa (>2 to <= 5 Years)

PCR-adjusted ACPR at Day 28 in the PP Population: Africa (All Ages)

PCR-adjusted ACPR at Day 28 in the PP Population: Asia (All Ages)

Number of Participants With One or More Birth Outcomes: Congenital Malformations, Spontaneous Abortion, LBW (<2500g), Still Birth, Pre-term Delivery

Prevalence of Anemia in Pregnant Women

Prevalence of Gametocytemia in Infants

Prevalence of Gametocytemia in Pregnant Women

Prevalence of Parasitemia at the Time of Monthly Routine Visits During Pregnancy

Prevalence of Parasitemia in Infants

Prevalence of Placental Malaria

Number of Participants With Blood Samples Positive for Parasites by Microscopy or LAMP

Number of Participants With Maternal Blood Samples Positive for Parasites by Microscopy and LAMP at Delivery

Incidence of Complicated Malaria in Infants

Incidence of Hospital Admissions in Infants

Intervention	% ACPR PCR-adjusted (Number)
A) Artefenomel 800mg: Piperaquine 640mg	65.0
B) Artefenomel 800mg: Piperaquine 960mg	65.7
C) Artefenomel 800mg: Piperaquine 1440mg	72.0

Intervention	% ACPR PCR-adjusted (Number)
A) Artefenomel 800mg: Piperaquine 640mg	53.8
B) Artefenomel 800mg: Piperaquine 960mg	55.4
C) Artefenomel 800mg: Piperaquine 1440mg	65.1

Intervention	% ACPR PCR-adjusted (Number)
A) Artefenomel 800mg: Piperaquine 640mg	70.8
B) Artefenomel 800mg: Piperaquine 960mg	68.4
C) Artefenomel 800mg: Piperaquine 1440mg	78.6

Intervention	% ACPR PCR-adjusted (Number)
A) Artefenomel 800mg: Piperaquine 640mg	71.4
B) Artefenomel 800mg: Piperaquine 960mg	63.4
C) Artefenomel 800mg: Piperaquine 1440mg	78.9

Intervention	% ACPR PCR-adjusted (Number)
A) Artefenomel 800mg: Piperaquine 640mg	77.8
B) Artefenomel 800mg: Piperaquine 960mg	90.5
C) Artefenomel 800mg: Piperaquine 1440mg	89.5

Intervention	% ACPR PCR-adjusted (Number)
A) Artefenomel 800mg: Piperaquine 640mg	61.1
B) Artefenomel 800mg: Piperaquine 960mg	38.1
C) Artefenomel 800mg: Piperaquine 1440mg	62.5

Intervention	% ACPR PCR-adjusted (Number)
A) Artefenomel 800mg: Piperaquine 640mg	75.6
B) Artefenomel 800mg: Piperaquine 960mg	74.0
C) Artefenomel 800mg: Piperaquine 1440mg	83.6

Intervention	% ACPR PCR-adjusted (Number)
A) Artefenomel 800mg: Piperaquine 640mg	72.8
B) Artefenomel 800mg: Piperaquine 960mg	69.6
C) Artefenomel 800mg: Piperaquine 1440mg	81.1

Intervention	Participants (Count of Participants)
Mothers - 3 Dose SP	19
Mothers - 3 Dose DP	19
Mothers - Monthly DP	9

Intervention	Positive blood smears (Number)
3 Dose SP Pregnancy / 3 Monthly DP Infancy	7
3 Dose DP Pregnancy / 3 Monthly DP Infancy	1
3 Dose DP Pregnancy / Monthly DP Infancy	0
Monthly DP Pregnancy / 3 Monthly DP Infancy	4
Monthly DP Pregnancy / Monthly DP Infancy	0